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Chapter 1 
General Introduction and Objective of the Thesis 
Abstract 
In the last decades, dry powder inhalation has become a very attractive option for pulmonary 
drug delivery to treat lung diseases like cystic fibroses and lung infections. In contrast to the 
traditional pulmonary application of drugs for asthma and chronic obstructive pulmonary 
disease, these therapies require higher lung doses to be administered. The developments and 
improvements towards high dose powder pulmonary drug delivery are summarized and 
discussed in this chapter. These include the invention and improvement of novel inhaler 
devices as well as the further development of formulation principles and new powder 
engineering methods. The implementation of these strategies is subsequently described for 
some prototypes and formulations in research and development stage as well as for already 
marketed dry powder products. Finally, possible adverse effects which can occur after 
inhalation of high powder doses are shortly addressed.  
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1 GENERAL INTRODUCTION 
1.1 WHY PULMONARY DRUG DELIVERY? 
The main benefit of pulmonary drug administration is the delivery directly to the location of 
the disease while minimizing systemic exposure and toxicity [1]. Pulmonary delivery is 
characterized by rapid clinical response and allows to bypass therapeutic barriers such as poor 
gastrointestinal absorption and first-pass metabolism in the liver [2]. It can achieve a similar 
or superior therapeutic effect at a fraction of the systemic dose. For example, an oral dose of 
2–4 mg salbutamol is therapeutically equivalent to 100–200 µg by inhalation [2]. This is 
particularly important when considering aminoglycoside antibiotics for the treatment of 
Pseudomonas aeruginosa infections of the lung. Only low sputum aminoglycoside 
concentrations are achieved by administration of relatively high intravenous doses which 
carry the potential for systemic toxicity whereas high sputum concentrations can be achieved 
by inhalation without the risk of systemic toxicity [3]. For the treatment of lung diseases like 
asthma and chronic obstructive pulmonary disease (COPD) inhaled medications have been 
available for many years. Devices and formulations were designed for the administration of 
relatively low doses ranging from 6 to 500 µg [4]. In recent years, the treatment of other 
diseases like cystic fibroses and lung infections, as well as systemic diseases by pulmonary 
administration, became more attractive. However, these therapies in general require higher 
doses to be effectively administered to the lung. 
1.2 DEVICES FOR PULMONARY DRUG DELIVERY 
Systems for pulmonary delivery include pressurized metered dose inhalers (pMDI), soft mist 
inhalers, nebulizer and dry powder inhalers (DPI). With respect to delivered dose, pMDIs and 
the Respimat® soft mist inhaler were designed for the delivery of highly potent drugs for the 
treatment of asthma and COPD but face several factors limiting high dose delivery. Due to a 
poor delivery efficiency (mean lung deposition of 12%), a small metering valve of 25-100 µl 
[5], and limited increase in concentration [6] only small delivered doses of less than a 
milligram per puff can be achieved with pMDIs [7]. The Respimat® soft mist inhaler 
improved delivery efficiency to about 40% but high dose delivery is still limited by a small 
metering chamber of only 15 µl [8]. Thus, pulmonary delivery of high drug doses has been 
realized by nebulization of liquid formulations. This way of administration has some 
drawbacks such as restricted portability of jet and ultrasonic nebulizers due to the required 
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power source as well as a noisy compressor for jet nebulizers. These drawbacks were 
improved for portable battery-powered vibrating mesh nebulizers. The administration is 
nevertheless time-consuming and regular cleaning and disinfection of the systems are 
required [9]. Particularly for cystic fibrosis (CF) patients, applying several aerosol therapies, 
the time burden is immense. It may take up to three hours per day for administration of drugs 
and then to clean and sanitize the aerosol equipment [7].  
DPIs have the capacity to deliver higher payloads of drug to the lung. The first DPI 
(Aerohaler) was used in 1964 for the inhalation of 100,000 units of crystalline penicillin G 
sodium dust (approximately 60 mg) three times a day to treat patients with various infections 
of the respiratory tract [10]. In 1971 the Spinhaler® was developed [11] and approved for the 
delivery of 20 mg of the anti-asthmatic drug cromolyn sodium [12]. However, early DPI 
devices featured poor delivery efficiencies (only 4 to 17% lung delivery for cromolyn sodium) 
and the dosing performance depends on the patient’s inspiratory flow rate [13, 14]. In order to 
be effectively delivered to the alveolar region, particles must have an aerodynamic size 
between 1 and 5 µm [2]. Particles in this size range are extremely adhesive and cohesive. To 
improve powder fluidization and aid in de-aggregation, the micronized drug is either 
formulated with controlled agglomeration (soft pellets) or, most often, blended with larger 
carrier particles [15] in a drug-carrier ratio of usually 1:67.5 [16, 17]. The high percentage of 
carrier particles and the poor delivery efficiency limit the maximum lung dose which can be 
delivered in one actuation to just a few milligrams [6]. For administration of an appropriate 
lung dose of the antiviral drug zanamivir, for example, the patient needs to inhale two blisters 
containing 5 mg zanamivir formulated with 20 mg lactose-monohydrate twice a day [18]. 
Additionally, the large variations in lung deposition which depend on the inspiratory flow rate 
restrict the standard blending technology to drugs with a relatively large therapeutic index 
[19]. To overcome these limitations, DPIs experienced continuous further development. A 
specific de-agglomeration zone was introduced for enhanced fine drug particle separation by 
turbulences and multi-dose DPIs were designed [4]. The Novolizer® and the AirMaxTM device 
use tangential air flow which forms a cyclone in the device for optimized powder dispersion 
[20]. This approach improves lung delivery [21] but still shows variable performance at 
different flow rates [22, 23]. In contrast, drug delivery of the Taifun® device, which 
incorporates a vortex chamber, is relatively independent of the inhalation flow [24]. Constant 
drug deposition at different flow rates is also shown for the Turbospin® device where the 
inspiratory air is drawn through aerodynamically designed slits of the capsule chamber, 
putting it in a vortical motion. This causes shaking and twisting of the capsule for efficient 
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powder release [25, 26]. DPIs which include an active mechanism for powder dispersion are 
less dependent on the patient’s inspiratory flow, which is particularly important when 
considering systemic drug delivery. The Exubera® and the AspirairTM device are aimed for 
systemic delivery and use compressed air for powder aerosolization [27-29]. Nevertheless, all 
of the devices described above are designed for the delivery of small doses. DPI with drugs 
like anticholinergics, beta-2-agonists or glucocorticoids to treat asthma and COPD contain 
between 6 and 500 µg drug per dose [4]. An apomorphine hydrochloride formulation at 400 – 
800 µg for the treatment of male erectile dysfunction was recently developed using the 
AspirairTM device [29]. The Exubera® device was designed for the delivery of 1 or 3 mg of a 
dry powder insulin formulation to treat diabetes [27, 28]. 
In spite of still existing limitations for the delivery of larger doses, Crowther-Labiris et al. [3] 
delivered a lactose-blended micronized gentamicin dry powder formulation from the 
Clickhaler® device (nominal dose of 160 mg gentamicin) to ten chronically Pseudomonas 
aeruginosa infected patients, which had to take 32 inhalations to achieve a cumulative lung 
dose of 60 mg gentamicin. A new device, designed for the delivery of high powder doses, is 
the Twincer® for the application of antibiotics and sugar glass formulations containing, for 
example, therapeutic proteins. De Boer et al. [30] demonstrated that powder doses up to 
25 mg of pure drug can effectively be de-agglomerated, which possibly could be further 
optimized to a dose of 50 mg. For 8 mg colistin sulfomethate, fine particle fractions between 
40 and 60% were achieved, depending on the size of the classifier chamber. The Twincer® 
was designed as a low cost disposable inhaler, which makes it also interesting for medications 
that have to be given only once (e.g. vaccines) [30]. Another interesting novel dry powder 
inhaler for the delivery of high dose (25-250 mg) cohesive powders was described by Young 
et al. [31, 32]. The inhaler aerosolizes powder by using pressurized canisters filled with 
nitrogen gas at a pressure of 6-14 bar. An FPF between approximately 20 and 40% related to 
delivered dose could be achieved with a loading dose of 120 mg. A similar approach by using 
a standard propellant canister is described by Winkler et al. [33]. Up to 16 mg fine particle 
dose is reported in combination with that device. Recently the Novartis Podhaler® (T-326 
Inhaler) was approved, which evolved from the Turbospin® device, to address the needs of 
high-payload delivery of engineered tobramycin particles of around 50 mg. Similar to the 
Turbospin® device, the vortical air flow causes the capsule to spin while powder is shaken out 
of two pierced holes and aerosolized [34]. In vitro particle deposition were found to be largely 
independent of the inhalation maneuver [35]. 
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1.3 NEW POWDER FORMULATION METHODS 
New powder formulation methods are equally important as sophisticated devices for an 
efficient delivery of high dose DPI products. Owing to their small size, micronsized particles 
are extremely adhesive and cohesive. To enhance powder flowability and dispersibility, the 
main formulation method is blending with large (30-90 µm) lactose carrier particles [17]. For 
these formulations two oppositional requirements must be fulfilled. On the one hand, 
adhesion between carrier and drug must be sufficient for the blend to be stable enough to 
allow handling like filling. On the other hand, it needs to be weak enough to enable the 
release of drug after inhalation when the carrier particles retain in the inhaler device or deposit 
in the oropharynx due to their large size. Drug detachment from the carrier during 
aerosolization is therefore crucial for efficient lung delivery [36]. To prevent incomplete de-
agglomeration and improve lung delivery, different methods have been applied to weaken the 
drug adhesion including smoothing the carrier surface [37], reducing the particle size of the 
carrier [38], and using ternary mixtures with fines of e.g. lactose or hydrophobic components 
like magnesium stearate or amino acids [37, 39, 40]. Surface roughness of the carrier particles 
(in contrast to the surface roughness of small inhalable particles) may introduce asperities 
which could entrap drug particles and may resist its detachment from the carrier during 
inhalation [41, 42]. Two mechanisms by which fines improve de-aggregation are suggested 
because the aerosolization performance of the drug was shown to be both affected and 
unaffected by the blending order [43]. First, fines could prevent the drug particles from 
adhering to the strongest binding sites on the carrier [39] and, second, fine excipient and drug 
particles form agglomerates which are more easily dispersed and de-aggregated during 
aerosolization [44].  
A second strategy to overcome uncontrolled agglomeration of micronsized particles is the 
controlled agglomeration into soft aggregates by spheronization. These soft pellets exhibit 
large particle sizes, which provide the required flow properties for accurate dosing and are 
hard enough to be handled and loaded into the inhaler but still easily break apart into primary 
particles during inhalation [45]. Nevertheless, the variability of dose emissions from such DPI 
systems has been found to be relatively high, with a total relative standard deviation of more 
than 15% of the average emitted dose [46]. Additionally, the formed soft aggregates can 
harden on the surface when exposed to moisture, which influences the dosing characteristics 
and the ability to disaggregate into primary particles at inhalation. Therefore, the inhaler 
(Turbohaler®) contains a desiccant, which is stored in the operating unit of the inhaler [45]. 
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1.4 ENGINEERED PARTICLES 
Drug delivery to the lung can also be improved by particle engineering, which aims at the 
production of drug particles of optimal size, morphology and structure [42]. At best, these 
engineered formulations can overcome the need of carrier blends to enhance powder 
flowability and thus reduce the need for large amounts of excipient in the formulation. Direct 
controlled crystallization, for example, enables the production of uniform crystal drug 
particles with better physical stability due to a lower amorphous content compared to 
micronized material [42]. Through the use of an antisolvent precipitation technique with 
growth-retarding stabilizers like hydroxypropylmethylcellulose, characteristic particle 
morphologies depending on crystalline polymorphs can be achieved [47]. Elongated particles 
show improved lung delivery because the aerodynamic diameter of a fiber is mainly 
determined by its width rather than by its length [48]. Ikegami et al. [49] performed solid-
state transformation of a steroid from one polymorph to another and demonstrated an 
eightfold increase of the FPF for the needle-like particles of the β-form compared to the plate-
like α-form. Nevertheless, particle size control remains a big challenge because most 
molecules tend to form relatively large crystals [42].  
Several particle engineering technologies with the supercritical fluid carbon dioxide have 
been applied for pulmonary powder production. Particles form either as the result of rapid 
expansion of the supercritical fluid in which the components are dissolved or when the 
supercritical fluid acts as an antisolvent and causes precipitation from a solution [50]. It has 
been shown that powders produced by supercritical antisolvent precipitation typically exhibit 
a platelet particle morphology with lower bulk density and smaller cohesive-adhesive 
interactions compared to micronized powder, which enhances its dispersibility at low airflow 
rates [42]. Additionally, the controlled production of different polymorphic forms of high 
purity has been demonstrated [51]. The rapid expansion technique is only applicable if the 
compound has a significant solubility in the supercritical fluid and, if so, it is the technique of 
choice because of its simple, direct, solvent-free and continuous production of respiratory 
powder [42].  
Spray drying is a well-established method in food and pharmaceutical industries with 
increasing popularity due to its applicability to formulate biopharmaceuticals [50, 52]. It is 
one of the most sophisticated drying techniques and offers many possibilities for modification 
and particle engineering. The product characteristics can be modified by process and 
formulation parameters like nozzle type and nozzle parameters, feed concentration and rate, 
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solvent, drying gas flow rate, temperature and humidity as well as excipients used [53, 54]. 
Spray drying is also applicable for many liquid systems like solutions, suspensions, as well as 
emulsions and it offers the possibility of mixing fluids immediately prior to or simultaneously 
with the atomization process [54]. Beside conventional spherical particles, spray drying 
permits also the controlled production of particles of different morphology. Corrugated 
particles can be attained, for example, by changing the spray drying process conditions [55-
57], by employing polymeric excipients like dextran to increase the solution viscosity [58] or 
by adding low soluble components like leucine and trileucine [59-61]. These particles have a 
lower density and thus a larger geometrical size which improves powder dispersibility due to 
higher drag forces in the air stream. In addition, cohesive forces are reduced due to a smaller 
radius of curvature in the contact zone [58]. Spray drying has also been used in various 
methods for the preparation of porous particles. Vanbever et al. [62] prepared large porous 
particles by spray drying of a combination of water soluble (e.g. lactose) and water insoluble 
materials (e.g. dipalmitoylphosphatidylcholine) in an 87% ethanolic solution at a relatively 
low solid content (0.1% w/v). The particles had mean geometric diameters between 3 and 
15 µm but very small densities (tap density of 0.04-0.06 g/cm3), resulting in high emitted 
doses and respirable fractions. Another technique for the production of porous particles by 
spray drying is the PulmoSphere® technology [63]. PulmoSphere® particles are manufactured 
by an emulsion-based spray drying process. The drug is incorporated in an oil-in-water 
emulsion, which is composed of perfluorooctyl bromide and water and stabilized by the 
phospholipid distearoylphosphatidylcholine (DSPC), an endogenous pulmonary surfactant. 
During spray drying the drug diffuses to the center of the atomized droplet whereas the 
excipients form a shell at the surface. The volatile perflubron evaporates after further drying, 
leaving behind pores in the particle which form a sponge-like morphology. The particles have 
geometric sizes between 1 and 5 µm and are spherical in shape with a porous surface. This 
decreases the contact area between particles and leads to less particle agglomeration. 
Additionally, the accumulated DSPC at the surface lowers the surface energy, which further 
aids in decreasing interparticle cohesive forces. Consequently, PulmoSphere® particles have 
good flow and dispersing properties [63], allowing processing and aerosolization without the 
need to blend with carriers [64].  
Spray freeze-drying is a related method and a useful process for drying thermosensitive 
molecules like proteins. An atomized liquid is frozen in liquid nitrogen and freeze-dried for 
the production of micronsized porous powder particles. Nevertheless, the atomization step 
and the extremely rapid freezing of droplets impose substantial stresses on proteins distinct 
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from those stresses created by conventional lyophilization [65]. Compared to spray drying the 
technique allows higher production yield and superior aerosol performance because of the 
particles’ porosity. On the downside, the process is more complex, time-consuming, and cost 
intensive [66]. Additionally, the fast freezing of small droplets produce very fine 
microstructures after drying resulting in friable powders [65, 67]. 
Particles for sustained release can be formed from liquid dispersed systems via emulsion-
based methods using biodegradable polymers like poly(lactide-co-glycolide) (PLGA) for 
microencapsulation of the drug. Traditionally, these methods have been applied for the 
preparation of injectables [42]. Numerous examples of sustained release microspheres for 
pulmonary delivery are published, which contain drugs like isoproterenol for sustained 
bronchodilation [68] or isoniazid/rifampicin for treatment of pulmonary tuberculosis [69]. 
Porous particles with increased delivery efficiency have also been prepared from liquid 
dispersed systems using PLGA. Applying this method, Edwards et al. [70] demonstrated 
improved bioavailability of large porous insulin particles which were about seven times 
bigger than small nonporous insulin particles. The positive effect was explained by two 
factors: first, the increased particle size results in decreased tendency to aggregate and 
therefore more efficient aerosolization; second, large particles may escape from phagocytosis 
by alveolar macrophages [70, 71]. However, it is important to note, that polylactide has been 
shown to cause adverse immunological responses, which result in a significant damage of the 
lung after 24 h [72]. 
Another particle engineering method for pulmonary drug delivery is a drug carrier technology 
developed by MannKind Biopharmaceuticals, which captures and stabilizes peptides or 
proteins in small precipitated particles. These light microspheres (Technospheres®) with a 
rough surface are formed by the pH-induced intermolecular self-assembly of 3,6-bis(N-
fumaryl-N-(n-butyl)amino)-2,5-diketopiperazine. During the precipitation process, peptides 
and proteins which are present in the solution are microencapsulated. The precipitates are 
freeze-dried and become a light powder [73]. Efficacy, reliability and short-term tolerability 
of this drug delivery system has been demonstrated in clinical studies for parathyroid 
hormone [74] and insulin [75]. 
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1.5 HIGH DOSE DPI FORMULATIONS ON THE MARKET AND IN RESEARCH 
AND DEVELOPMENT 
As the first high dose antibiotic dry powder formulation (european medicines agency (EMA) 
approval in July 2011), tobramycin PulmoSphere® reached the market with the TOBI® 
Podhaler® (Novartis AG, Basel, Switzerland). The total amount of 112 mg of tobramycin 
formulation is administered by the inhalation of four capsules twice a day [76]. This portable 
passive delivery system demonstrates the same delivery efficiency as the jet nebulized 300 mg 
tobramycin solution for inhalation (TOBI® Pari-LC Plus), which is powered by an air 
compressor and requires an administration time of 15 to 20 min [77] as well as additional 
cleaning time. Fine particle dose (FPD) values of the market product are not published, 
however, an earlier study with 25 mg/capsule demonstrated a mean lung deposition of 34% 
[78]. 
In February 2012, the EMA approved Colobreath® (Forest Laboratories, Inc.). It is a dry 
powder formulation of colistimethate sodium administered using the Turbospin® DPI. One 
capsule contains 125 mg colistimethate to be inhaled twice a day [79]. The lung delivery 
efficiency is not published. 
Several other high dose dry powder antibiotic formulations are in development. A 
ciprofloxacin PulmoSphere® formulation (Cipro Inhale) is currently in phase II clinical trial 
[80]. For a study in healthy volunteers, capsules were filled with 50 mg powder containing an 
active dose corresponding to 32.5 mg ciprofloxacin betain and was administered via the T-326 
Nektar Inhaler (Podhaler®) [81]. The achieved FPD is not published. 
Positive results were recently demonstrated in a phase I clinical study for AeroVanc® (Savara 
Inc.), a dry powder formulation of vancomycin. It is the first inhaled antibiotic being 
developed for the treatment of respiratory methicillin-resistant Staphylococcus aureus 
(MRSA) infection in patients with CF. The dose-escalating study included doses between 16 
and 80 mg and examined the tolerability, safety, and pharmacokinetics of AeroVanc in non-
MRSA infected CF patients in comparison to a 250 mg dose of vancomycin administered 
intravenously [82]. The lung delivery efficiency is not published, however, sputum 
concentrations of vancomycin known to effectively kill MRSA could be demonstrated [83]. 
Aquino et al. developed a dry powder formulation of gentamicin by particle engineering via 
spray drying. The formulation including 15% (w/w) leucine was spray dried from a water/co-
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solvent system containing 30% (w/v) isopropyl alcohol and resulted in corrugated particles. A 
capsule charged with 120 mg powder introduced into the Turbospin® emitted almost the 
whole dose and achieved an in vitro FPD of 56 mg [59]. 
Not only antibiotics exist among high dosed dry powder formulations for inhalation. Mannitol 
(Aridol®, Pharmaxis Pharmaceuticals Limited), for example, is used in asthma diagnosis to 
identify persons with bronchial hyper-responsiveness [84]. For the bronchial provocation test 
patients are supposed to inhale the mannitol powder in increasing doses with the following 
protocol: 0 (empty capsule acting as a placebo), 5, 10, 20, 40, 80, 160, 160, and 160 mg 
mannitol whereby the 80-, and 160-mg doses are given in multiples of 40-mg capsules [85]. 
Another inhalative mannitol product is Bronchitol®, which was recently approved by the 
EMA for the treatment of CF patients aged 18 years and above for the improvement of lung 
function. A dose of 400 mg spray-dried mannitol is administered twice a day by inhalation of 
10 capsules using the Cyclohaler®. The osmotic active mannitol helps in rehydration and 
clearance of the tenacious mucus [86, 87]. Achieved FPDs are not published. 
Several other drugs for high dose pulmonary administration are considered in research. 
Among them are, for example, low molecular weight heparin [88], lung surfactant [89] and an 
NK1 receptor antagonist [90]. 
1.6 ADVERSE EFFECTS OF HIGH DOSED POWDER PULMONARY DELIVERY 
The inhalation of large powder doses is regarded critical compared to nebulized liquids 
because of potential induction of bronchoconstriction in hyper-responsive lungs (e.g. asthma 
patients). Dry powder mannitol has been shown to present an osmotic challenge to hyper-
responsive lungs at high dose and is therefore used for asthma diagnosis [84, 91]. 
Nevertheless, in non-asthmatic patients, large amounts of inhaled powder can also provoke 
upper-airway irritation, coughing, and bronchospasm which were reported as primary adverse 
events in various clinical studies. For Colobreath® these adverse effects normally diminish 
upon continued application or can be weakened by additional inhalation of β2-agonists [79]. 
Mannitol for inhalation in CF patients provoked cough during the first treatment but was 
overall well tolerated [87]. The inhalation of tobramycin dry powder formulation most 
commonly caused cough, followed by lung disorders (generally reported as a pulmonary or 
CF exacerbation) and pharyngolaryngeal pain (sore throat) but were considered as not serious. 
Both phase III studies demonstrated that tobramycin inhalation powder was well tolerated in 
CF patients [92, 93]. Crowther-Labiris et al. [3] reported in a comparative study of dry 
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powder versus intravenous and nebulized gentamicin, that nebulization of gentamicin caused 
significantly more mouth and throat irritation, induced coughing, and an unpleasant taste 
compared to the dry powder inhalation. 
1.7 CONCLUSION 
The growing interest in the pulmonary administration of larger powder doses triggered both, 
the invention of novel inhaler devices with enhanced efficiency and the development of 
improved inhalation formulations. Another goal was to minimize variations in the 
aerosolization and delivery performance and to reduce the dependency on the patient’s 
inspiratory flow. New sophisticated systems demonstrated their capability to deliver 
significantly increased lung doses compared to the simple early devices. Active as well as 
some passive devices achieved also inspiratory flow-independent delivery. In particular, 
particle engineering to improve powder properties play a significant role in leading dry 
powder formulations towards efficient delivery of large powder quantities. The engineered 
PulmoSphere® particles, for example, facilitated the development of the first marketed high 
dose antibiotic dry powder for pulmonary administration. Nevertheless, to achieve sufficiently 
high lung doses, every drug administration consists of multiple inhalations, which still leaves 
enough room for further improvement. The reported advances in particle engineering also 
opened the opportunity for the formulation and delivery of more complex and labile drugs 
like biopharmaceuticals. 
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2 OBJECTIVE OF THE THESIS 
For pulmonary delivery of small molecules, as well as high-molecular-weight drugs like 
proteins and peptides, Yamashita et al. [94] developed a new dry powder inhalation system 
based on the dispersion of lyophilisates by impacting air. As the freeze-dried preparation is 
disintegrated into fine inhalable particles at the time of inhalation, the formulation is stored as 
a coherent bulk in a non-powdered form. This avoids formulation problems like poor 
flowability and re-dispersibility. The objective of the thesis was to evaluate the new concept 
of Yamashita et al. [94] and prove the possibility of creating individual inhalable particles 
from a coherent bulk via disintegration of lyophilisates by an air jet. It was aimed to assess 
possible methods for improvement of this technology as well as to explain underlying 
mechanisms. This includes first the development and evaluation of an output test system with 
reproducible and optimized performance as well as its characterization (Chapter 2). Second, 
in order to understand the aerosolization behavior, various placebo formulations were 
examined with respect to lyophilisate characteristics and particle size distributions 
(Chapter 3). In the following the suitability of this technology for the delivery of high powder 
doses was to be investigated. The main focus was thereby on the improvement of the 
formulation in order to achieve high fine particle doses (FPD - amount of drug that can be 
delivered to the side of action, the alveolar region of the lung). In a first approach ways and 
limitations to elevate the metered dose were studied (Chapter 4). For optimization of the FPD 
of a model drug which demonstrated poor delivery efficiency the addition of excipients was 
investigated (Chapter 5). To possibly increase the FPD of various freeze-dried substances, the 
impact of different lyophilisate morphologies on lyophilisate characteristics and their 
aerosolization performance was evaluated (Chapter 5 and Chapter 6). Furthermore, storage 
stability for three months at 25°C/60% RH and 40°C/75% RH was investigated for selected 
formulations (Chapter 5 and Chapter 7). 
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Chapter 2 
The Test System 
Abstract 
Dry powder inhalers and dry powder formulations experience a growing interest and are the 
subject of continuous further development. The objective of this study was to evaluate the 
possible aerosolization of lyophilisates by an air impact. Therefore an output test system for 
disintegration of the lyophilisate and for delivery of the generated fine particles was 
developed. The output system uses compressed air at a preselectable pressure for reproducible 
generation of inhalable particles. The influence of several variable parameters on the fine 
particle output was investigated to decide for a standard setting for further development work. 
With respect to the compressed air, the final standard setting included a pressure of 3 bar and 
a volume for dispersion of 20 ml. Regarding the air inlet and outlet capillaries, the position 
was fixed at 5 mm below the stopper and the diameter to 0.75 mm. To possibly further 
improve the powder delivery, the influence of vial and stopper geometry of the implemented 
container housing the formulation and a modified mouthpiece with sheath air were 
investigated. In order to characterize and understand the disintegration and aerosolization 
process, the air flow through the test system was simulated and the lyophilisate dispersion 
was visualized by high speed camera recordings. Although the air flow impacted at about 
90 m/s on the lyophilisate, the cake was not compressed but was lifted up and broken apart 
into fragments, which swirled around the endings of the capillaries. The aerosol finally had a 
velocity of 3 m/s when leaving the mouthpiece. The investigation of the influence of particle 
size on the output revealed an enhanced emission of larger particles due to larger target 
surfaces to the expelling air flow and less wall adhesion. However, also very fine particles (D 
(v, 0.5) of 3 µm) demonstrated a slightly increased emitted dose as a result of superior flight 
properties. Beside the successful dispersion of lyophilisates in the novel active test system, 
the possibility to disintegrate very soft lyophilisates was also demonstrated for the passive 
capsule based HandiHaler®. However, only small fine particle doses could be achieved.  
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1 INTRODUCTION 
Inhalation therapy is the most common treatment for pulmonary diseases like asthma and 
chronic obstructive pulmonary disease (COPD). In the last decades, the evolution of dry 
powder inhalers (DPIs) experienced increasing attraction, which led to the development of 
several different devices and powder formulations. Islam and Gladki [1] divided the DPI 
devices available on the market into three generations of DPIs. The first generation DPIs are 
breath activated single unit dose devices like the Spinhaler®, for which the doses are factory 
metered into single capsules. Among the second generation DPIs, there are multi-dose 
reservoir inhalers and multiple unit dose inhalers, which are both breath activated devices as 
well. The Turbohaler®, for example, includes a powder reservoir and a disk with metering 
holes where the dose is metered right before inhalation [2]. The MAGhaler®, another multi-
dose reservoir inhaler with a different metering system, is loaded with a ring-tablet from 
which small amounts are grated with a ceramic milling disk [3]. A multiple unit dose inhaler 
like the Diskus® contains a coiled blister strip with every blister containing one factory 
metered dose which is opened and inhaled [4]. The third generation DPIs are active devices 
like the Exubera® device, which uses patient-generated compressed air for powder 
aerosolization [5]. A new system, described by Yamashita et al. [6], consists of a freeze-dried 
preparation which is disintegrated into fine particles by impacting air at the time of inhalation. 
Therefore, it is a DPI system in which the formulation is stored in a non-powdered form. 
Formulation problems like inadequate flowability and redispersibility of powders are thereby 
avoided. The disintegration and delivery of the lyophilisate is achieved by an air jet, produced 
by contracting a bellows. Another interesting novel dry powder inhaler for the delivery of 
high dose (25-250 mg) cohesive powders was described by Young et al. (2003, 2004). The 
inhaler aerosolizes powder by using pressurized canisters filled with nitrogen gas at a pressure 
of 6-14 bar. The objective of this study was to prove the possibility of disintegrating 
lyophilisates by an air impact. For this purpose, an output test system with reproducible air jet 
generation was designed and evaluated with respect to the volume and pressure of the 
compressed air as well as position and diameter of in and outlet. Potential causes for reduced 
output of the test system like vial and stopper geometry as well as the mouthpiece were 
examined. To understand the aerosolization behavior of the system, high speed camera 
recordings were performed as well as a simulation of the air flow through the test system for a 
better understanding of the air flow upon impact on the cake. Furthermore, output 
characteristics were inspected separately from the disintegration process to understand how 
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different particle sizes generated from the lyophilisate can escape the container. Additionally, 
the possibility of disintegrating lyophilisates in the capsule-based passive HandiHaler® was 
investigated. 
2 MATERIALS AND METHODS 
2.1 MATERIALS 
Excipients used were: L-isoleucine (Ile) (Fluka Chemie GmbH, Buchs, Switzerland), L-
phenylalanine (Phe) (Merck KGaA, Darmstadt, Germany), L-valine (Val) (Fagron GmbH&Co 
KG, Barsbüttel, Germany), lactose-monohydrate (Lac) (Fagron GmbH&Co. KG, Barsbüttel, 
Germany), trehalose (Tre) (Hayashibara Co Ltd, Okayama, Japan); dye for quantification was 
rhodamine B (Sigma-Aldrich, Chemie GmbH, Steinheim, Germany); filters used in Andersen 
cascade impactor analysis were type A/E glass fiber filters 76 mm (Pall Corporation, Ann 
Arbor, MI, USA) 
Lactose samples of different particle size were obtained from DFE pharma (Goch, Germany) 
in the following qualities: Lactohale® LH 100 (sieved), Lactohale® LH 200 (milled), 
Lactohale® LH 201 and Lactohale® LH 300. 
2.2 DESIGN OF EXPERIMENTS (DOE) 
A design of experiments was planned and evaluated with Modde 8 (Umetrics AB, Umeå, 
Sweden) 
2.3 FORMULATION PREPARATION IN GLASS VIALS 
0.5 ml solutions containing 4 mg/ml of the excipient and 0.2 mg/ml rhodamine B were filled 
into 2R glass vials (Fiolax® clear, Schott AG, Müllheim, Germany) and vials were equipped 
with rubber stoppers (C1503, Stelmi, Villepinte, France). Freeze-drying was carried out in a 
laboratory scale freeze-drier (Lyostar II, FTS Systems, Stone Ridge, NY, USA). The samples 
were frozen at -1°C/min to -45°C. Primary drying was performed at a shelf temperature of 
-20°C and a pressure of 34 mtorr for 14 h. In the secondary drying step shelf temperature was 
increased to 30°C and the pressure was decreased to 8 mtorr for 6 h. 
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For evaluation of serum stoppers (1104-PH 701/40/ow/wine-red, West Pharmaceutical 
Services, Eschweiler, Germany) as closure material, stoppers were exchanged after 
lyophilization in a glove box at approximately 10% relative humidity. 
For evaluation of tubes, Rotilabo®-sample vials (Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany) were cut to the same height as 2R vials. 0.5 ml solution containing 4 mg/ml 
trehalose and 0.2 mg/ml rhodamine B was filled into the tube and freeze-dried according to 
the above process. Afterwards, tubes were removed from the freeze-dryer to a glove box and 
sealed with 20 mm serum stoppers (1242 4110/40/grey West, Pharmaceutical Services, 
Eschweiler, Germany). 
2.4 FORMULATION PREPARATION IN POLYETHYLENE CAPSULES 
150 µl solution containing 4 mg/ml excipient and 0.2 mg/ml rhodamine B were filled into the 
base part of polyethylene capsules (size 3) arranged in a capsule tray of a handfill capsule 
machine (aponorm®, Wepa Apothekenbedarf GmbH & Co KG, Hillscheid, Germany). The 
tray was loaded onto a freeze-drier shelf and freeze-drying was carried out as described 
above. Afterwards, capsules were removed from the freeze-dryer to a glove box and closed 
with the corresponding top parts in the capsule machine. Until usage capsules were stored in a 
desiccator above silica orange gel. 
2.5 ANDERSEN CASCADE IMPACTOR (ACI) ANALYSIS 
The emitted dose (ED), delivered dose (DD), and fine particle fraction (FPF) of the 
formulations were evaluated using an Andersen cascade impactor (ACI) (8-Stage Non-Viable 
Sampler Series 20-800, Thermo Andersen, Smyrna, GA, USA). The ACI was operated at a 
flow rate of 39 l/min (corresponds to a pressure drop of 4 kPa with the HandiHaler®). The 
baffle plates were coated with a solution of 83% glycerin, 14% ethanol and 3% Brij 35. In 
6.15 s a total air volume of 4 l passed through the impactor. During this time period, the 
aerosol was sprayed into the induction port. The total particle mass impacting below stage 1 
equals to the FPF. By removing stages 2 to 7, the FPF is collected on the filter of the ACI. 
This configuration is called short stack ACI in this study. The amount of powder deposited on 
the filter was determined by washing with water and rhodamine B quantification at 554 nm in 
an Agilent 8453 UV-Vis spectrophotometer (Agilent Technologies, Santa Clara, CA, USA). 
Therefore the filter solution was ultra-centrifuged (OptimaTM TLX Ultracentrifuge, Beckman 
Coulter, Brea, CA, USA) at 186000 g for 45 min before UV-Vis spectroscopic analysis. The 
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FPF (= fraction of particles in an inhalable size range with an aerodynamic diameter below 
4.94 µm), the DD (dose that could be delivered to the ACI) and the ED (dose that was emitted 
off the vial) were calculated as percentage of the metered dose (nominal dose). The 
comparability of the FPF measured with the normal eight-stage ACI and the short stack 
version was tested with a flow rate of 39 l/min using the HandiHaler® in an unpublished study 
showing no significant difference of the measured FPF. Therefore the experiments of this 
study were performed with a flow rate of 39 l/min instead of the recommended 28.3 l/min of 
the pharmacopoeia. All ACI measurements were performed in triplicate. 
2.6 SIMULATION OF THE AIR FLOW THROUGH THE DEVICE 
Simulation of the air flow through the device and the vial was simulated by Ralf Kröger of 
Ansys Germany GmbH using Ansys Workbench 13. Employed subprograms were 
Designmodeller for modeling of the geometry of the test system, Workbench Meshing for 
superimposing the calculation network comprising 3.14 million polygonal cells, and Fluent 13 
for executing the simulation at time intervals of 1∙10-6 s. Due to the high time resolution and 
the fine calculation network, the simulation was terminated after 17 ms in order to keep the 
effort manageable. 
2.7 HIGH SPEED CAMERA RECORDINGS 
The aerosolization behavior of the lyophilisates in the vial was recorded using a Fastcam 1024 
PCI (Photron, San Diego, CA, USA) with a sample rate of 1000 fps. 
2.8 PARTICLE SIZE DISTRIBUTION (PSD) ANALYSIS 
The PSD of lactose powder was measured by laser diffractometry using a Helos Sympatec 
(Sympatec GmbH, Clausthal-Zellerfeld, Germany) equipped with a Rodos dry dispersion unit 
and a Vibri feeding. The powder was dispersed at a pressure of 3 bar and extracted by suction. 
The size distribution was calculated as volume distribution using the Fraunhofer theory. The 
aerosolized powder was collected in a beaker and measured similarly to the basic powder. 
2.9 ED ANALYSIS OF LACTOSE POWDERS OF DIFFERENT PARTICLE SIZE 
For analysis of the ED independent of the cake disintegration process, 24 mg of lactose 
powder (2.1) was weighed into a 2R vial and aerosolized using the test system at default 
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settings. The generated aerosol was extracted by suction. ED was quantified by weighing the 
vial before and after aerosolization and calculated as percentage of the MD. 
2.10 MECHANICAL TESTING 
The mechanical properties of the lyophilisates were investigated using a Texture Analyzer 
(TA.XT.plus, Stable micro Systems, Godalming, UK) equipped with a 5 kg load cell and a 
cylindrical stainless steel probe with a diameter of 5 mm at a test speed of 1 mm/s and a 
maximal immersion into the lyophilisate of 2 mm. The resulting immersion-force curve 
demonstrated steady fracture at a constant force visible as a horizontal plateau. For 
comparison of different formulations, the measured data points of the plateau were averaged. 
The obtained force value represents the force necessary to fracture the lyophilisate. 
3 RESULTS AND DISCUSSION 
3.1 CONSTRUCTION OF AN OUTPUT TEST SYSTEM 
For disintegration of lyophilisates into fine particles suitable for inhalation and delivery of 
these fine particles, an output test system was developed (Figure 1). The system was designed 
on the basis of an active DPI described by Yamashita et al. [6], but with the focus on 
reproducibility. It consists of two capillaries pierced through the stopper of the vessel housing 
the lyophilisate. One capillary is the air inlet, the other capillary is the air outlet, which is 
connected to the mouthpiece. The test system uses compressed air for disintegration of the  
 
Figure 1: Schematic drawing of the output test system for disintegration of the lyophilisates. 
bar
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lyophilisate into fine particles. For reproducible performance of the test system, the 
compressed air is stored in a pressure reservoir, holding a defined air volume at a 
preselectable pressure. Pressing a lever releases the compressed air through the inlet capillary. 
This pressure impulse starts dispersion and delivery of the powder. For comparison, the 
system of Yamashita et al. [6] has a similar configuration, but the air jet is generated manually 
by contraction of a 20 ml bellows.  
The output test system has several variable parameters: the pressure and the volume of the 
compressed air reservoir, the diameter of the air inlet and air outlet capillary as well as their 
position. To identify the parameters influencing the FPF, DoE was used (see Table 1 for 
factors and corresponding settings). A fractional factorial resolution 4 screening design was 
performed which consisted of 19 runs, including 3 center points. The fine particle fraction 
was determined by short stack ACI analysis of isoleucine.  
Table 1: The design of experiments factors and settings for evaluation of the variable 
parameter of the output test system. 
Name Settings 
Pressure 1 to 3 bar 
Reservoir volume 10 to 30 ml 
Air inlet capillary diameter 0.25 to 0.75 mm 
Air outlet capillary diameter 0.25 to 0.75 mm 
Air inlet capillary position 0 to 10 mm below stopper 
Air outlet capillary position 0 to 10 mm below stopper 
 
The coefficient plot of the DoE (Figure 2) shows that only the pressure had a significant 
influence on the FPF and higher pressure led to larger FPF. On closer inspection, the air outlet 
capillary diameter (OCD) possibly had an effect on the fine particle fraction as well. A bigger 
air outlet capillary diameter led to slightly larger fine particle fractions, which might be due to 
a different flow behavior in container and outlet capillary resulting in a more effective 
destruction of the lyophilisate. A higher pressure is responsible for a larger total amount of air 
in the reservoir which could aid in the fine particle output. The total amount of air is the same 
for a pressure of 1 bar and an air volume of 30 ml or a pressure of 3 bar and an air volume of 
10 ml. However, the FPF was substantially higher for a pressure of 3 bar in comparison to a 
pressure of 1 bar. For example, capillary diameters of 0.75 mm, a volume of 10 ml and a 
pressure of 3 bar achieved a FPF (related to MD) of 27%, whereas a volume of 30 ml and a 
pressure of 1 bar only attained a FPF of 18%. For capillary diameters of 0.25 mm this effect 
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was even higher. A volume of 10 ml and a pressure of 3 bar achieved a FPF of 19%, whereas 
a volume of 30 ml and a pressure of 1 bar only attained a FPF of 9%. Therefore, it was not the 
total amount of air which led to a larger FPF, but the high pressure. A higher pressure induced 
a stronger impaction on the lyophilisate which consequently disintegrated into finer particles. 
By taking this into account, the output test system was fixed to the following parameters: The 
pressure was set to 3 bar and the compressed air reservoir to a volume of 20 ml. For the air 
inlet and air outlet capillary a diameter of 0.75 mm was chosen. The position of the ending of 
the capillaries was fixed to 5 mm below the stopper of the vessel. All further experiments 
were carried out using this standard setting of the output test system. This should allow for 
reproducible results and substantial FPF. 
 
Figure 2: Scaled and centered coefficients for the fine particle fraction of the screening design 
DoE. The investigated factors were the compressed air pressure (P), reservoir volume (Vol), 
air inlet capillary diameter (ICD), air outlet capillary diameter (OCD), air inlet capillary 
position (ICP) and air outlet capillary position (OCP). 
3.2 INFLUENCE OF VIAL AND STOPPER GEOMETRY ON FINE PARTICLE 
OUTPUT 
When inspecting the vial after aerosolization, particles accumulated particularly in the cavity 
of the lyophilization stopper. In order to evaluate whether the geometry of the stopper hinders 
the particle output, lyo stoppers were replaced by flat serum stoppers after freeze-drying. No 
significant difference for ED, DD and FPF of trehalose lyophilisates in 2R vials equipped 
with the two different stoppers were detected (Figure 3a). Visual inspection of the vial after 
-2
0
2
4
6
8
10
P
V
ol
IC
D
O
CD IC
P
O
CP
%
The Test System 
  29 
aerosolization revealed a particle accumulation in the neck of the vial for samples with serum 
stopper. Thus the stopper replacement could not prevent particle accumulation at the top of 
the vial and therefore an increase in the ED was not possible. 
a 
 
b 
 
Figure 3: ED, DD and FPF of trehalose lyophilisates in a 2R vial equipped either with a 
lyophilization stopper or a serum stopper (a) or aerosolized from a necked 2R vial in 
comparison to a straight vial in the same dimensions (b). 
To evaluate the influence of the vial neck on the ED, straight sample vials were compared to 
the normal 2R vials. The straight vials were sealed with 20 mm serum stoppers to eliminate 
any cavity where particles could accumulate. However, the straight vial geometry hindered 
the output from the vial as can be seen from Figure 3b. ED, DD, and FPF for trehalose 
lyophilisates decreased by about 10%. Possibly, the rounded neck edges of the vial benefit the 
output from the vial and the neck demonstrates a less negative effect compared to a straight 
geometry. The pass through of the air stream is generally enhanced with rounded edges, 
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whereas the sharp edges of the straight geometry could cause increased turbulences resulting 
in increased particle deposition. In conclusion, the 2R vial and lyo stopper geometry do not 
restrain fine particle output and can be used for all further studies. 
3.3 INFLUENCE OF MOUTHPIECE WITH SHEATH AIR 
After aerosolization a fine particle film covered the mouthpiece. The particles particularly 
deposited at the bottom of the mouthpiece due to a sudden expansion of the air flow leaving 
the narrow outlet capillary and entering the mouthpiece (Figure 4a). This sudden expansion to 
a larger diameter produces a zone of backflow with turbulences [7], resulting in a backward 
deposition at the bottom of the mouthpiece. In order to prevent this particle deposition and 
possibly enhance the FPF, a mouthpiece with sheath air was constructed. The sheath air is 
produced by suction through small holes positioned at the transition between outlet capillary 
and mouthpiece. It is supposed to focus the particle aerosol stream and guide it through the 
mouthpiece (Figure 4b). An adapter between the suction induction port (SIP) of the ACI and 
the mouthpiece assured for a tight connection. This enabled the vacuum pump simulating the 
inspiration to produce the sheath air inside the mouthpiece during the aerosolization process. 
The sheath air successfully reduced the deposition in the mouthpiece for phenylalanine and 
trehalose lyophilisates but increased the deposited fraction in the SIP as can be seen from 
Figure 5. All other fractions including the FPF remained the same. Visual inspection of the  
a 
 
b 
     
Figure 4: Schematic drawing of the aerosol behavior in the basic mouthpiece (a) and in the 
mouthpiece with sheath air (b). 
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SIP revealed a deposition of a particle film right at the beginning. Thus, the particle 
deposition which previously took place in the mouthpiece was only shifted to the beginning of 
the SIP when using the mouthpiece with sheath air. At this position, the same effect as 
reported for the mouthpiece without sheath air occurred. The air stream comprising the 
particle aerosol experienced a sudden expansion from the narrower sheath air to the broader 
diameter of the SIP, resulting in turbulences and consequently the deposition of finer particles. 
In summary, the improved mouthpiece with sheath air was not able to prevent the premature 
deposition of finer particles before entering the ACI. Therefore, the normal mouthpiece 
without sheath air will be used for all further experiments. 
a b 
   
Figure 5: Material distribution after aerosolization of trehalose (a) or phenylalanine (b) 
lyophilisates using the basic mouthpiece or the one with sheath air. 
3.4 SIMULATION OF THE AIR FLOW IN THE VIAL 
To study the air flow through the device and the vial, a simulation was conducted. The 
geometry of the test system with the standard settings was modeled and a calculation network 
comprising 3.14 million polygonal cells was superimposed. The simulation was performed 
using very small time periods of 1∙10-6 s. For the first milliseconds the simulation revealed 
compressional waves which were reflected at edges and constrictions of the interior of the test 
system, resulting in pressure fluctuations until the inlet capillary was reached. The pressure 
fluctuations were eliminated in the narrow inlet capillary and therefore did not influence the 
air flow behavior in the vial. The pressure in the reservoir decreased from 3 bar overpressure 
to 2.8 bar within 17 ms, whereas the pressure in the vial increased to 0.7 bar (Figure 6).  
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Figure 6: Simulated pressure variations of the air in the test system within 17 ms of actuation. 
This huge pressure drop across the inlet capillary is a consequence of its small cross section 
and length. According to the equation of Hagen-Poiseuille when assuming laminar flow, the 
ratio of the length and the radius of the tube to the power of four determine the pressure drop 
across the tube. Hence, the radius of the tube plays a particularly important role: at a constant 
flow rate a reduction of the radius to the half, increases the pressure drop across the tube by 
16-fold, which is an approximation because the equation of Hagen-Poiseuille is only valid for 
Newtonian and non-compressible fluids. Nevertheless, the DoE of the variable parameters of 
the test system revealed that the diameter of the capillaries, which were varied between 0.25 
and 0.75 mm, did not significantly influence the FPF. On closer inspection, a capillary 
diameter of 0.75 mm achieved higher FPF than a capillary diameter of 0.25 mm, however the 
differences in FPF were considerably small compared to the pressure drop which should raise 
81-fold. Comprising similar dimensions, the outlet capillary exhibited a comparable pressure 
drop, which caused the increasing pressure inside the vial. The pressure in the vial will rise 
until both capillaries demonstrate the same massflow. After 17 ms, the massflow into the vial 
was 1.1∙10-4 kg/s, whereas the massflow through the outlet capillary was only 4.0∙10-5 kg/s. 
Consequently, the vial still filled after 17 ms, which implies a still rising pressure in the vial. 
The air flow achieved a velocity of approximately 350 m/s when leaving the inlet capillary 
and entering the vial during the first 2 ms (Figure 7). This air flow velocity was subsequently 
reduced to about 225 m/s after 17 ms. The velocity in the outlet capillary increased to 185 m/s 
within the 17 ms. The velocity of inlet and outlet flow will presumably average at 205 ms. 
Figure 8 shows the air movement inside the empty vial. The inlet air jet expands due to 
suction of surrounding air and finally impacts on the level of the cake surface at about 90 m/s. 
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Figure 7: Simulated velocity variations of the air flow through the test system within 17 ms of 
actuation. 
 
Figure 8: The pathlines of the air flow through the vial and its corresponding velocity at 
t=17 ms. 
Turbulences of minor velocity occurred particularly at the bottom half of the vial, including 
some escapes to the top. At entering the outlet capillary, the air flow accelerated to 150 to 
180 m/s. When considering aerosols, the velocity at which the aerosol leaves the device is of 
special interest because aerosol velocity influences lung deposition [8]. Inhalation devices 
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which emit aerosolized particles at a high velocity generally lead to a higher deposition in the 
oropharynx [9]. The air flow demonstrated a simulated velocity of 4.8 m/s at the bottom of the 
mouthpiece which was subsequently reduced to 0.7 m/s when leaving the mouthpiece. This 
velocity is comparable to the aerosol velocity of Respimat® Soft MistTM Inhaler (0.8 m/s). The 
low velocity results in a higher lung and lower oropharyngeal deposition compared to 
pressurized metered dose inhalers (pMDI) [10] which have greater aerosol velocities (2 to 
8 m/s) [11]. Nevertheless, the actual velocity of the powder aerosol needs to be tested (see 
3.5). 
3.5 THE AEROSOLIZATION BEHAVIOR OF THE LYOPHILISATE IN THE VIAL 
In order to gain insights into the aerosolization behavior of the lyophilisate and understand the 
way of destruction and disintegration of the formulation by the air impact, the aerosolization 
of the lyophilisate was recorded with a high speed camera. As can be seen from Figure 9, the 
disintegration started on the left side of the vial, right below the air inlet capillary. The air 
impact on the lyophilisate caused an impact and eruption which disintegrated the lyophilisate 
into very small fragments. These fragments were lifted into the air and swirled around the 
endings of the capillaries. This swirling motion continued and after about 200 ms most of the 
fragments had left the vial. Thus, the lyophilisate was not compressed by the incoming 
airstream despite its high velocity of about 90 m/s, but broken apart and, with the reflection of 
the airstream in the bottom segment of the vial, the cake and cake fragments were lifted up in 
a circular and swirling fashion. The swirling particles were mainly focused on the upper half 
of the vial where air turbulences were less pronounced and at lower velocity compared to the 
bottom half (Figure 8). Whether this swirling motion induced further particle size reduction 
could not be clarified. The variable parameters tested with DoE (see 3.1) were also analyzed 
with the high speed camera in order to confirm and understand their influence. The position of 
the capillaries had no influence on the swirling behavior of the cake fragments: the center of 
the vortex was always located in the upper two thirds of the vial. Another parameter, the 
pressure for dispersion of the lyophilisates, had a significant effect on the size of the produced 
fragments. Reducing the pressure to 1 bar (Figure 9c), for example, led to apparently larger 
fragments as compared to the regular pressure of 3 bar (Figure 9a). Lyophilized cakes 
prepared of different excipients reacted differently to the air impact at the beginning of the 
aerosolization. For the valine lyophilisate, for example, shortly after the initial impact of the 
compressed air, the whole cake was lifted up and subsequently disintegrated into small 
fragments.  For the phenylalanine lyophilisate, in contrast, the cake broke into large  pieces  
The Test System 
  35 
a 
 
b 
 
c 
 
Figure 9: High speed recordings of the aerosolization behavior of lyophilized cakes prepared 
of different excipients like valine (a) and trehalose (b) as well as the disintegration of the 
valine lyophilisate using a reduced compressed air pressure of 1 bar (c). 
which were then lifted up and disintegrated into smaller fragments. The lyophilisates 
produced of sugars such as lactose and trehalose mostly showed cracks on the surface which 
acted as predetermined breaking points, separating the cake into large pieces before further 
disintegration (Figure 9b). Apart from insights into the aerosolization process, high speed 
recordings also allowed to determine the aerosol velocity. Within a time period of 9 ms the 
aerosol covered a distance of 27 mm, resulting in an approximate velocity of 3 m/s at the end 
of the mouthpiece. This is comparable to pMDI, which have an aerosol velocity of 2.0-8.4 m/s 
[11]. The actual aerosol velocity was clearly greater compared to the simulated air flow 
velocity when leaving the mouthpiece (0.7 m/s). The particles might be accelerated to a high 
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velocity in the flow during the passage of the narrow outlet capillary, almost like darts in a 
blow-pipe and experience less deceleration compared to the air flow due to their mass inertia.  
3.6 INFLUENCE OF THE PARTICLE SIZE ON THE OUTPUT 
To investigate the influence of particle size on the ED, independent of the cake disintegration 
process, lactose powder (Lactohale®) of different particle sizes between 3 and 130 µm (D (v, 
0.5)) were filled into vials (24 mg) and aerosolized using the output test system. The particle 
size distribution (PSD) of these powders was analyzed by laser diffractometry before and after 
aerosolization. Only the powder with the largest particle size (D (v, 0.5) of approx. 130 µm), 
showed a shift to smaller particle sizes after aerosolization (Table 2). Possibly the active 
aerosolization by compressed air caused a comminution of some accelerated larger particles 
like in a jet mill. A potential explanation could be also that very large particles were not able 
to pass the narrow capillary with a diameter of 0.75 mm and remained in the vial. The two 
coarse lactose qualities LH 200 and LH 201 experienced a reduced fraction of fines, possibly 
as a result of the fines remaining in the vial and mouthpiece because of adhesion to surfaces. 
Interparticulate interactions (cohesion and adhesion) are dominated by van der Waals forces 
for small particle (<<100 µm), whereas gravitational forces are expected to dominate for 
larger particles (>>100 µm) [12]. Adhesion to device surfaces is therefore reduced for larger 
particles which can influence the ED (see below). The fine lactose quality LH 300 
demonstrated no difference of the PSD of the powder before and after aerosolization. 
Table 2: PSD of the different sized lactose powders before and after aerosolization in the test 
system. 
 
D(v, 0.1) (µm) D(v, 0.5) (µm) D(v, 0.9) (µm) 
LH 100, start 66.1 129.4 209.2 
              aerosolized 50.1 108.6 167.7 
LH 200, start 8.8 73.8 143.4 
              aerosolized 10.2 69.9 139.0 
LH 201, start 2.9 22.6 56.4 
              aerosolized 3.5 23.5 54.8 
LH 300, start 0.7 2.5 6.3 
              aerosolized 0.7 2.6 6.4 
 
Figure 10 shows a decrease in the ED for smaller particle sizes. The biggest particles with a 
median size of 129 µm demonstrated an ED of 31%, which decreased to 9% for particles with 
a median size of 23 µm. Fine particles having a median particle size of 3 µm exhibited an 
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increased ED of 18%. On the one hand, large particles should display a larger target surfaces 
to the discharging air flow compared to smaller particles. On the other hand, smaller particles 
demonstrate stronger adhesion to surfaces resulting in a greater loss of free particles in the 
aerosol and became apparent as particle films on the inner surfaces of the vial and the 
mouthpiece by visual inspection after aerosolization. This latter effect is stressed by the 
difference between ED and DD, which increased with decreasing particle size, indicating a 
greater particle loss by adhesion on the mouthpiece. It has been also considered that fine 
particles (D (v, 0.5) of 3 µm), exhibit superior flight properties partly compensating for the 
above described disadvantages. They can better follow changes of air flow direction, which is 
also used for particle size classification in cascade impactor analysis. An increased ED for 
lactose powders at increased particle size was already demonstrated by Bell et al. [13] for a 
capsule based DPI. The loss of powder from the capsule increased at increasing particle size 
between 4 and 100 µm but decreased again for powders of larger particle size until 400 µm 
due to intermittent blocking of the capsule holes. For the finer particles an extensive coating 
of the internal capsule walls was reported, leading to the conclusion that interparticulate and 
adhesive forces of finer particles hinder their discharge from the capsule. An increased 
emission of polyethylene glycol 8000 particles with increased particle size as a result of the 
diminished cohesive forces of the particles was also shown by French et al. [12].  
 
Figure 10: ED and DD of lactose powders aerosolized with the test system. 
For the interpretation of this finding, one needs to consider that the delivery of particles to the 
alveolar region of the lung requires an aerodynamic size between 1 and 5 µm [14]. The 
aerodynamic diameter (dA) is defined by the relationship  
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0
VA χρ
ρdd ≅  (1) 
and is dependent on the size (dV), shape (χ) and mass density of the particle (ρ) for 
ρ0 = 1g/cm3. It has been demonstrated that large porous particles display less cohesive and 
adhesive forces compared to small and nonporous particles and show more efficient delivery 
[15]. In order to take advantage of the improved emission, large porous particles with a small 
density could be beneficial. 
3.7 EVALUATION OF LYOPHILISATE DISPERSION IN THE PASSIVE 
HANDIHALER® 
Beside the advantage of inspiratory effort-independent delivery, active devices show some 
disadvantages such as the need for an energy source and the required coordination of 
activation and simultaneous inspiration by the patient. Alternatively, a high number of passive 
DPI devices are available on the market, which are easy to use and environmentally 
sustainable. In order to compare the described active system to a passive system, lyophilisate 
dispersion in a passive capsule-based device was studied. Excipient solutions of 
phenylalanine, valine and lactose in a concentration of 4 mg/ml were freeze-dried in 
polyethylene capsules for disintegration in the passive HandiHaler® and compared to 
lyophilisates in 2R vials aerosolized by the active test system. It is important to note that the 
base part of the capsule can only hold less than 200 µl for freeze-drying. Compared to a 2R 
vial, the metered dose is therefore limited. For aerosolization of a formulation in the 
HandiHaler®, a capsule is inserted into the device and pierced. The capsule vibrates in the 
capsule chamber as a result of the inspiratory flow. Particles which are arranged near one of 
the holes are sucked out of the capsule due to a flow dependent pressure difference (Venturi 
effect) and are subsequently carried along by the inspiratory air flow [16]. The lyophilisate 
needs to disintegrate into fine particles inside the capsule in order to pass through the small 
holes. This can either occur by agitation due to capsule vibration or by an air flow through the 
capsule. Figure 11 shows the high DD of around 80% for valine and lactose lyophilisates 
aerosolized by the passive HandiHaler® but only rather small FPF related to DD of 21.7% and 
8.6%, respectively. For phenylalanine lyophilisates, in contrast, only a fraction of 10% left the 
capsule (data not shown). This demonstrates a successful disintegration of valine and lactose 
lyophilisates into particles which can leave the capsule. However, the disintegration was not 
very effective in producing fine particles with an aerodynamic diameter of less than 5 µm. 
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Phenylalanine lyophilisates, in contrast, were not adequately disintegrated into particles by 
the passive capsule-based device. Considering the FPD, the passive device demonstrated 
drastically reduced values in comparison to the active test system. The FPD of valine 
lyophilisates was reduced to about one tenth from 0.99 mg to 0.11 mg and for lactose 
lyophilisates from 0.42 mg to 0.04 mg. This was a result of a smaller metered dose in 
combination with a strongly decreased FPF. 
In order to evaluate the mechanical stability of the lyophilisates inside the vials, texture 
analyses were performed. The cylindrical probe acts on the lyophilisate and the force needed 
for the immersion is recorded. The immersion-force curve of phenylalanine lyophilisates 
demonstrated a plateau indicating a force necessary to fracture the lyophilisate of about 
0.014 N. Valine and lactose lyophilisates both exhibited softer cake structures with a force 
necessary to fracture the lyophilisate of less than 0.001 N, which was the lowest level of 
detection. Consequently, only very soft lyophilisates could be disintegrated in the passive 
HandiHaler®. 
 
Figure 11: DD versus its related FPF as well as the FPF related to MD of valine and lactose 
lyophilisates aerosolized by the active test system in comparison to the passive HandiHaler®. 
4 SUMMARY AND CONCLUSION 
The output test system, which was designed with several variable parameters, enabled the 
disintegration of lyophilisates into fine particles in the vial and the delivery of these fine 
particles. With the exception of the factor pressure, the screening design DoE identified the 
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variable parameters of the output test system as not influencing FPF within the specified 
limits. For further experiments, the output test system was fixed to a standard parameter 
setting including a pressure of 3 bar, a compressed air reservoir of 20 ml, and a diameter of 
the air inlet and air outlet capillary of 0.75 mm. An observed particle accumulation in the 
cavity of the lyophilization stopper or neck of the 2R vial could neither be reduced via 
replacing the lyo stopper by a flat serum stopper nor by substituting the necked vial with a 
straight one. It was also not possible to increase the FPF by using a mouthpiece with sheath 
air. Although the deposition of fine particles in the mouthpiece was reduced, the same 
problem occurred at entering the SIP, resulting in deposition of finer particles due to 
turbulences of the expanding air stream. The test system was therefore by default used with a 
2R vial equipped with lyophilization stoppers and with the basic mouthpiece. 
A simulation of the air flow through the device demonstrated great pressure drops across the 
narrow inlet and outlet capillaries, resulting in a pressure increase inside the vial to 0.7 bar 
within the first 17 ms. At this time point, the pressure drop of the inlet capillary amounted to 
2.1 bar. This can possibly explain the positive influence of a high compressed air pressure for 
a good disintegration and particle output. If considering a similar setting for a passive device, 
which was also described in the patent [6], such a high device resistance would not be 
acceptable. Taking only one capillary into account and assuming laminar flow (equation of 
Hagen-Poiseuille), an inspiration at 1.7 l/min over 2.3 min would be required to achieve the 
recommended pressure drop across the device of 4 kPa in combination with a suction volume 
of 4 l [17]. For a passive setup, the capillary must therefore have a much greater diameter and 
shorter length. The narrow capillaries contribute also to an acceleration of the air flow up to 
sonic velocity which was subsequently reduced at entering the vial. It finally impacted on the 
level of the cake surface at about 90 m/s. However, the cake was not compressed by the 
incoming air stream but was lifted up and broke apart into fragments, which swirled around 
the endings of the capillaries. Differences in the aerosolization behavior of different excipient 
formulations were identified. The produced particle aerosol had a velocity of 3 m/s at the exit 
of the mouthpiece, which is similar to pMDIs. Compared to capsule-based passive DPIs, the 
emission of larger particles is enhanced due to a larger cross-section and less wall adhesion. 
Only very fine particles (D (v, 0.5) of 3 µm) demonstrated a slightly increased ED as a result 
of superior flight properties.  
The evaluation of the lyophilisate dispersion in the passive capsule based HandiHaler® 
demonstrated a possible disintegration for very soft lyophilisates like valine or lactose at a 
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concentration of 4 mg/ml. Nevertheless, the comminution process in the capsule was less 
effective compared to the air impact at high velocity of the active test system, resulting in a 
small FPF. In combination with the small metered dose, only small FPD were achieved. 
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Chapter 3 
Evaluation of the Performance of the Test System 
Abstract 
During the last years, new technological ideas for dry powder inhalers were developed. A new 
concept is the creation of individual particles from a coherent bulk at the time of inhalation by 
disintegration of lyophilisates. The evaluation and characterization of the possible dispersion 
of lyophilisates by an air impact and the achievement of high fine particle fractions were the 
objectives of this study. In order to understand the aerosolization of lyophilisates, different 
formulations of amino acids and sugars were investigated. Besides the characterization of the 
different formulations by microscopy and x-ray diffractometry, the main focus was on the 
particle size distributions (PSD) of the dispersed particles. Thereby the geometric PSD was 
analyzed by laser diffraction, whereas the aerodynamic PSD was characterized by time of 
flight and Andersen cascade impactor analysis. The destruction of the porous structure of the 
lyophilisates resulted in large geometric particle sizes but aerodynamic particle sizes in the 
inhalable range with relatively large fine particle fractions (FPF) between 20 and 50% 
calculated as a percentage of the metered dose. Despite potential differences in freezing 
behavior and thus cake structure within lyophilization batches, reproducible fine particle 
fractions were attained. Overall, it could be concluded that the controlled disintegration of 
lyophilisates into inhalable particles by an air impact is possible and substantial FPF are 
achieved. Therefore, the method represents a promising new dry powder inhalation 
technology. 
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1 INTRODUCTION 
Beside the local treatment of pulmonary diseases, a systemic delivery of therapeutic proteins 
by inhalation is of high commercial interest [1]. For their formulation, the proteins’ limited 
physical and chemical stability pose additional challenges. Conventionally, the powders 
formulated for the use in dry powder inhalers (DPI) are produced by milling to micronize the 
drug or by spray drying [2, 3]. These powder production and formulation techniques have 
several disadvantages. Especially during milling the drug is exposed to high temperatures 
which can be a problem for thermolabile drugs. Micronization is also notorious for inducing 
electrostatic charges and generating amorphous domains on the particle surface [4]. Freeze-
drying is a common method for stabilizing proteins and peptides. The result after a freeze-
drying process is a cake in the size of the filling volume. For generation of an aerosol, the 
freeze-dried cake needs to be micronized for example by jet-milling to prepare fine particles. 
Additionally, spray drying or spray freeze drying are potential formulation methods to 
improve the stability and long term storage stability of these biological drugs. However, DPIs 
prepared by spray drying or freeze-drying-jet-milling method have been reported to cause 
partial deactivation of the peptides and proteins such as interferons [2]. 
A new DPI system initially introduced by Yamashita et al. [5], comprises a freeze-dried 
preparation which is aerosolized into inhalable particles by an air jet at the time of inhalation. 
The authors claim rather high fine particle fractions (FPF) of 10% or more, in some examples 
up to 81% related to delivered dose. Summarizing the advantages of this new system, it has a 
formulation process particularly suitable for thermolabile drugs like proteins and peptides and 
the manufacturing process is relatively simple, with extremely high accuracy at dose metering 
and high preparation yield as the formulation is metered as a liquid. On the other hand, the 
freeze-drying process could be a disadvantage concerning reproducibility and batch 
uniformity [6, 7]. Furthermore, freeze-drying is an energy intensive and time consuming 
manufacturing process [8]. 
The aim of this study was to verify the new concept of Yamashita et al. [5] of creating 
individual particles in an inhalable size range with high fine particle fraction from a coherent 
bulk by an air jet. To further understand the aerosolization behavior of the system, besides 
lyophilisate characteristics, the geometric and aerodynamic particle size distribution (PSD) of 
different placebo formulations were examined. In order to restrict influencing factors of the 
formulation, only placebo formulations containing a single excipient were used in this study. 
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2 MATERIALS AND METHODS 
2.1 MATERIALS 
Excipients used were: L-isoleucine (Ile) (Fluka Chemie GmbH, Buchs, Switzerland), L-
phenylalanine (Phe) (Merck KGaA, Darmstadt, Germany), L-valine (Val) (Fagron GmbH&Co 
KG, Barsbüttel, Germany), lactose-monohydrate (Lac) (Fagron GmbH&Co. KG, Barsbüttel, 
Germany), D-mannitol (Man) (Riedel-de Haën, Seelze, Germany), trehalose (Tre) 
(Hayashibara Co Ltd, Okayama, Japan); dye for quantification was rhodamine B (Sigma-
Aldrich, Chemie GmbH, Steinheim, Germany); filters used in Andersen cascade impactor 
analysis were type A/E glass fiber filters 76 mm (Pall Corporation, Ann Arbor, MI, USA) 
2.2 FORMULATION PREPARATION 
0.5 ml solutions containing 4 mg/ml of the excipient and 0.2 mg/ml rhodamine B were filled 
into 2R glass vials (Fiolax® clear, Schott AG, Müllheim, Germany) and vials were equipped 
with rubber stoppers (C1503, Stelmi, Villepinte, France). Freeze-drying was carried out in a 
laboratory scale freeze-drier (Lyostar II, FTS Systems, Stone Ridge, NY, USA). The samples 
were frozen at -1°C/min to -45°C. Primary drying was performed at a shelf temperature of 
-20°C and a pressure of 34 mtorr for 14 h. In the secondary drying step shelf temperature was 
increased to 30°C and the pressure was decreased to 8 mtorr for 6 h. 
2.3 MICROSCOPY 
The morphology of the lyo cakes was analyzed with a digital reflected light microscope 
(Keyence VHX-500F, Keyence Corporation, Osaka, Japan). The particle morphology of the 
dispersed particles was analyzed with a Jeol Scanning Electron Microscope (JSM-6500F, Jeol, 
Ebersberg, Germany). The samples were fixed with self-adhesive tape on aluminium stubs 
and were sputtered with carbon. 
2.4 X-RAY DIFFRACTOMETRY (XRD) 
The lyophilisates were investigated with a Seifert X-ray diffractometer XRD 3000 TT 
(Seifert, Ahrensburg, Germany). The samples were measured from 5 – 40° at a step rate of 
2Ө=0.05° with 2 sec measuring time per step. 
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2.5 RESIDUAL MOISTURE CONTENT ANALYSIS 
The residual moisture content of lyophilisates was determined by Karl-Fischer titration 
(Metrohm 756 KF Coulometer, Herisau, Switzerland) using Hydranal Coulomat AG (Riedel-
de Haën, Seelze, Germany) as titration reagent. The lyophilisates were dissolved in 1.0 ml of 
anhydrous methanol (Hydranal-Methanol dry, Riedel-deHaën, Seelze, Germany), additionally 
dried with molecular sieve 3A (VWR International GmbH, Darmstadt, Germany), right in the 
production vials. As blanks, empty freeze-dried vials, similarly filled with 1.0 ml of dry 
methanol, were used. The injection volume was 500 µl each. The measurements were 
performed in triplicate. 
2.6 DIFFERENTIAL SCANNING CALORIMETRY (DSC) 
The DSC experiments were performed with 4 – 8 mg of freeze-dried sample sealed in 
aluminium pans (ME-26763) on a Mettler Toledo DSC821e (Mettler Toledo, Giessen, 
Germany). Phenylalanine samples were heated from 25°C to 295°C at 10°C/min. 
2.7 PARTICLE SIZE DISTRIBUTION (PSD) ANALYSIS 
2.7.1 Laser diffraction (LD) measurements 
The geometric PSD was investigated with a Malvern Mastersizer X (Malvern Instruments 
Ltd, Worcestershire, England). A 300 mm lens with a measurement range of 0.5 to 600 µm 
was used. The size distribution was calculated using the Fraunhofer theory. The aerosol was 
sprayed into the laser beam using the output test system at a distance of approximately 5 cm 
and extracted by suction. 
2.7.2 Time of flight (TOF) measurements 
The aerodynamic PSD was determined with the API Aerosizer® LD (TSI Inc., Amherst, MA, 
USA) in combination with the Aero-Breather® for sample presentation. A 700 µm nozzle was 
used with a display range of 0.1 to 200 µm. The Aero-Breather® was operated at a breath rate 
of 39 l/min, a breath volume of 1 l with an acceleration of 19 l/s2. For measurement, the 
aerosol was sprayed into the Aero-Breather® using the output test system. 
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2.7.3 Andersen cascade impactor (ACI) analysis 
The aerodynamic PSD of the formulations was also evaluated using an Andersen cascade 
impactor (ACI) (8-Stage Non-Viable Sampler Series 20-800, Thermo Andersen, Smyrna, GA, 
USA). The ACI was operated at a flow rate of 39 l/min (corresponds to a pressure drop of 
4 kPa with the HandiHaler®) with cut off diameters outlined in Table 1. The baffle plates were 
coated with a solution of 83% glycerin, 14% ethanol and 3% Brij 35. In 6.15 s a total air 
volume of 4 l passed through the impactor. During this time period, the aerosol was sprayed 
into the induction port. The amount of powder deposited on each stage of the impactor was 
determined by washing with water and rhodamine B quantification at 554 nm in an Agilent 
8453 UV-Vis spectrophotometer (Agilent Technologies, Santa Clara, CA, USA). The FPF (= 
fraction of particles with an aerodynamic diameter below 4.94 µm) and the DD (dose that 
could be delivered to the ACI) were both calculated as percentage of the metered dose 
(nominal dose). A plot of the cumulative amount of powder deposited on each stage against 
the cut-off-diameter allowed calculation of the mass median aerodynamic diameter (MMAD) 
[9]. The total particle mass impacting below stage 1 equals to the FPF. By removing stages 2 
to 7, the FPF is collected on the filter of the ACI. This configuration is called short stack ACI 
in this study. The filter solution was ultra centrifuged (OptimaTM TLX Ultracentrifuge, 
Beckman Coulter, Brea, CA, USA) at 186000 g for 45 min before UV-Vis spectroscopic 
analysis. The comparability of the FPF measured with the normal eight-stage ACI and the 
short stack version was tested with a flow rate of 39 l/min using the HandiHaler® in an 
unpublished study showing no significant difference of the measured FPF.  
All PSD measurements were performed in triplicate. 
Table 1: Used cut off diameters for the ACI at flow rate of 39 l/min 
Stage Cut off diameter at 39 l/min 
0 7.65 
1 4.94 
2 4.00 
3 2.81 
4 1.79 
5 0.94 
6 0.60 
7 0.34 
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2.8 TAP DENSITY MEASUREMENT 
The tap density measurements were performed using a 10 ml-graduated cylinder fixed in a 
jolting volumeter (STAV 2003, JEL Engelsmann AG, Ludwigshafen, Germany) and tapped 
1250 times. Particles were generated by evacuation of the lyophilisate in the vial and 
stoppering of the vials (inside the freeze-dryer) at a pressure of <0.1 mtorr. Piercing a needle 
through the stopper of the vials caused quick ventilation and thereby destruction of the 
lyophilisate into small particles. The similarity of these particles and the particles generated 
by aerosolization with the output test system was verified by scanning electron microscopy 
(SEM). The measurements were performed in triplicate. 
3 RESULTS AND DISCUSSION 
3.1 PHYSICOCHEMICAL CHARACTERIZATION OF EXCIPIENT 
FORMULATIONS 
In order to understand the impact of the lyophilisate characteristics on the aerosolization 
performance, the morphology of different placebo formulations was inspected with the 
reflected light microscope. The placebo formulations were single excipient formulations 
containing an amino acid (isoleucine, phenylalanine, valine) or a sugar (lactose, mannitol - 
knowing that mannitol is a sugar alcohol it is termed sugar in this study for the sake of 
simplicity - , trehalose) and were freeze-dried using a standard freeze-drying process with a 
cooling rate of -1°C/min. The lyophilisates had a porous comb like structure, with a skinny 
coating, covering the top of the cake. This is exemplarily shown for phenylalanine in 
Figure 1. An explanation for the feasible disintegration of the lyophilisate into inhalable 
particles is this highly porous structure with its filmy walls. The preparations have a very low 
mass density and feature big air filled cavities which enable easy penetration of the air into 
the whole cake and impact on the thin fragile wall structures. 
Surface energy and adhesion/cohesion was considered less relevant for this system because 
the formulation is stored in a non-powdered form and the inhalable particles are generated at 
the time of inhalation. 
For a better understanding of differences in the aerosolization behavior and fine particle 
output of different excipient formulations, the physical state of the formulations has to be 
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analyzed. The investigation of the lyophilisates by x-ray diffractometry demonstrated a 
crystalline structure for the isoleucine, valine and mannitol samples. The x-ray diffraction 
pattern of the freeze-dried mannitol sample showed the peak pattern of the δ-polymorph [10]. 
In contrast, the freeze-dried sugars lactose and trehalose were amorphous. For the freeze-dried 
phenylalanine sample the peaks reflected the monohydrate comparing the peak pattern with 
literature diffraction patterns [11]. The residual moisture analysis by Karl-Fischer titration 
indicated a content of phenylalanine monohydrate of approx. 50%. The existence of the 
hydrate could be confirmed by differential scanning calorimetry (DSC). Besides the melting 
endotherm of phenylalanine at 270°C, the DSC trace showed an endothermal event at 136°C, 
followed by an exothermal event at 146°C that was related to the crystallization of the 
anhydrous form of phenylalanine (data not shown). In a secondary reheating the thermal 
events at 136°C and 146°C did not occur. Phenylalanine exhibits pseudopolymorphism: it can 
exist as a monohydrate and in the anhydrous form. The transition point in water is at 37°C. 
The needle-shaped monohydrate is stable below, and the flake-shaped anhydrate above the 
transition point [11]. Thus it is not surprising that the phenylalanine solution crystallizes as 
the monohydrate during freeze-drying. Because the XRD pattern does not show any other 
peaks except those related to the monohydrate, and the moisture analysis indicated a 
phenylalanine monohydrate content of only 50%, the remaining 50% appeared to be present 
in the amorphous state. 
a 
 
b 
 
Figure 1: Morphology of the freeze-dried phenylalanine formulation: top of the cake (a) and 
bottom of the cake (b). 
The different physical state of the formulations, being crystalline or amorphous, might have 
an effect on the stability and rigidity of the wall structures of the porous lyophilisates. This 
can furthermore influence the disintegration of the lyophilisates and the fine particle output 
which was analyzed in the following experiments. The physical state of the freeze-dried 
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excipients can also be important for stability issues. On the one hand, amorphous 
formulations are less stable against humidity as water has a plasticizing effect and amorphous 
regions can also change the physical state and crystallize during storage [12]. Considering 
incorporation of an active pharmaceutical ingredient, on the other hand, amorphous excipients 
might be favored e.g. for stabilizing proteins [13]. The following analysis of the PSD and the 
FPF of the different excipient formulations should give further information about the 
applicability of crystalline and amorphous formulations. 
3.2 PSD OF DIFFERENT EXCIPIENT FORMULATIONS 
The output test system was used to analyze the particle sizes which can be achieved by 
disintegration of the lyophilisates using the developed output system. In order to determine 
size and shape of the dispersed particles released from the output system, the particles were 
investigated with scanning electron microscopy (SEM). Specimens were prepared by 
collecting the aerosol leaving the output test system directly on a specimen stub. Particles 
observed were clearly separated from each other (Figure 2) having diameters between 5 µm 
and approximately 100 µm. Their shape appeared to reflect agglomerates of small fragments. 
During the disintegration process, the ordered pore structure of the lyophilisate was 
completely destroyed. Small fragments of the former pore walls formed these agglomerative 
particles, leading to a different morphology compared to the lyophilisates. The particles, 
however, still feature a highly porous structure and a low mass density.  
Besides the agglomerative shape of all samples, particles of the various excipient 
formulations differed in shape. Phenylalanine particles had a netting structure formed by 
needles, whereas valine particles exhibited a platelet-like structure. A needle-shaped 
morphology has already been reported for phenylalanine monohydrate [11]. 
Using laser diffraction (LD) the geometric PSD was examined. The results of the PSD are 
outlined in Table 2. The distributions of the different excipient formulations were relatively 
broad. The particle sizes ranged from smaller than 1 µm to 100 µm and even larger as can be 
seen from Figure 3a. These particles are relatively large and rather unusual for pulmonary 
delivery. For non-spherical particles, such as plates and needles orientated randomly, the 
geometric volume diameter is typically overestimated because of the large projection diameter 
for these shapes [14]. This is certainly also the case for the non-spherical particles from this 
study. Furthermore, the PSD shown in Figure 3a is a volume distribution for which the 
calculation is based on the assumption that the particles measured are spherical. Nevertheless, 
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the microscopic pictures (Figure 2) of the dispersed particles confirmed that range of 
relatively large particles. 
a 
 
b 
 
c 
 
d 
 
Figure 2: Scanning electron microscope pictures of dispersed particles of phenylalanine (a, c) 
and valine (b, d). 
For evaluation of aerosols, the aerodynamic PSD is determining. Therefore the aerodynamic 
PSD was analyzed by time of flight (TOF) measurement with the Aerosizer®. The Aero-
Breather®, which imitates the breath by moving a plunger, was used for sample presentation. 
The results of the PSD are outlined in Table 2 as well. The aerodynamic PSD was much 
narrower than the geometric PSD and shifted to smaller particle sizes (Figure 3b). It is also 
noticeable that the aerodynamic PSD of the amino acid formulations had a stronger relative 
variation compared to those of the geometric PSD. The FPF of the Aerosizer®, which 
corresponds to the analyzed amount of particles having an aerodynamic particle size <5 µm, 
differed between 51 and 100%. These results indicate the potential for very effective 
pulmonary delivery.  
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Table 2: The geometric and aerodynamic volume PSD (± S.D. n=3) of the different excipient 
formulations aerosolized with the standard output test system. The geometric PSD was 
measured by laser diffraction analysis, the aerodynamic PSD by time of flight analysis. 
 D(v, 0.1) (µm) D(v, 0.5) (µm) D(v, 0.9) (µm) ≤ 5 µm (%) 
Geometric PSD (by LD) 
Isoleucine 5.22 ± 0.11 20.49 ± 1.28 72.53 ± 8.15 10.06 ± 0.27 
Phenylalanine 2.86 ± 0.13 15.81 ± 0.89 61.09 ± 5.61 20.57 ± 0.67 
Valine 3.78 ± 0.28 14.44 ± 1.99 53.84 ± 8.91 16.35 ± 1.68 
Lactose 3.23 ± 0.22 11.12 ± 0.64 41.16 ± 4.02 21.90 ± 0.76 
Mannitol 3.10 ± 0.04 12.40 ± 0.42 57.51 ± 8.55 20.98 ± 0.23 
Trehalose 3.04 ± 0.32 12.29 ± 1.43 61.68 ± 12.50 23.82 ± 2.85 
          
  D(v, 0.1) (µm) D(v, 0.5) (µm) D(v, 0.9) (µm) FPF rel. to DD (%) 
Aerodynamic PSD (by TOF) 
Isoleucine 2.56 ± 0.07 3.64 ± 0.18 5.61 ± 0.68 83.64 ± 7.10 
Phenylalanine 0.89 ± 0.03 1.58 ± 0.08 2.39 ± 0.19 99.92 ± 0.13 
Valine 1.31 ± 0.05 2.73 ± 0.53 4.51 ± 0.22 96.96 ± 2.38 
Lactose 20.8 ± 0.09 4.49 ± 0.05 7.82 ± 0.50 57.22 ± 0.67 
Mannitol 2.09 ± 0.10 4.36 ± 0.27 7.49 ± 0.64 60.02 ± 4.20 
Trehalose 2.40 ± 0.16 4.96 ± 0.37 7.63 ± 0.79 51.17 ± 6.60 
 
Equation 1 is the simplified expression for Stokes aerodynamic diameter, widely used in 
aerosol literature: 
0
VA χρ
ρdd ≅  (1) 
Where dA is the aerodynamic diameter, dV is the volume-equivalent diameter, ρ0 is the unit 
density of calibration spheres, ρ is the particle density and χ is the dynamic shape factor. A 
smaller aerodynamic particle size compared to the geometric particle size can thus be 
explained by a particle density smaller than 1 g/cm3 or a large dynamic shape factor. Non-
spherical particles have rather large shape factors. For a density of 1 g/cm3, a sphere has a 
dynamic shape factor of 1, a fiber with a diameter of 3.56 µm and a length of 100 µm for 
example has a dynamic shape factor of 13.5 [15]. As the geometric and aerodynamic size of 
our dispersed particles differed to a great extent, the shape factor of our particles must be 
large and/or the particles must have a very low density. As the SEM pictures show, the 
particles consisted of fragments which are loosely agglomerated into particles, thus particle 
density should be very low. The tap density of the particles was measured as an estimate for 
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the particle density. For the valine particles e.g., a tap density of 0.009 g/cm3 was measured. 
Using the obtained values for geometric and aerodynamic size (D(v,0.5)) as well as tap 
density in equation 1 renders a very small dynamic shape factor of 0.25. This indicates a high 
air resistance and deceleration resulting in good lung deposition. Vanbever et al [16] already 
reported on large porous particles for inhalation with tap densities between 0.04 and 
0.6 g/cm3.  
a 
 
b 
 
Figure 3: Cumulative geometric volume PSD of different excipient formulations investigated 
with LD (a) and TOF (b) measurements. 
The aerodynamic PSD was also investigated using the ACI. Cascade impactor analysis is 
considered the most important and precise in vitro testing of aerosols. It is recommended by 
both the United States and the European pharmacopoeia. The detected FPF and DD of the 
different formulations are shown in Figure 4. Depending on the excipient, FPF between 20 
and 50% calculated as a percentage of the metered dose (MD) could be determined. These 
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Figure 4: FPF related to DD as well as related to metered dose (MD) and DD of different 
excipient formulations investigated by short stack ACI analysis. 
FPF are rather large compared to FPF of DPIs on the market which range from 9 to 36% [17, 
18]. FPF related to DD ranged from 52 to 79%. These results are comparable to examples 
given by Yamashita et al. [19]. A novel DPI device described by Young et al. [20, 21], which 
also uses a pressurized gas (8 – 14 bar) for aerosolization of high powder loads of 120 mg, 
achieved lower mean FPF of 36% related to DD. The DD of the excipient formulations varied 
between 40 and 65%. Especially for the sugar formulation, this entails a major loss in the 
vessel and the mouthpiece (Figure 5). This has to be optimized in further studies. A MMAD 
of 3.2 µm was measured for the isoleucine and lactose formulation, and a MMAD of 3.1 µm 
for the mannitol formulation. These values are well below 5 µm, which is required for 
pulmonary delivery [22]. With a combination of SEM and ACI analysis it was possible to 
 
Figure 5: Fractions related to metered dose deposited on the different components of the short 
stack ACI. 
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measure the aerodynamic and geometric particle size of the same particle. Self-adhesive tapes 
for SEM were placed on each baffle plate of an eight stage ACI. Figure 6 shows the relation 
of the aerodynamic and the geometric size of dispersed isoleucine particles. It can be seen that 
large particles with mean diameters up to 100 µm are still in the respirable range with an 
aerodynamic size smaller than 5 µm. Therefore, the particle density must be very low. 
 
Figure 6: Relation between geometric and aerodynamic size of dispersed isoleucine particles 
analyzed with a combination of SEM and ACI. 
By comparison of the two methods, TOF and ACI, it is noticeable that there is no significant 
difference in the FPF values for the sugar formulations. The FPF values of the amino acid 
formulations measured by TOF are overall greater compared to those measured by the ACI as 
can be seen from Figure 7. This poor agreement between TOF and ACI measured FPF was 
already reported by Vanbever et al. [16]. An explanation of this phenomenon may be found in 
the different analytical methods. The aerodynamic PSD measured by ACI is based on inertial 
impaction of the particles on coated plates comparable to the deposition mechanism in the 
upper human airways. Thereby bounce and blow-off at the stages and also wall or inter-stage 
losses may occur and bias the result [23]. Vanbever et al. [16], for example, assume that 
porous particles experience less lubrication-layer repulsion than small nonporous particles 
used for impactor calibration and are therefore overestimated. De Boer et al. [24] state in their 
critical evaluation of cascade impactor analysis that the aerodynamic diameter of irregular 
particles measured with an impactor is not necessarily the same as its equivalent diameter 
obtained from a sedimentation experiment, which yields the aerodynamic diameter by its 
definition. This is because there are different forces acting on a particle traveling between the 
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Figure 7: Comparison of the FPF of different excipient formulations measured by TOF and 
ACI analysis. 
nozzle and the collection plate. The centrifugal force and the drag force are both not constant 
and additionally change their direction in contrast to the force of gravity. This results in a 
dynamic force system acting on the particle which reacts in a different way than during 
stationary settling. Irregular particles may start to rotate which affects in a different 
aerodynamic shape factor (χ) [24]. However, the magnitude of bias of the mentioned possible 
problems ought to be very small. Olsson et al. [25] i.e. reported total inter stage losses in an 
ACI of 1.6 – 3.5%. The Aerosizer®, in contrast, determines the aerodynamic particle size by 
measuring the time of particle flight. For transformation of the TOF data to an aerodynamic 
volume-weighted size distribution, the software uses the sample density and instrument 
calibration curves, assuming the particles to be spherical [26]. As the true particle density is 
not known, the material density was utilized for the TOF analysis in order to take differences 
between excipients into account. Furthermore, it has been reported that the Aerosizer® 
significantly undersizes non-spherical particles whereby the degree of size reduction is size-
dependent. In the range between 7 and 19 µm, TOF results are 21 to 51% lower than the true 
aerodynamic diameter measured by sedimentation [27]. Potentially particle and material 
density were in better accordance for the sugar formulations as compared to the amino acid 
based formulations or the particles created from amino acid formulations are less spherical 
than the sugar based particles. Because the crystalline mannitol sample behaved similar to the 
other sugar formulations, which were amorphous, the physical state can not help explaining 
this phenomenon. Therefore most likely the differences could be explained by the unknown 
true density of the particles which is needed for the Aerosizer analysis. The Aerosizer® 
nevertheless can be used as a quick screening method for aerodynamic PSD. 
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As the freeze-drying process is known to have the problem of intra and inter-vial 
heterogeneity because of the stochastic nature of ice nucleation [6] as well as temperature 
gradients on the shelves and radiation from the wall [7], the reproducibility of the FPF is an 
important issue to analyze. Therefore all FPF analyses were performed in triplicate. The 
standard deviations of the FPF measured with the ACI and the Aerosizer® were both relatively 
small. For the FPF measured with the ACI and related to metered dose, the SD ranged from 1 
to 4%. The SD of the FPF measured with the Aerosizer® ranged from 1 to 7% related to DD. 
Thus we can state that the FPF is robust against freeze-drying batch heterogeneity. 
4 SUMMARY AND CONCLUSION 
For dry powder formulations for inhalation it is of utmost importance that the particles 
generated can penetrate into the lung. Therefore the PSD produced by the novel inhalation 
system was analyzed by different methods considering geometric and aerodynamic PSD. The 
porous lyophilisates disintegrated into particles of large geometric size up to 100 µm and 
above. The aerodynamic size of these particles, however, was much smaller and a substantial 
fraction was in the respirable range of 1 – 5 µm due to low particle density. Overall, FPF of 
20 – 50% calculated as a percentage of the metered dose could be determined by ACI 
measurements. Despite major losses in the vessel and the mouthpiece, these values were 
rather large compared to DPIs on the market. Fine Particle doses up to about 1 mg could be 
reached at relatively low DD of 40 – 65% which needs to be optimized in further studies. 
Differences in the aerosolization behavior of the different excipient formulations could be 
identified. Among the tested samples, the amino acid formulations of phenylalanine and 
valine performed best. The effect did not correlate with the physical state of being crystalline 
or amorphous and must therefore be caused by other material properties. Inhomogeneities in 
the structure of the lyophilisates were not identified to affect the reproducibility of the FPF of 
the different formulations. The standard deviations of the different samples measured in 
triplicate by ACI were relatively small between 1 and 4%. Therefore the aerosolization of the 
lyophilisates and its fine particle output was robust against freeze-drying batch heterogeneity 
in the investigated lab scale. Nevertheless, freeze-drying process parameters like freezing 
conditions can have an effect on the aerosolization of the lyophilisates and need to be 
analyzed in further studies. Overall, the disintegration and aerosolization of lyophilisates by 
an air impact is possible and a promising new concept for dry powder inhalation. 
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Chapter 4 
Optimization of the FPD by Increase of the 
Solution Concentration and the Fill Volume 
Abstract 
There is a growing interest in the pulmonary administration of larger powder quantities, 
which would enable the treatment with high dosed drugs e.g. antibiotics. The aim of this study 
was to investigate the suitability of the lyophilisate based dry powder inhalation system for 
the delivery of high powder doses. This was to be achieved by elevation of the metered dose 
by varying the solution concentration and the fill volume of valine and cromolyn sodium 
lyophilisates. An increase in dose could be achieved by a controlled increase in the solution 
concentration at a low fill volume, whereas an increased fill volume as well as a substantially 
increased concentration resulted in a drastic decrease of the fine particle output. This latter 
negative impact was a consequence of impaired disintegration on the one hand due to 
increased cake hardness at elevated solution concentration. On the other hand, a higher fill 
volume resulted in reduced milling efficiency of softer cakes, whereas for harder cakes the 
product movement was reduced as less free space was available. The maximum fine particle 
dose (FPD) achieved was 1.2 mg for valine lyophilisates and 2.6 mg for cromolyn sodium 
lyophilisates. An increased pressure of the air used for dispersion resulted only in an increased 
emitted dose for the highest fill volume of 2 ml but did not further enhance the FPD of 
cromolyn sodium lyophilisates in 2R vials. However, utilization of a larger container in 
combination with an adapted amount of compressed air rendered a FPD of 3.7 mg cromolyn 
sodium in a single shot and is considered as a promising approach to deliver high drug doses 
to the lung. 
  
Chapter 4 
62 
1 INTRODUCTION 
Currently marketed dry powder inhalers (DPI) mostly contain relatively low doses of drugs 
like anticholinergics, beta-2-agonists or glucocorticoids, ranging from 6 to 500 µg [1]. 
However, in the case of less potent drugs DPIs with e.g. 20 mg cromolyn sodium [2], 28 mg 
tobramycin [3] or 40 mg mannitol for asthma diagnosis [4] are used and there is a growing 
interest in the pulmonary administration of higher doses [5]. Some traditional dry powder 
formulations consist of micronized drug blended with larger lactose carrier particles to 
enhance flow and re-dispersibility [6]. The high percentage of carrier to drug particle ratios of 
typically 67.5:1 (w/w) [7] and the moderate lung delivery efficiencies limit the maximally 
delivered lung dose with these mixtures to just a few milligrams per inhalation [8]. This was 
for example illustrated for gentamicin in a study, where 32 inhalations were necessary for the 
delivery of a therapeutic dose because of only 1.9 mg fine particle dose (FPD) per inhalation 
[9]. To overcome the poor delivery efficiency of DPIs, de Boer et al. [5] developed the DPI 
Twincer® which was designed for effective de-agglomeration of high powder doses up to 
25 mg of pure drug. Young et al. [10] introduced an active device utilizing pressurized gas for 
aerosolization and delivery 20-250 mg of highly cohesive pumactant powder and in vitro 
studies showed fine particle fractions (FPF) of >30% (~30 mg FPD) when loaded doses of 
120 mg were delivered using 8–14 bar aerosolization pressures. A new dry powder inhalation 
system based on dispersion of lyophilisates which was initially introduced by Yamashita et al. 
[11] and developed further within this thesis (see Chapter 2 for details) also comprises an 
active test system utilizing compressed air for aerosolization and delivery of fine particles. 
The aim of this study was to investigate the suitability of this technology for the delivery of 
high powder doses. Possible approaches to increase the FPD of such a lyophilisate based DPI 
system were the elevation of the metered dose (MD) by varying the solution concentration 
and the fill volume of valine and cromolyn sodium lyophilisates. In a second attempt the 
influence of increased pressure of the compressed air used for dispersion was tested to further 
increase the FPD. Additionally, a bigger container holding the freeze-dried formulation was 
evaluated. Finally, the FPD achieved for the model drug cromolyn sodium were compared to 
commercial products. 
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2 MATERIALS AND METHODS 
2.1 MATERIALS 
L-valine and cromolyn sodium were purchased from Fagron GmbH&Co KG (Barsbüttel, 
Germany). Solutions were prepared with highly purified water (Purelab Plus, Elga LabWater, 
Celle, Germany). The commercial product Lomudal® cromolyn sodium Inhalatiepoeder 
20 mg (Lot No. 0060K, Sanofi-Aventis Netherlands B.V., Gouda) was used for comparison. 
2.2 FORMULATION PREPARATION 
0.5 to 2 ml aqueous solutions of 6 – 36 mg/ml valine or 12 – 28 mg/ml cromolyn sodium were 
filled into 2R glass vials (Fiolax® clear, Schott AG, Müllheim, Germany) equipped with 
rubber stoppers (1079-PH 701/40/ow/wine-red, West Pharmaceutical Services, Eschweiler, 
Germany). Freeze-drying was carried out in a laboratory scale freeze-drier (Lyostar II, FTS 
Systems, Stone Ridge, NY, USA). The samples were frozen at -1°C/min to -45°C for 2 h 
including two 30 min holding steps at +5°C and -5°C for temperature equilibration across the 
high fill depth. Primary drying was performed at a shelf temperature of -15°C (shelfs were 
ramped at +0.2°C/min) and a pressure of 100 mtorr for 30 h. For secondary drying the shelf 
temperature was increased to +30°C at a ramp rate of +0.1°C/min for 10 h. Additionally, 0.5 
to 3 ml aqueous solutions of 12 mg/ml cromolyn sodium were filled into 6R glass vials 
(Fiolax® clear, Schott AG, Müllheim, Germany) equipped with rubber stoppers (1319 PH 
4023/50, gray, 20 mm, West Pharmaceutical Services, Eschweiler, Germany) and freeze-dried 
as mentioned above. 
2.3 FPF ANALYSIS 
The formulations were aerosolized using a custom design inhaler (see chapter 2 for details) 
with the standard setting of 20 ml compressed air at a pressure of 3 bar, 0.75 mm of inlet and 
outlet capillary diameter and a capillary position of 5 mm below the stopper for 0.5 to 1.5 ml 
lyophilisates or right below the stopper for 2 ml lyophilisates. The FPF was measured using a 
short stack version of the Andersen Cascade Impactor (8-Stage Non-Viable Sampler Series 
20-800, Thermo Andersen, Smyrna, GA, USA) at a flow rate of 39 l/min (corresponds to a 
pressure drop of 4 kPa with the HandiHaler®). Baffle plates were coated with a solution of 
83% glycerin (AppliChem GmbH, Darmstadt, Germany), 14% ethanol (central supply LMU, 
Munich, Germany) and 3% Brij 35 (Serva Electrophoresis GmbH, Heidelberg, Germany). 
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Filters used were type A/E glass fiber filters 76 mm (Pall Corporation, Ann Arbor, MI, USA). 
By removing stages 2 to 7, the whole FPF (particle fraction <4.94 µm) is collected on the 
filter directly below stage 1 and can easily be quantified by weighing the filter before and 
after powder deposition. The resulting amount of powder is the FPD. The emitted dose (ED) 
was measured by weighing the vial before and after aerosolization and calculated as the 
percentage of the MD. The FPF was calculated either as the percentage of the MD or of the 
ED. The measurements were performed in triplicate. 
2.4 MECHANICAL TESTING 
The mechanical properties of the lyophilisates were investigated using a Texture Analyzer 
(TA.XT.plus, Stable micro Systems, Godalming, UK) equipped with a 5 kg load cell and a 
cylindrical stainless steel probe with a diameter of 5 mm at a test speed of 1 mm/s and a 
maximal immersion into the lyophilisate of 2 mm for 0.5 ml fill volume or 5 mm for 1-2 ml 
fill volume. The resulting immersion-force curve demonstrated steady fracture at a constant 
force visible as a horizontal plateau. For comparison of different formulations, the measured 
data points of the plateau were averaged. The obtained force value represents the force 
necessary to fracture the lyophilisate. At the end of the immersion, the probe touches the 
bottom of the vial which results in a steep increase of the immersion force curve and can 
therefore be disregarded. 
2.5 HIGH SPEED CAMERA RECORDING 
The aerosolization behavior of the lyophilisates in the vial was recorded using a Fastcam 1024 
PCI (Photron, San Diego, CA, USA) with a sample rate of 1000 fps. 
3 RESULTS AND DISCUSSION 
3.1 OPTIMIZATION OF THE FPD OF VALINE LYOPHILISATES 
In order to enhance the FPD of the inhalation systems based on dispersion of lyophilisates, the 
MD was elevated. Therefore, lyophilisates with increasing solution concentrations from 
6 mg/ml to 36 mg/ml valine and increasing fill volume from 0.5 ml to 2 ml were prepared and 
the aerosolization performance was tested. Figure 1a shows the FPF related to MD of the 
different formulations. The FPF decreased drastically with increasing solution concentration  
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Figure 1: Effect of elevated MD by increased fill volume and concentration on the FPF 
related to MD (a), on FPF related to ED (b) as well as on ED (c) and the consequently 
resulting FPD (d) for valine lyophilisates. 
as well as with increasing fill volume. Similar to an increased drug concentration for metered 
dose inhalers reported in [8], the increased loading resulted in a significantly decreased 
delivery efficiency. This led to the question whether the decrease in FPF is a result of a less 
effective disintegration into larger particles or a decreased output from the vial. In Figure 1b 
the FPF related to ED of the different formulations is plotted against the fill volume and the 
concentration. The graph similarly demonstrates a dramatic decrease of the FPF at increasing 
solution concentration and at increasing fill volume. The ED, as can be seen from Figure 1c, 
markedly decreased only for combinations of fill volume and concentration, starting at 
18 mg/ml, 24 mg/ml and 36 mg/ml for fill volumes of 2, 1.5 and 1 ml, respectively. For these 
samples, a residual piece of cake was observed in the vial after the active disintegration 
process. The decrease in FPF could therefore be mainly referred to an impaired disintegration. 
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With respect to FPD, the increased initial loading at higher concentration or fill volume 
partially compensated for the reduced FPF as can be seen from Figure 1d. The maximum FPD 
of 1.2 mg was obtained at 30 mg/ml/0.5 ml. Thus, a dose increase could be achieved by 
increasing the solution concentration at a low fill volume. However, due to the rather low FPF 
of 7.7%, the loss in dose is substantial and, particularly when considering expensive drugs, 
possibly not economical.  
 
Figure 2: Mechanical testing of valine lyophilisates at varying concentration and fill volume. 
The shown force is the average value of the immersion-force-curve plateau and represents the 
force necessary to fracture the lyophilisate. 
Obviously, the impact of the compressed air was not able to adequately break up lyophilisates 
of elevated fill volume and concentration. In order to gain insights into the mechanical 
properties of the different formulations, texture analyzer measurements were performed. The 
mechanical testing revealed that a higher force was necessary for fracturing the lyophilisates 
with increasing concentration as can be seen from Figure 2. As a consequence, the impact 
force of the compressed air on the lyophilisate becomes insufficient for adequate 
comminution of the harder cakes into fine particles at higher initial solution concentration. In 
contrast, the force necessary for fracturing the lyophilisate was independent of the fill volume 
and the cake hardness can therefore not explain the disintegration problems for lyophilisates 
of higher fill volume. To further elucidate the disintegration and aerosolization behavior of the 
lyophilisates at the lower concentration of 8 mg/ml, high speed camera recordings were 
performed. For the lowest fill volume of 0.5 ml (Figure 3a), the cake was lifted up in a 
rotational movement and was subsequently disintegrated in the impacting air stream. The 
fragments swirled in the upper part of the vial around the endings of the capillaries until they  
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Figure 3: Aerosolization behavior of 8 mg/ml valine lyophilisates at 0.5 ml (a) and 2 ml (b) 
fill volume visualized with high speed camera recordings at 1000 fps. 
left the vial through the outlet capillary. Lyophilisates at higher fill volume were also lifted up 
and disintegrated into particulate fragments. Because of an instantaneous and complete 
disintegration of the lyophilisates, larger lyophilisates result in a higher number of free 
swirling particles inside the vial. For a fill volume of 2 ml, a part of these particles initially 
accumulated right below the stopper in a waiting position as can be seen from Figure 3b 
(20 ms). Later, after enough particles had left the vial, these accumulated particles re-entered 
the swirling air flow. Probably, the amount of particles in the swirling air flow also affects the 
comminution into fine inhalable particles. The disintegration process of the lyophilisate by the 
swirling air flow is comparable to the jet-milling process. The particles to be pulverized are 
accelerated by pressurized gas whereby the grinding effect is produced either by interparticle 
collision or by impact against solid surfaces [12]. Thereby an important variable is the amount 
of particles inside the mill chamber because the frequency and intensity of collisions 
determines the grinding efficiency [13]. An increase of the feed rate and therefore an 
increased particle amount leads to a coarser product [14]. Not every particle in the mill will 
break upon colliding with another particle or with the wall, the kinetic energy of the collision 
has to be taken into account [13]. A high number of particles cause more frequent collision 
whereupon the kinetic energy of these particles is reduced resulting in less impact velocity at 
following collisions. This probably can explain the less effective size reduction of the 
fragmented lyophilisate to inhalable fine particles at higher fill volume. 
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3.2 OPTIMIZATION OF THE FPD OF CROMOLYN SODIUM LYOPHILISATES 
AND COMPARISON TO A HIGH DOSE MARKET PRODUCT 
Options for enhancing the FPD of the lyophilisate based DPI system were also evaluated for 
the model drug cromolyn sodium. The MD was raised by increasing the initial solution 
concentrations from 12 to 28 mg/ml cromolyn sodium, and the fill volume from 0.5 to 2 ml.  
a 
 
b 
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d 
 
Figure 4: Effect of elevated MD by increased fill volume and concentration on the FPF 
related to MD (a), on FPF related to ED (b) as well as on ED (c) and the consequently 
resulting FPD (d) for cromolyn sodium lyophilisates. 
Similar to valine lyophilisates, the FPF related to MD (Figure 4a) dropped with increasing fill 
volume and in particular with increasing solution concentration from 24 mg/ml on. The 
decrease in FPF must be also a result of a hindered cake disintegration because FPF related to 
ED (Figure 4b) demonstrated similar to valine lyophilisates a strong decrease with increasing 
concentration as well as with increasing fill volume. The ED in contrast increased with 
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increasing concentration at a fill volume of 0.5 ml until a concentration of 24 mg/ml but 
strongly decreased at elevated fill volume as can be seen from Figure 4c. Probably a higher 
loading dose is necessary to compensate for the loss due to particle accumulation at the top of 
the vial and in the cavity of the lyophilization stopper. The maximum FPD of approx. 2.6 mg 
was obtained with a concentration of 20 mg/ml and a fill volume of 0.5 ml. As already 
observed for valine, a dose increase could be best achieved by increasing the solution 
concentration at a low fill volume (Figure 4d). There appears to be a critical limit of 
dispersibility between 24 and 28 mg/ml of cromolyn sodium because 28 mg/ml showed a 
drastic decrease of ED and FPF already for the 0.5 ml lyophilisate.  
 
Figure 5: Mechanical testing of cromolyn sodium lyophilisates at varying concentration and 
fill volume. The shown force is the average value of the immersion-force-curve plateau and 
represents the force necessary to fracture the lyophilisate. 
Mechanical testing revealed that higher forces are necessary for fracturing the lyophilisate of 
elevated concentration and fill volume as can be seen from Figure 5. It is noticeable, that the 
plateau indicating the force necessary for fracturing was attained later during the immersion 
process for lyophilisates of 1 ml fill volume compared to 0.5 ml. For fill volumes of 1.5 and 
2 ml, the plateau was not reached within the tested 5 mm of immersion, but the immersion-
force-curve steadily raised (Figure 6). The steady slope of the curve indicates a more elastic 
behavior of the lyophilisates at elevated fill volume where initially mainly compression takes 
place instead of steady fracture. This less brittle behavior of lyophilisates at elevated fill 
volume and their harder structure can possibly explain the inferior disintegration into fine 
particles. Approximately at 0.27 N, a critical hardness limit was reached for which 
disintegration by the impacting air stream was not possible anymore. Comparing the hardness 
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of valine and cromolyn sodium lyophilisates, it is important to note that valine lyophilisates 
were more than ten times softer and exhibited a less elastic lyophilisate structure. This could 
be the reason for a mostly complete disintegration of valine lyophilisates in contrast to only 
partly disintegration of cromolyn sodium lyophilisates until a critical hardness limit for 
disintegration. Beside already identified differences in the aerosolization behavior and fine 
particle output of different excipient formulations (see chapter 2 and 3 for details), the 
hardness of a lyophilisate is also dependent on the freeze-dried material properties which 
again affects the dispersibility. 
 
Figure 6: Immersion-force-curves of 12 mg/ml cromolyn sodium lyophilisates at varying fill 
volume. 
Visualization of the disintegration process for 12 mg/ml cromolyn sodium lyophilisates by 
high speed camera recording revealed that it is of utmost importance that the lyophilisate can 
rotate in the vial for a good disintegration or that it is at least fractured into smaller pieces 
which can rotate in the vial. Large lyophilisates of 2 ml (Figure 7b) for example were not able 
to perform rotational movements and were not fractured into smaller pieces. In contrast, the 
whole cake was lifted up remaining more or less stationary at the top of the vial for a few 
milliseconds. At the end of the disintegration process, a substantial piece of the cake remained 
in the vial resulting in a low ED. In contrast, valine lyophilisates at low and high fill volume 
were also lifted up but subsequently disintegrated into fragments even if no rotational 
movement was possible. Furthermore, the complete disintegration process occurred within the 
first milliseconds whereas the cromolyn sodium lyophilisates were fractured into pieces 
rotating at the bottom of the vial while fine particles were scaled off (Figure 7a). Therefore, a 
possibly hindered comminution process due to a high number of fragments in the swirling air 
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flow was probably less important for cromolyn sodium lyophilisates. Nevertheless, the 
hindered disintegration indicated by the decrease in FPF related to ED was most likely 
attributed to the increased hardness. 
a 
 
b 
 
Figure 7: Aerosolization behavior of 12 mg/ml cromolyn sodium lyophilisates at 1 ml (a) and 
2 ml (b) fill volume visualized with high speed camera recordings at 1000 fps. 
This led to the question whether an increased pressure of 4 bar for dispersion compared to 
standard 3 bar can result in improved disintegration and elevated ED and FPF. Figure 8 shows 
the FPF related to MD of 12 mg/ml lyophilisates. A significant difference was only detectable 
for a fill volume of 2 ml where the FPF related to MD doubled from 6.2% to 12.4% for 3 and 
4 bar pressure. The plot also clearly demonstrates that the FPF related to ED remained the 
same for all fill volumes. The increased FPF related to MD of the 2 ml-formulation was 
therefore only due to the enormous increase of the ED from 24.8% to 54.0%. An increased 
pressure for dispersion consequently resulted in an elevated output from the vial but not in an 
enhanced comminution process into finer particles. Therefore, an increased pressure for 
dispersion showed no benefit. Since the poorer disintegration of formulations with a high fill 
volume appeared to be the consequence of insufficient vial volume, freeze-dried formulations 
of various fill volumes were prepared in 6R vials, thus doubling the container volume, in 
order to further enhance the FPD. A fill volume of 2 ml in a 6R vial has about the same fill 
depth than a fill volume of 1 ml in a 2R vial. As can be seen from Figure 9, small fill volumes 
demonstrated less fine particle output compared to the normal 2R vials when disintegrated at  
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Figure 8: ED and FPF related to ED as well as FPF related to MD of 12 mg/ml cromolyn 
sodium lyophilisates aerosolized using 3 and 4 bar compressed air pressure for dispersion. 
the standard test system settings. An elevated FPD compared to the same fill volume in a 2R 
vial was only achieved for the highest fill volume of 2 ml. This increase was a result of an 
improved comminution into fine particles because the FPF related to ED increased from 25% 
to 35% whereas the ED remained about the same. Figure 10a demonstrates the disintegration 
process in the larger 6R vial. The cake was lifted up and broke apart during a first rotation. 
The resulting pieces rotated at the bottom of the vial while particles were scaled off. This 
confirms the above statement  that enough space  for rotational movements of the cake  is 
 
Figure 9: FPD of 12 mg/ml cromolyn sodium lyophilisates aerosolized from 2R or 6R vials 
applying the standard setting of 20 ml compressed air at 3 bar or an increased amount of 
compressed air with 30 ml at 4 bar. 
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Figure 10: Aerosolization behavior of 12 mg/ml cromolyn sodium lyophilisates at 2 ml 
dispersed with 20 ml compressed air at 3bar (a) or with 30 ml at 4bar (b). 
important for a good disintegration process. Nevertheless, the achieved FPD was not higher 
than the FPD of the 1 ml and 1.5 ml formulations in a 2R vial. The impact velocity/force of 
the incoming air stream must be about the same for both the 2R and 6R vial. The vial height 
differs only by 5 mm and the position of the capillaries of the test system was previously 
identified as not influencing the FPF (see chapter 2 for details). However, the same amount of 
air passed through the small 2R vial as well as the bigger 6R vial possibly resulting in a 
change in air flow behavior. Consequently a test was performed with a doubled volume of 
compressed air to 120 ml (30 ml at 4 bar) compared to the standard 60 ml (20 ml at 3 bar). 
Applying these adapted disintegration conditions, the FPD of the 2 ml formulation in 6R vials 
could be elevated to 3.7 mg. This increase was a result of an elevated ED from 28% to 48% 
whereas the FPF related to ED remained about the same similarly to the previous reported 
pressure increase for the 2R vials. The reference aerosolization of the 2R vial formulation at 
4 bar and 30 ml revealed also an enhanced FPD as a result of the previously reported 
increased ED for a pressure of 4 bar but lacked the improved comminution due to the small 
vial volume. This showed that employing a bigger 6R vial with an adapted amount of 
compressed air could be used to further enhance the FPD of this lyophilisate based DPI 
system. Furthermore this clearly demonstrated that the disintegration of harder lyophilisates 
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like of cromolyn sodium required a certain amount of space which enables rotational 
movements for an effective comminution into fine particles. 
For comparison, the micronized cromolyn sodium from one capsule of the commercial 
product Lomudal® (~26 mg) was filled into a 2R vial and aerosolized using the same 
conditions. The micronized drug achieved a FPD of 2.1 mg which corresponds to a FPF of 
7.8%. The lyophilisate in 2R vial with the best performance (20 mg/ml and 0.5 ml) achieved a 
higher FPD of 2.6 mg in combination with a substantially lower metered dose of only 10 mg 
because of a markedly higher FPF of 26%. However, the FPF of Lomudal® could be higher 
when aerosolized using the original Eclipse® inhaler. For another commercial cromolyn 
sodium product formulated without excipient (Intal®), Steckel et al. [2] obtained a FPF of 
14.1% and a FPD of 3.5 mg aerosolized using the intended inhalation device (Spinhaler®) and 
a Multistage Liquid Impinger (MLI) at a flow rate of 100 l/min. In a former study Steckel et 
al. [15] demonstrated a lower FPF for Intal® Spinhaler® of only 10% when measuring with the 
Twin Stage Impinger or 4% FPF using the MLI both operated at a flow rate of 60 l/min. 
Employing a 6R vial with an adapted amount of compressed air, a similar FPD of 3.7 mg was 
achieved while the FPF was again slightly higher at 15.5%. In both comparator products the 
FPF was significantly lower, and therefore a substantially higher MD was needed compared to 
the lyophilisate to deliver an appropriate FPD. A particularly high FPD is achieved with the 
PulmoSphereTM tobramycin dry powder formulation. In a study in healthy volunteers using 
gamma scintigraphy a mean FPF of 34% which corresponds to a FPD of 4.6 mg tobramycin 
following inhalation of a single capsule containing 25 mg of radiolabeled PulmoSphereTM 
tobramycin formulation was determined [16]. The marketed product TOBI® Podhaler® with 
an MD of 112 mg tobramycin (4 capsules) shows systemic tobramycin exposure comparable 
to a 300 mg nebulized tobramycin solution (TOBI® PARI-LC® Plus) [3] the latter resulting in 
5% or 9% total lung deposition [16, 17]. Thus, the FPD of the TOBI® Podhaler® formulation 
must be around 3.75-6.75 mg per capsule.  
With the novel dry powder inhalation system a FPD comparable to high dose market products 
could be achieved. Considering valine lyophilisates, the maximum FPD of 1.2 mg was 
significantly lower compared to cromolyn sodium. It is therefore dependent on the material 
properties whether the novel DPI system is suitable for the delivery of higher doses. It is also 
important to note that the novel DPI system is an active device which requires compressed air 
in contrast to the mentioned passive DPIs. 
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4 SUMMARY AND CONCLUSION 
The aim of this study was to investigate the suitability of the lyophilisate based inhalation 
system for the delivery of high powder doses. The idea was to enhance the FPD of the system 
by elevation of the MD. Therefore, valine and cromolyn sodium lyophilisates at increasing 
solution concentration and at increasing fill volume were evaluated with respect to their 
aerosolization behavior and mechanical properties. An increase in dose could only be 
achieved by increasing the solution concentration at a low fill volume. However, the increase 
of the solution concentration was also limited. Although valine lyophilisates were ten times 
softer, the mechanical testing revealed for both substances an increasing hardness at 
increasing solution concentration ultimately responsible for an inferior disintegration and 
decrease in FPF. At a solution concentration of 28 mg/ml, cromolyn sodium lyophilisates 
reached a critical hardness limit for which disintegration was not possible anymore. The 
decrease in FPF at higher fill volume was also caused by an impaired disintegration of the 
lyophilisate. This was primarily a result of a reduced milling efficiency in the case of softer 
lyophilisates (e.g. valine lyophilisates) which were instantaneously and completely 
disintegrated into particles by the air impact. For harder lyophilisates (e.g. cromolyn sodium 
lyophilisates), the hindered disintegration was attributed to the increased hardness which 
prevented an immediate and complete fragmentation into particles. These harder lyophilisates 
required enough space to perform rotational movements in order to fracture in smaller pieces 
for a following scaling off of particles. With respect to FPD, the higher initial MD due to 
higher solution concentration partially compensated for the decrease in FPF so that a 
maximum FPD of 1.2 mg was achieved for valine and 2.6 mg for cromolyn sodium 
lyophilisates. Nevertheless, due to the small FPF, the loss in dose was immense. An increased 
pressure for dispersion of 4 bar resulted only in an increased ED for the highest fill volume of 
2 ml and was not able to further enhance the FPD in the standard 2R vial for cromolyn 
sodium. Taking the required space for rotational movements into account, employing bigger 
6R vials enabled improved cake disintegration. By applying an adapted amount of 
compressed air to the doubled vial volume (30 ml at 4 bar), the increased pressure for 
dispersion enhanced the ED and therefore the FPD to 3.7 mg. Overall, the novel DPI system 
based on dispersion of lyophilisates can keep up with marketed DPI products of higher 
metered dose. 
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Chapter 5 
Optimization of the FPF of a Lyophilized 
Lysozyme Formulation for Dry Powder Inhalation 
Abstract 
Purpose: A new dry powder inhalation technology creates inhalable particles from a coherent 
lyophilized bulk at the time of inhalation. The aim of this study was to evaluate several 
approaches to improve the fine particle output and to understand underlying aerolization 
mechanisms. 
Methods: Lysozyme was chosen as model drug. Phenylalanine and valine were added, and the 
freezing process employed in lyophilization was varied (shelf ramped, with annealing, on 
precooled shelf, in liquid nitrogen, and vacuum induced). For characterization of the 
lyophilisates, x-ray diffractometry, residual moisture analysis, mechanical testing, and 
microscopy was performed. The fine particle fraction (FPF) was measured and the 
aerosolization behavior was recorded with a high speed camera. Furthermore, the particles 
were investigated by scanning electron microscopy. 
Results: The addition of 14 to 40% of the crystalline amino acids phenylalanine and valine to 
the lysozyme solution prior to freeze-drying rendered a dose independent increase of the FPF 
from 5% to 17% and 14%, respectively. This is possibly due to enhanced fracture properties 
of the lyophilisates upon impact of the air stream as well as reduced particle agglomeration 
and cohesion caused by a rougher surface. This positive effect on aerosolization performance 
was well preserved over three months of storage at 40°C/75% RH. The structure of the freeze-
dried product was influenced by the freezing process which in turn affected the aerosolization 
behavior. Freezing by immersion in liquid nitrogen and vacuum-induced freezing performed 
best, doubling the FPF. Despite poor fracture properties, the special cake morphology with 
elongated channels enabled easy disintegration. The resulting large particles comprise a very 
low density and a high porosity, which are advantageous for a high emitted dose and FPF. 
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Conclusion: The variation of the lyophilization process and formulation utilizing excipients 
enabled an optimization of the FPF of the novel lyophilisate based DPI system. 
1 INTRODUCTION 
Since first marketed in 1970, dry powder inhalers (DPIs) have been subject to continuous 
improvement. Device technology developed continuously to overcome the relatively low 
efficiency in fine particle fraction (FPF) and inconsistencies in the emitted dose (ED) of the 
first generation DPIs [1]. Most DPIs are breath-activated passive systems where powder 
aerosolization is achieved by the patient's own inspiration. These devices mostly have the 
disadvantage of inspiratory flow-dependent de-agglomeration of the powder [2]. Some newer 
devices like the Clickhaler® and the Taifun® show an in vivo deposition which is relatively 
independent from the inspiratory effort [3, 4]. Furthermore, active devices were developed 
which enable respiratory force independent dosing precision and reproducible aerosolization 
[5]. These devices are primarily designed for systemic pulmonary delivery and for conditions 
where the inspiratory power of the patient cannot be relied upon [6]. Examples for active 
devices are the Nektar Pulmonary Inhaler for Exubera® or the AspirairTM device, which both 
use compressed air for the powder de-agglomeration and aerosolization process [6, 7]. 
New powder formulation methods are equally important to sophisticated devices. The two 
main formulation methods to enhance powder flowability and dispersibility are carrier 
systems mainly utilizing lactose and controlled agglomeration of pure drug particles, called 
pelletization [8]. The growing interest in pulmonary delivery of therapeutic proteins, nucleic 
acid nanocarriers, and vaccines as dry powder aerosols demands for alternative formulation 
methods to replace the commonly used but problematic micronization of the active 
pharmaceutical ingredient (API). Micronization may generate local hot spots in the processed 
materials and reduces their stability which is particularly a problem for thermolabile 
biopharmaceuticals [9]. A variety of new methods like controlled crystallization, supercritical 
fluid precipitation, spray drying, and spray freeze-drying were recently summarized by Chow 
et al. [9] with regards to the production of more uniform particles in terms of morphological 
state (e.g. crystallinity), particle size distribution, and shape. All these particle engineering 
methods directly produce a powder, which can reduce some challenges of micron-sized 
powder particles such as poor flow behavior and a high tendency to aggregate, but handling 
and precise metering remain difficult. 
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Freeze-drying is a common method for the stabilization of labile bioproducts. The lyophilized 
products are porous cakes in the dimensions of the former fill volume. For the production of 
inhalable particles the lyophilisate can be milled, which adds another manufacturing step and 
additional stress for the API. Alternatively, impacting air can be used for the disintegration of 
a freeze-dried preparation into inhalable particles [10]. Thus, DPI formulation is stored in a 
non-powdered form and the formation of fine particles occurs at the time of inhalation, 
thereby avoiding formulation problems like inadequate flowability and dispersibility of the 
powder. In addition, the manufacturing process is suitable for chemical entities as well as 
labile biopharmaceuticals. Because the formulation is metered as a liquid, extremely high 
accuracy at dose metering and a high preparation yield are further advantages of this 
technology. Nevertheless, freeze-drying is a time consuming and energy intensive 
manufacturing process [11]. A previous study revealed that placebo lyophilisates, 
disintegrated by compressed air in a custom designed test device, show material dependent 
differences in the fine particle output (Chapter 3). This led to the question whether the FPF of 
lyophilisates which exhibit poor dispersing behavior can be enhanced by the addition of 
excipients which demonstrate good aerosolization performance. The freeze-drying process or, 
more specifically, the freezing step is considered as another possible approach to increase fine 
particle output. The freezing process is a key step in lyophilization because it determines the 
ice crystal structure (shape and dimensions) and therefore governs the resulting lyophilisate 
morphology [12, 13]. The morphology of the lyophilisate should impact the dispersibility and 
aerosolization of the freeze-dried cake. Overall, the ice nucleation temperature, the freezing 
rate, as well as the freezing mechanism influence the ice crystal formation [14]. Shelf-ramped 
freezing renders a low ice nucleation temperature and fast ice crystal growth, resulting in a 
high number of small ice crystals. The addition of an annealing step enables a rearrangement 
and secondary ice crystal growth [15]. Freezing on a precooled shelf causes higher nucleation 
temperatures and slower freezing rates from vial bottom to top compared to shelf-ramped 
freezing and leads to a large heterogeneity between vials [16]. Vacuum-induced freezing 
allows controlled ice nucleation at a defined temperature. The ice nucleation starts at the top 
surface, followed by a top-down freezing which results in vertical ice crystals [17]. A very 
fast cooling method is immersion in liquid nitrogen, where freezing occurs by directional 
solidification resulting in small lamellar-oriented pores [18]. 
The aim of this study was to optimize the fine particle output of the model API lysozyme 
which demonstrated a poor emitted dose and fine particle fraction when lyophilized solitarily. 
High molecular weight species such as proteins form soft and elastic sponges after freeze-
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drying, which is utilized, for example, in flexible gelatin-containing wound dresses [19]. For 
the disintegration into small particles by an air impact, these properties could be 
impedimental. Lysozyme was used as a model substance and the intention was to develop a 
pulmonary delivery system for lyophilisted formulations in general. Therefore protein 
stability and activity was not tested specifically. Instead, in a first approach, it was intended to 
achieve an optimized FPF by the addition of excipients. The two amino acids phenylalanine 
and valine performed best as single excipient lyophilisates in a previous study, showing FPF 
related to metered dose (MD) of nearly 50% (Chapter 3). They were therefore chosen as 
potential excipients to enhance the fine particle output of lysozyme. To gain a better 
understanding of the underlying mechanisms of the improvement, lyophilisate characteristics 
as well as aerosolization properties were investigated in addition to fine particle 
measurements. Furthermore, storage stability for three months at 25°C/60% RH and 
40°C/75% RH was evaluated for a selected formulation. In a second approach to increase the 
fine particle output, various freezing methods as part of the lyophilization process of two 
selected formulations were applied. The obtained lyophilisates were investigated with respect 
to their morphology, mechanical properties, and aerosolization performance. 
2 MATERIALS AND METHODS 
2.1 MATERIALS 
The model protein lysozyme from chicken egg white (Lys) was purchased from Serva 
Electrophoresis GmbH (Heidelberg, Germany) as a crystalline powder in hydrochloride form. 
Excipients used were L-phenylalanine (Phe) (Merck KGaA, Darmstadt, Germany) and L-
valine (Val) (Fagron GmbH&Co KG, Barsbüttel, Germany). Solutions were made with highly 
purified water (Purelab Plus, Elga LabWater, Celle, Germany).  
2.2 FORMULATION PREPARATION 
0.5 ml aqueous solutions of 12 mg/ml lysozyme with 2 to 8 mg/ml phenylalanine or valine 
were filled into 2R glass vials (Fiolax® clear, Schott AG, Müllheim, Germany) and vials were 
equipped with rubber stoppers (1079-PH 701/40/ow/wine-red, West Pharmaceutical Services, 
Eschweiler, Germany). Freeze-drying was carried out in a laboratory scale freeze-drier 
(Lyostar II, FTS Systems, Stone Ridge, NY, USA). The samples were frozen at -1°C/min to 
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-45°C for 1 h. Primary drying was performed at a shelf temperature of -15°C (shelfs were 
ramped at +0.2°C/min) and a pressure of 100 mtorr for 20 h. For secondary drying the shelf 
temperature was increased to +30°C at a ramp rate of +0.1°C/min for 6 h. For comparison 
purposes also 4 mg/ml phenylalanine and 12 mg/ml valine solutions were freeze-dried 
similarly. 
Additional four different freezing methods were tested besides the normal shelf ramped 
freezing at -1°C/min: 
- Annealing at -10°C for 10 h: The samples were frozen at -1°C/min to -45°C with a 
hold at -45°C for 1 h, followed by a shelf temperature increase to -10°C at +1°C/min 
and annealing for 10 h at -10°C before the samples were frozen again at -1°C/min to 
-45°C with another hold at -45°C for 1 h. 
- Precooled shelf at -70°C: The samples were placed on a precooled shelf at -70°C for 
1.5 h.  
- In liquid nitrogen: Samples were immersed in liquid nitrogen for 1 min and were 
subsequently placed on a precooled shelf. 
- Vacuum-induced at -3°C: The samples were equilibrated on the shelfs at -3°C for 1 h. 
According to [17] the chamber was evacuated as fast as possible to 600 mtorr to 
induce freezing. Afterwards the shelf temperature was quickly decreased to -45°C for 
1 h. 
2.3 X-RAY DIFFRACTOMETRY (XRD) 
The content of three vials was pooled for investigation with a Seifert X-ray diffractometer 
XRD 3000 TT (Seifert, Ahrensburg, Germany) equipped with a copper anode (40 kV, 30 mA, 
wavelength 154.17 pm). The samples were measured from 5 – 40° 2-Ө at a step rate of 
0.05° 2-Ө with 2 s measuring time per step. 
2.4 DEVICE 
The lyophilized formulations were dispersed into aerosols using a custom-designed device 
(Chapter 2). Briefly, it consists of two capillaries with a diameter of 0.75 mm pierced through 
the stopper of the vial housing the lyophilisate. One capillary is the air inlet, the other 
capillary the air outlet, which is connected to the mouthpiece. Compressed air is stored in a 
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20 ml pressure reservoir at a pressure of 3 bar. Pressing a lever releases the compressed air 
through the inlet capillary, thereby starting dispersion of the powder. 
2.5 FINE PARTICLE FRACTION (FPF) ANALYSIS 
The FPF was measured using a short stack version of the Andersen cascade impactor (ACI) 
(8-Stage Non-Viable Sampler Series 20-800, Thermo Andersen, Smyrna, GA, USA) at a flow 
rate of 39 l/min (corresponds to a pressure drop of 4 kPa with the HandiHaler®, which is 
recommended by USP <601> [20]). Baffle plates were coated with a solution of 83% glycerin 
(AppliChem GmbH, Darmstadt, Germany), 14% ethanol (central supply LMU, Munich, 
Germany) and 3% Brij 35 (Serva Electrophoresis GmbH, Heidelberg, Germany). Filters used 
were type A/E glass fiber filters 76 mm (Pall Corporation, Ann Arbor, MI, USA). By 
removing stages 2 to 7, the whole FPF (particle fraction <4.94 µm) is collected on the filter 
directly below stage 1 and can easily be quantified by weighing the filter before and after 
powder deposition. The herein contained total lysozyme content was calculated by taking the 
varying amount of excipients into account. The FPF was calculated as the percentage of the 
total lysozyme content in the vial. The emitted dose (ED) was measured by weighing the vial 
before and after aerosolization and also calculated as the percentage of the total lysozyme 
content in the vial. The FPF analyses were performed in triplicate and the mean value 
including the standard deviation is presented in the figures. 
2.6 MECHANICAL TESTING 
The mechanical properties of the lyophilisates were investigated using a Texture Analyzer 
(TA.XT.plus, Stable micro Systems, Godalming, United Kingdom) equipped with a 5 kg load 
cell and a cylindrical stainless steel probe with a diameter of 5 mm at a test speed of 1 mm/s 
and a maximal immersion into the lyophilisate of 2 mm. The cylindrical probe acts on the 
lyophilisate by proceeding at constant speed and the force needed for the immersion is 
recorded. The resulting force represents the force necessary for breakage of the lyophilisate. 
At the end of the immersion, the probe touches the bottom of the vial which results in a steep 
increase of the immersion force curve and can therefore be disregarded. Measurements were 
performed in triplicate and averaged. 
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2.7 HIGH SPEED CAMERA RECORDING 
The aerosolization behavior of the lyophilisates in the vial was recorded using a Fastcam 1024 
PCI (Photron, San Diego, CA, USA) with a sample rate of 1000 fps. Dispersion of the 
lyophilisates was performed using the device (2.4) at standard settings (20 ml compressed air 
at 3 bar). 
2.8 MICROSCOPY AND SCANNING ELECTRON MICROSCOPY (SEM) 
The morphology of the lyophilisates was analyzed by digital light microscopy (VHX-500F, 
Keyence Corporation, Osaka, Japan) equipped with a VH-Z20R objective with variable 
lighting.  
The particle morphology of the dispersed fine particles was analyzed with a Jeol Scanning 
Electron Microscope (JSM-6500F, Jeol, Ebersberg, Germany) at 5 kV. Sample preparation 
was performed using a second short stack version of the ACI where stages 3 to 7 have been 
removed. Conductive self-adhesive tape (Ø 12 mm Leit-Tabs, Plano GmbH, Wetzlar, 
Germany) was placed on the coated baffle plate after stage 2. The particles collected on the 
tape therefore have an aerodynamic cut off diameter between 4-4.94 µm at a flow rate of 
39 l/min (Chapter 3). The samples were sputtered with carbon under vacuum. 
2.9 STABILITY TESTING 
For stability testing the sealed lyophilized samples were stored at 25°C and 60% relative 
humidity (RH) above a saturated ammonium nitrate (VWR International, Leuven, Belgium) 
solution or at 40°C and 75% RH above a saturated sodium chloride (Merck KGaA, 
Darmstadt, Germany) solution for three months. Stoppers used were dried before 
lyophilization at 105°C for 4 h.  
The lyophilisates were analyzed for morphological state (2.3), moisture content (2.10), 
mechanical properties (2.6), microscopic morphology (2.8), as well as ED and FPF (2.5). 
2.10 RESIDUAL MOISTURE CONTENT ANALYSIS 
The residual moisture content of lyophilisates was determined by Karl-Fischer titration 
(Metrohm 756 KF Coulometer, Herisau, Switzerland) using Hydranal Coulomat AG (Riedel-
deHaën, Seelze, Germany) as titration reagent. The lyophilisates were dissolved in the vials in 
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1.0 ml of anhydrous methanol (Hydranal-Methanol dry, Riedel-deHaën, Seelze, Germany), 
additionally dried with molecular sieve 3A (VWR International GmbH, Darmstadt, 
Germany). As blanks, empty freeze-dried vials, treated similarly, were used. The injection 
volume was 500 µl each. The measurements were performed in triplicate in order to calculate 
mean values. 
3 RESULTS 
3.1 OPTIMIZATION OF THE FPF BY ADDITION OF EXCIPIENTS 
A custom-designed test device was used for disintegration of the lyophilisates and delivery of 
the fine powder. The resulting FPF of the lysozyme formulations were measured with a short-
stack version of the ACI. Lyophilized lysozyme from 12 mg/ml lysozyme solution showed an 
ED of 37.4% and a small FPF of only 4.8% related to the MD of 6 mg. In order to improve 
the FPF, 2 to 8 mg/ml phenylalanine and valine, which demonstrated good performance in a 
previous study (Chapter 3), were added.  
XRD demonstrated that freeze-dried lysozyme without excipients was completely amorphous. 
Mixtures with the amino acids demonstrated an increase in crystallinity of the formulations 
for concentrations > 4 mg/ml of phenylalanine or > 2 mg/ml of valine (Figure 1). The XRD 
patterns of these lyophilisates showed crystalline reflections of phenylalanine-monohydrate 
and valine, respectively.  
The different lysozyme formulations demonstrate that the addition of phenylalanine or valine 
resulted in a dose-independent increase of the FPF of lysozyme. The ED is plotted against the 
FPF related to ED (left y-axis) in Figure 2. From the contour lines and the right y-axis, it is 
also possible to determine the FPF related to MD from the same plot. The ED was almost 
doubled to around 70% by addition of the excipients. The FPF related to MD was increased 
up to 17.0% by adding 4 mg/ml phenylalanine or elevated up to 14.1% by adding 6 mg/ml 
valine, mainly a consequence of the doubled ED.  
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a 
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Figure 1: XRD patterns of 12 mg/ml lysozyme lyophilisates and the mixtures with 
phenylalanine (a) or valine (b) in the concentration of 2 to 8 mg/ml. 
a b 
  
Figure 2: ED versus its related FPF as well as the FPF related to metered dose of 
lyophilisates of pure lysozyme and lysozyme formulated with 2-8 mg/ml phenylalanine (a) or 
valine (b). 
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To understand underlying mechanisms for the successful FPF optimization, the lyophilisate 
characteristics as well as the aerosolization properties were further investigated. The force 
necessary for breakage of the lyophilisate was tested by immersion of a cylindrical probe. 
Steady fracture at a constant force, resulting in a plateau, was found for pure phenylalanine 
and valine lyophilisates in the concentration of 4 mg/ml and 12 mg/ml (Figure 3) with force 
values of 0.014 N and 0.006 N, respectively. For lysozyme, a continuous increase of the 
immersion-force-curve at a slope of 0.07 N/mm was observed which represents a more elastic 
structure where mainly compression takes place. The immersion-force-curves of the mixtures, 
in contrast, revealed a plateau, indicating steady fracture at 0.08 N in the case of the 
phenylalanine mixture or 0.09 N for the valine mixture, exemplarily shown for the two 
formulations with the best performance. 
 
Figure 3: The texture characterization of lysozyme 12 mg/ml lyophilisates in comparison to 
lysozyme 12 mg/ml + phenylalanine 4 mg/ml, lysozyme 12 mg/ml + valine 6 mg/ml, 
phenylalanine 4 mg/ml and valine 12 mg/ml. 
High speed camera recordings were performed in order to gain insights into the aerosolization 
behavior of the different lyophilisates. For all formulations the disintegration of the 
lyophilisate started by fragmentation into larger subunits (Figure 4). These pieces 
disintegrated further into fine particles which swirled around the endings of the capillaries 
until they left the vial. After aerosolization of pure lysozyme, a substantial amount of particles 
adhered to the capillaries (Figure 4a). If lysozyme was formulated with one of the crystalline 
amino acids, in contrast, adhesion of the dispersed particles to the capillaries and other 
surfaces in the vial was lower, as can be seen from Figure 4b/c. For the lysozyme lyophilisate 
almost all particles, which did not stick to the surfaces, left the vial after about 100 ms. Fine 
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particles of those formulations that included an amino acid in contrast swirled in the vial for a 
longer period of time until about 500 ms. This could be a result of the larger total content in 
the vial. 
a 
 
b 
 
c 
 
Figure 4: High speed camera recordings of lysozyme lyophilisate (a), lysozyme in the 
combination with 4 mg/ml phenylalanine (b) or with 6 mg/ml valine (c). 
The microscopic morphology of the different freeze-dried formulations was inspected with 
the reflected light microscope. The lyophilisates of both pure lysozyme and the mixtures 
showed a porous comb-like structure. Figure 5 demonstrates the pore size for the upper 
surface of the lyophilisates of around 100 µm for pure freeze-dried lysozyme and slightly 
bigger pores of around 150 µm for the formulation with phenylalanine. The pore walls of pure 
lyophilized lysozyme were very thin and translucent. Whereas the pore walls of the mixtures 
appeared whitish and clearly visible. This is exemplarily shown for the phenylalanine mixture 
in Figure 5b.  
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Figure 5: Microscopic morphology of lysozyme lyophilisates: upper surface of pure lysozyme 
(a) in comparison to lysozyme with 4 mg/ml phenylalanine (b). 
In order to determine the geometric size and shape of the dispersed particles released from the 
test device, the particles were investigated with SEM. For comparison of particles with 
identical aerodynamic size, the specimens were collected on the baffle plate after stage 2 of 
the ACI, having an aerodynamic cut off diameter of 4-4.94 µm. At the border of the impacted 
particle spots (Figure 6a/c/e), it was possible to observe particles which were clearly separated 
from each other. These geometric particle sizes of approximately 10-30 µm were comparable 
for the different lysozyme formulations. The fragments of the pure lysozyme lyophilisates 
showed a very smooth surface (Figure 6b), whereas the fragments of the lysozyme 
phenylalanine formulation revealed a rough surface with needle-shaped crystal structures 
embedded (Figure 6d). The fragments of the lysozyme valine formulation demonstrated also a 
rougher surface (Figure 6f). 
a 
 
b 
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Figure 6: SEM of the particles with an aerodynamic cut off diameter between 4 and 4.94 µm 
of lysozyme 12 mg/ml (a, b) and lysozyme 12 mg/ml + phenylalanine 4 mg/ml (c, d) as well as 
lysozyme 12 mg/ml + valine 6 mg/ml (e, f). 
3.2 STORAGE STABILITY OF 12 MG/ML LYSOZYME-4 MG/ML 
PHENYLALANINE-FORMULATION 
Freeze-drying is known to improve the stability of labile drugs [21]. If a freeze-dried 
formulation contains amorphous or partially crystalline modifications which are 
thermodynamically unstable, one always has to consider the possibility of recrystallization 
during storage [13]. Furthermore, the moisture content of a freeze-dried formulation during 
storage may increase due to moisture coming from the vial stopper [22] or insufficient 
integrity of the container adversely influencing physicochemical stability and aerosol 
performance [9]. Consequently, freeze-dried 12 mg/ml lysozyme with 4 mg/ml phenylalanine 
formulation was stored at 25°C/60% RH and 40°C/75% RH up to three months. 
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Figure 7: XRD pattern of 12 mg/ml lysozyme/4 mg/ml phenylalanine lyophilisates before and 
after one and three months of storage. 
 
Figure 8: Mechanical testing of 12 mg/ml lysozyme/4 mg/ml phenylalanine lyophilisates 
before and after one and three month of storage. 
The XRD pattern of the lyophilized lysozyme phenylalanine formulation showed no 
difference between freshly freeze-dried or stored lyophilisates (Figure 7). The crystalline 
reflections of phenylalanine-monohydrate remained at the same peak position and height. 
During storage the moisture increased from 0.3% to 0.8% and 1.9% after one month and to 
1.5% and 2.7% after three month at 25°C/60% RH and 40°C/75% RH, respectively. Samples 
stored at the higher temperature and relative humidity absorbed significantly larger amounts 
of water. The mechanical behavior of the lyophilisates remained stable during storage. The 
position and shape of the immersion-force-curve of the mechanical testing did not change 
(Figure 8). Furthermore, no change in the microscopic morphology was detectable. ACI 
measurements revealed slight but not significant differences in ED as well as FPF of the 
lyophilisates. At t0 samples demonstrated an ED of 57% which slightly increased to 64% 
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during storage. The FPF related to ED amounted to 34% at t0 and varied between 30% and 
34% after one and three months of storage. Thus, stability of the formulation with respect to 
physicochemical properties and aerosol performance over three months at 40°C/75% RH 
could be demonstrated. 
3.3 VARIATION OF THE FPF BY VARIATION OF THE FREEZING METHOD 
The morphology of the solid matrix of a lyophilisate is determined by the freezing process, 
comprising ice nucleation and ice crystal growth [17]. Different freezing methods were 
applied to alter the lyophilisate properties in order to improve ED and FPF. 12 mg/ml 
lysozyme solutions containing 4 mg/ml phenylalanine or 6 mg/ml valine were freeze-dried. 
Besides the normal shelf-ramped freezing at -1°C/min, an additional annealing step at -10°C 
for 10 h, freezing on a precooled shelf at -70°C, freezing by immersion into liquid nitrogen 
and vacuum-induced freezing at -3°C were performed. The crystallinity of the lyophilisates 
was analyzed by XRD. Lysozyme was always present in the amorphous state. All 
lyophilisates in the combination lysozyme and valine showed the characteristic peak pattern 
of crystalline valine with the main peaks at 7.4° and 19.5° 2θ (Figure 9a). Phenylalanine 
exhibited very small peaks, indicating a partial crystallinity in the form of the monohydrate 
for all different frozen lyophilisates (Figure 9b). The partial crystallinity of phenylalanine was 
analyzed in Chapter 3. 
Mechanical testing revealed marked differences of the mechanical properties of lyophilisates 
prepared with different freezing processes, as can be seen in Figure 10. For samples frozen in 
liquid nitrogen, a constant positive slope of the immersion-force-curve was observed. 
Vacuum-induced freezing resulted in a force peak with a maximum at 0.09 N at the beginning 
of the immersion for the lysozyme/phenylalanine lyophilisates, whereas the lysozyme/valine 
lyophilisates required a higher overall force of 0.16 N for fracture. The lysozyme/valine 
lyophilisates frozen on a precooled shelf required also a higher force for breakage of 0.11 N 
compared to the lyophilisates frozen in the conventional shelf-ramped process or additionally 
with annealing, which both demonstrated a force of 0.09 N for breakage. 
Lysozyme/phenylalanine lyophilisates frozen on a precooled shelf as well showed a plateau of 
constant fracture at 0.09 N which was higher than the lyophilisate frozen by shelf-ramping 
(0.08 N) or including annealing (0.07 N). 
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a 
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Figure 9: XRD pattern of 12 mg/ml lysozyme/6 mg/ml valine (a) and 12 mg/ml 
lysozyme/4 mg/ml phenylalanine (b) lyophilisates prepared with different freezing procedures. 
a b 
a  b  
Figure 10: The mechanical testing of 12 mg/ml lysozyme/4 mg/ml phenylalanine (a) or 
12 mg/ml lysozyme/6 mg/ml valine (b) prepared with different freezing procedures. 
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Figure 11: The bottom surface morphology of lyophilisates frozen in liquid nitrogen (a) and 
the upper surface morphology of the vacuum induced frozen lyophilisates (b) of 12 mg/ml 
lysozyme/4 mg/ml phenylalanine. 
Microscopy of lyophilisates frozen via shelf-ramping, with an annealing step, or on a 
precooled shelf showed a similar pore structure.  Differences in the pore sizes, particularly at 
the bottom side, were apparent. For the lysozyme/phenylalanine lyophilisates, for example, 
the pore size at the bottom was around 100 µm for samples frozen via shelf-ramping. 
Annealing caused an increase to about 160 µm, whereas precooled shelf freezing resulted in 
smaller pores of approximately 30 µm. Both samples frozen in liquid nitrogen demonstrated a 
special morphology with lamellar pores oriented in the direction from outside to the center, 
which was clearly visible for the inner and bottom structure of the lyophilisate (Figure 11a). 
The samples obtained by vacuum-induced freezing had a very dense upper surface structure 
with tiny little pores of approximately 30 µm for the formulation with phenylalanine 
(Figure 11b) and 20 µm for the formulation with valine. The bottom of these lyophilisates 
showed small pores of 50-60 µm as well. 
Analysis of the dispersed particles by SEM demonstrated that the fragments of the 
conventionally frozen (at -1°C/min) lysozyme/phenylalanine lyophilisates had a platelet-like 
structure, whereas the samples frozen in liquid nitrogen or by vacuum-induced freezing were 
fluffy and porous. The fine particles with an aerodynamic size between 4 and 4.94 µm 
consisted of agglomerates of smaller fragments and demonstrated different geometric sizes, 
depending on the freezing process: particles from normal freezing were 10-30 µm, the 
particles from vacuum-induced freezing of approx. 80 µm, and the ones frozen in liquid 
nitrogen of approx. 110 µm in size (Figure 12). The aerodynamic diameter (dA) is defined by 
the relationship  
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0
VA χρ
ρdd ≅  (1) 
and is dependent on the size (dV), shape (χ) and mass density of the particle (ρ) for 
ρ0 = 1g/cm3. By disregarding the shape assuming round particles, a particle density can be 
estimated based on the aerodynamic and geometric size. The particle density decreased from 
around 0.05 g/cm3 for the small particles generated from lyophilisates prepared by normal 
freezing to a density of around 0.002 g/cm3 for the large particles generated from lyophilisates 
prepared by liquid nitrogen freezing. 
a 
 
b 
 
c 
 
d 
 
Figure 12: SEM of the particles with an aerodynamic cut off diameter between 4 and 4.94 µm. 
Aerosolized 12 mg/ml lysozyme/4 mg/ml phenylalanine lyophilisates frozen in liquid nitrogen 
(a, b) and frozen vacuum induced (c, d). 
Additional high speed camera recordings revealed a different behavior of the various frozen 
lyophilisates during the disintegration process in the vial. For the lysozyme/phenylalanine 
formulation, for example, the disintegration into particles of the lyophilisates frozen at 
-1°C/min (Figure 4b) and with the annealing step (Figure 13a) was already finished after 
about 25 ms. The disintegration into small particles of samples prepared by precooled shelf 
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Figure 13: High speed camera recordings of 12 mg/ml lysozyme/4 mg/ml phenylalanine 
lyophilisates frozen with annealing (a), on precooled shelf (b), in liquid nitrogen (c) and 
vacuum induced (d). 
freezing lasted about 50 ms (Figure 13b). Lyophilisates from vacuum-induced freezing 
(Figure 13d), in contrast, disintegrated into smaller subunits from which particles were scaled 
off over a longer period of time (more than 100 ms). The lyophilisates frozen in liquid 
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nitrogen disintegrated quickly into voluminous particles, resulting in a complete fill of the vial 
(Figure 13c). The valine formulations showed similar aerosolization behavior. 
a b 
  
Figure 14: The impact of the different freezing processes of lyophilized 12 mg/ml 
lysozyme/4 mg/ml phenylalanine (a) or 12 mg/ml lysozyme/6 mg/ml valine (b) on the ED and 
the FPF related to ED as well as the FPF related to metered dose. 
The described variations of lyophilisate morphology and properties partly resulted in 
differences in the fine particle output, as can be seen from Figure 14. For both, 
lysozyme/phenylalanine and lysozyme/valine formulations annealing did not result in a 
significant difference in ED and FPF compared to regular shelf freezing. The precooled shelf 
method in comparison to shelf-ramped freezing led to a significant increase of the ED from 
63% to 79% and therefore also to an increase of the FPF related to MD from 17% to 30% for 
the phenylalanine formulation. The valine formulation, in contrast, showed no significant 
differences. By freezing in liquid nitrogen, it was possible to significantly enhance the ED and 
the FPF for both formulations. The ED increased to 88% in the case of the phenylalanine 
formulation with an increase in the FPF related to ED from 27% to 44% while the valine 
formulation showed an enhanced ED from 69% to 86% and FPF related to ED from 20% to 
30%. The samples from vacuum-induced freezing also exhibited a significant escalation of the 
FPF for both formulations to 49% and 32% as well as a significant increase of the ED to 80% 
for the phenylalanine formulation. Freezing in liquid nitrogen and vacuum-induced freezing 
resulted for the phenylalanine formulation in a more than twofold elevation of the FPF related 
to MD from 17% to 39%. 
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4 DISCUSSION 
4.1 OPTIMIZATION OF THE FPF BY ADDITION OF EXCIPIENTS 
It was possible to significantly increase the FPF of the lyophilized model API lysozyme by 
addition of the amino acids phenylalanine or valine. These two excipients are not commonly 
used in freeze-drying or dry powder formulation for inhalation but were chosen because of 
their good performance in a previous study exhibiting high FPF related to MD of nearly 50% 
(Chapter 3). In principle, most amino acids crystallize during freeze-drying and are therefore 
suitable as bulking agents [23]. Glycine, for example, is a commonly used bulking agent in 
freeze-dried formulations [24]. Valine crystallizes as well during freeze-drying whereas 
phenylalanine forms a monohydrate and is only present in a partially crystalline state 
(Chapter 3). 
The magnitude of the FPF elevation of 12 mg/ml lyophilized lysozyme was independent of 
the amount of excipient added. A small amount of 2 mg/ml phenylalanine or valine was 
sufficient to double the FPF related to MD from 4.8% to 11.7% and 9.4%, respectively. 
Consequently, the amino acids had a great effect on the lyophilisate properties and 
aerosolization behavior of freeze-dried lysozyme. These lyophilisate properties and 
characteristics are discussed in the following to understand underlying mechanisms. 
As expected, lysozyme was present in the amorphous state in all formulations. Proteins, in 
general, do not crystallize during freezing but form an amorphous solid at the glass transition 
temperature of the freeze concentrate (Tg’) [13]. This purely amorphous glass appeared 
translucent in light microscopy, resulting in a glassy sheen on the lyophilisate surface [25], 
whereas the pore walls appeared whitish in the formulations with an amino acid. As intended, 
valine crystallized during freeze-drying. In contrast, phenylalanine was partly present in the 
amorphous state. Because crystallization is dependent on the presence of other solutes [26], 
the amorphous protein prevented phenylalanine from crystallization at the highest protein to 
amino acid ratio of 6:1. At higher phenylalanine concentrations, the amino acid was only 
partially crystalline as indicated by small crystalline reflections appearing in combination 
with an amorphous halo. This was not only caused by the presence of the amorphous protein 
since pure freeze-dried phenylalanine also exists in a partly amorphous state (Chapter 3). 
During freeze-drying phenylalanine crystallizes in the form of the needle-shaped 
monohydrate which is the stable pseudo-polymorph when crystallization occurs at 
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temperatures below 37°C [27]. The crystalline nature of formulations containing an amino 
acid corresponded to a rough surface of the pore wall fragments in SEM. The distinct striped 
appearance of the needle-shaped phenylalanine-monohydrate crystals coated with a thin layer 
of amorphous material was also reported previously [28]. This surface roughness could 
explain the lower adhesiveness of the particles to the capillaries and the vial surface, as well 
as to each other, because of a smaller effective contact area compared to the planar surface of 
lyophilized lysozyme fragments. The enhanced dispersibility of particles with irregular 
surfaces was also observed for spray-dried particles [8, 29, 30]. Less adhesion to the 
capillaries and vial surface enhanced the ED and consequently the FPF related to MD. A 
longer time period during which particles swirled in the vial until their escape through the 
outlet capillary was noticeable, which could be an effect of a larger total content in the vial or 
of less adhesion resulting in a larger amount of free swirling particles in the vial. 
The rough surface is not the only parameter responsible for the successful increase of the FPF 
by addition of phenylalanine or valine. Mechanical properties of the lyophilisates can be 
examined by texture analysis. The cylindrical probe acts on the lyophilisate by proceeding at a 
constant speed. The resulting force needed for the immersion is constantly measured and 
represents the force necessary for breakage of the lyophilisate. The texture analysis revealed 
that lyophilisates containing phenylalanine or valine, which show steady fracture at a constant 
force, have good aerosolization properties with a high ED and FPF. It is important to note, 
that the force necessary to fracture the lyophilisate was much higher in the lysozyme/amino 
acid combinations (0.08-0.09 N) compared to the pure amino acid (0.006-0.014 N) but did not 
hinder the disintegration of the lyophilisates. Lysozyme, on the other hand, showed a 
continuous positive slope of the immersion-force curve, which points to an elastic structure 
for which mainly compression takes place instead of breakage. Since the lyophilisate needs to 
fracture into fine particles during the dispersion process, one can easily conclude that 
brittleness and fragility of lyophilisates shown by a plateau in the immersion-force curve of 
the mechanical testing and therefore steady fracture at a constant force are beneficial for a 
good dispersibility and a high fine particle output. By the addition of crystalline excipients it 
was possible to improve the fracture properties of lyophilized lysozyme and consequently the 
FPF. 
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4.2 STORAGE STABILITY OF 12 MG/ML LYSOZYME-4 MG/ML 
PHENYLALANINE-FORMULATION 
During storage the aerosolization performance of the lyophilisates may become reduced and 
amorphous material may recrystallize due to moisture uptake. The formulation was stored at 
25°C and 60% RH or 40°C and 75% RH, as recommended by the International Conference on 
Harmonization [31]. The morphological state of the lyophilisate did not change during storage 
of 3 months. Even during storage at 40°C, which is above the transition point of 
phenylalanine in water where the anhydrous form is more stable [27], phenylalanine remained 
a monohydrate. Furthermore, the partly amorphous phenylalanine state was preserved over 
the storage period. The residual moisture of lyophilisates immediately after freeze-drying was 
less than 1%, which is considered optimal for storage stability [21]. The moisture content of 
the freeze-dried formulation increased during storage. The higher the storage temperature, the 
greater was the increase in moisture content, which agrees with other storage stability studies 
[23, 32]. Residual moisture in the stopper is often responsible for the moisture uptake of the 
formulation up to an equilibrium value which is characteristic for the product, amount of 
product, and stopper treatment method, whereby the time to the equilibrium is dependent on 
the temperature [22]. Lyophilisates stored at 25°C did not reach the equilibrium of greater or 
equal to 2.7% within three months. Since water has a plasticizing effect on amorphous 
materials [33], variations in the mechanical characteristics were expected. Nevertheless, the 
mechanical property of the formulation did not change for all storage conditions and time 
periods. Potentially the crystalline component had a stabilizing effect on the mechanical 
behavior of the lyophilisate. The cascade impactor measurements demonstrated that an 
increased moisture content was not detrimental for the aerosolization performance of the 
formulation. 
4.3 VARIATION OF THE FPF BY VARIATION OF THE FREEZING METHOD 
As the manner of ice crystal formation and growth during the freezing process fixes the 
texture and porosity of the final dried product, the degree of supercooling, the freezing rate, 
and the time required for complete solidification directly impact ice crystal morphology [14]. 
In general, freezing methods for which supercooling exceeds 5°C result in a freezing of 
samples by global supercooling, which causes a spherulitic morphology. This was the case for 
lyophilisates prepared with standard shelf-ramped freezing, annealing, and precooled shelf 
freezing. Directional solidification, in contrast, is often seen at very high cooling rates, or 
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when ice nucleation is induced close to the equilibrium freezing point [14]. Lyophilisates 
frozen by directional solidification show lamellar plate morphology [34], which was in this 
study only observed for freezing by immersion in liquid nitrogen. It causes extreme 
temperature gradients along the vial bottom and sides, resulting in directional solidification 
from those surfaces inward [16]. The microscopic morphology of both liquid nitrogen frozen 
formulations showed the characteristic thin pores of lamellar-orientation in the direction from 
outside toward the middle. A supercooling of less than 5°C occurred also for the controlled 
nucleation at -3°C by vacuum-induced freezing. Nevertheless, these formulations were frozen 
by global supercooling, which resulted in spherulitic pore morphology visible on the bottom 
of the lyophilisates (Figure 9a). In addition, observation of the formulations during the 
freezing process showed a sudden change in the appearance of the vial content from a clear 
liquid to an opaque/translucent slush, which is indicative of global supercooling [35]. 
As Table 1 summarizes, the different freezing processes applied resulted not only in a varied 
morphology but also in a variation of cake characteristics and aerosolization performance. For 
both lysozyme formulations (with 4 mg/ml phenylalanine or 6 mg/ml valine), freezing in 
liquid nitrogen and vacuum induced freezing demonstrated the best results for ED and FPF by 
about doubling again the FPF related to metered dose. In the following, differences and 
commonalities of the samples prepared by the different freezing procedures are discussed in 
order to understand underlying mechanisms of the aerosolization performance improvement. 
The physical state of the compounds in a lyophilisate can be influenced by the freezing 
procedure. In addition to enabling rearrangement and growth of ice crystals, annealing or 
thermal treatment of frozen systems is a process which facilitates crystallization of a bulking 
agent such as glycine or mannitol [13]. On the other hand, fast freezing, for example by 
immersion into liquid nitrogen, can prevent solutes from crystallizing. XRD, however, 
showed no differences in the peak height of the different frozen lyophilisates. Thus, no further 
crystallization of phenylalanine occurred during annealing and fast freezing by immersion 
into liquid nitrogen did not prevent valine or phenylalanine from crystallization. 
For the differently frozen lyophilisates, texture analysis revealed a different mechanical 
behavior. Because the physical state remained the same, the differences must be a result of the 
structural properties. Conventional shelf-ramped freezing and annealing resulted, for all 
samples, in an immersion-force curve with a plateau that indicates brittle cake fracture. Both 
samples prepared by precooled shelf freezing demonstrated a steeper slope of the immersion- 
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Table 1: Results overview of the cake characteristics and aerosolization performance of 
lysozyme/phenylalanine or lysozyme/valine lyophilisates prepared with different freezing 
procedures. 
Lyozyme 12 mg/ml + phenylalanine 4 mg/ml 
 
standard 
shelf-ramped annealing 
precooled 
shelf 
liquid 
nitrogen 
vacuum 
induced 
pore structure spherulitic spherulitic spherulitic lamellar spherulitic 
mechanical 
testing 
force plateau 
at 0.08 N 
force plateau 
at 0.07 N 
force plateau 
at 0.09 N 
constant slope 
of 0.06 N/mm 
force peak 
max at 0.09 N 
disintegration 
characteristics 
fast,  
within 25 ms 
fast, 
within 25 ms 
within 50 ms fast into 
voluminous 
particles 
into subunits 
and scaling 
off  
ED 63% 72% 79% 88% 80% 
FPF (ED) 27% 29% 38% 44% 49% 
FPF (MD) 17% 21% 30% 39% 39% 
particle 
morphology 
platelet-like - - fluffy, porous fluffy, porous 
particle size 10-30 µm - - 80 µm 110 µm 
      Lysozyme 12 mg/ml + valine 6 mg/ml 
 
standard 
shelf-ramped annealing 
precooled 
shelf 
liquid 
nitrogen 
vacuum 
induced 
pore structure spherulitic spherulitic spherulitic lamellar spherulitic 
mechanical 
testing 
force plateau 
at 0.09 N 
force plateau 
at 0.09 N 
force plateau 
at 0.11 N 
constant slope 
of 0.03 N/mm 
force plateau 
at 0.16 N 
ED 69% 73% 75% 86% 73% 
FPF (ED) 20% 17% 22% 30% 32% 
FPF (MD) 14% 13% 16% 25% 23% 
 
force-curve until the plateau was reached, suggesting that a higher force was needed to break 
at least the upper half of the cake. Freezing on a precooled shelf can cause an enormous 
temperature gradient throughout the fill volume, which leads to smaller pores at the bottom 
and large pores near the top [14] as observed in this study. Phenylalanine samples from 
vacuum-induced freezing demonstrated a peak at the beginning of the immersion-force-curve, 
indicating that a higher force was needed to break the top part. Compared to the other freezing 
methods, the microscopic picture revealed a very dense upper surface of this sample, which 
therefore can explain the harder and more destruction resistant structure. The reduction of the 
pressure to 600 mtorr for vacuum-induced freezing results in an evaporation of water, which 
lowers the temperature on the surface of the solution and induces ice nucleation [17]. During 
this vaporization process, the solutes concentrate at the surface [12] and thus form a dense 
upper surface layer. Both formulations frozen in liquid nitrogen showed a constant slope of 
the immersion-force-curve without a plateau and thus demonstrated an elastic behavior. These 
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sample characteristics conflict with the above conclusion that brittleness of the lyophilisate 
instead of an elastic behavior is beneficial for a good disintegration and a high fine particle 
output. This demonstrates, however, that there must be several factors influencing the 
aerosolization behavior which more or less can compensate for other characteristics. While a 
brittle structure can improve the disintegration behavior for lyophilisates with a spherulitic 
morphology, it is not essential for good disintegration of samples with a special morphology 
such as the narrow lamellar oriented pores resulting from directional solidification. Possibly, 
the narrow pore structure does not fracture in the same way as the spherulitic pores but 
particles form due to separation and rupture of the lamellae. 
High speed camera recordings demonstrated quick and complete disintegration of 
lyophilisates frozen in liquid nitrogen into voluminous particles. Consequently, the directional 
lamellar pore structure of the cake can easily disaggregate into particles without the need of 
superfine breakup. SEM showed highly porous particle agglomerates with a huge geometric 
size of about 110 µm but an aerodynamic size in the respirable size range. Therefore, these 
porous particles must have a very small density. The harder samples of vacuum-induced or 
precooled shelf freezing disintegrated first into smaller pieces, from which fine particles were 
scaled off continuously. SEM revealed that cakes from vacuum-induced freezing disintegrated 
also into porous particles which had a bigger geometric size of about 80 µm compared to the 
conventionally frozen samples with a geometric particle size of approx. 20 µm. Porous 
particles with a big geometric size and a low density are therefore advantageous for a high ED 
and FPF, which can be most effectively achieved by freezing by immersion in liquid nitrogen 
prior to lyophilization. It has been already demonstrated in literature that porous particles can 
be efficiently aerosolized from standard DPIs, exhibiting elevated respirable fractions. These 
porous particles were produced by spray drying [36]. 
Despite good performance of the sample frozen in liquid nitrogen, one should consider that 
freezing sensitive proteins by immersing the vial in liquid nitrogen can result in increased 
protein aggregation or decreased enzyme activity compared to a slow cooling rate [37]. The 
reason for this is the formation of higher surface areas by quench freezing [35], resulting in 
increased surface denaturation at the ice-water interface. A protection can be achieved by the 
addition of surfactants as cryoprotectants [37]. Furthermore, freezing in liquid nitrogen is not 
appropriate for full-scale GMP production of sterile pharmaceuticals [34]. Vacuum-induced 
freezing, in contrast, can be considered more suitable for production scale. 
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5 SUMMARY AND CONCLUSION 
This study demonstrates two methods for a successful improvement of the FPF of a 
lyophilization-based novel formulation for inhalation. This includes the addition of excipients, 
as well as the variation of the lyophilisate structure by varying the freezing method. It was 
also possible to demonstrate some underlying mechanisms responsible for the improved 
disintegration and aerosolization behavior of the lyophilized formulations. Furthermore, 
storage stability and unchanged aerosolization property of a selected formulation was 
demonstrated.  
In summary, the FPF of lyophilized lysozyme formulations could be enhanced by addition of 
the crystalline excipients phenylalanine or valine. The amount of excipient added was less 
important. The crystalline excipients improved the fracture properties of the lyophilisate and 
enhanced its dispersibility and fine particle output. Additionally, crystals possibly coated with 
a thin layer of amorphous material resulted in a rough surface of the fragments which reduced 
particle aggregation and adhesion to vial and capillary surfaces and therefore enhanced the 
ED.  
Storage at 25°C/60% RH and 40°C/75% RH for three months demonstrated physical stability 
and unchanged aerosolization performance, despite a slight increase in the moisture content. 
Possibly, the crystalline excipients served as mechanical stabilizers. 
Different freezing methods resulted not only in different pore structures of the lyophilisates 
but also in a variation of the mechanical properties as well as in the aerosolization behavior. A 
further improvement of the FPF of lyophilized lysozyme formulated with phenylalanine or 
valine could be achieved by freezing in liquid nitrogen or by vacuum-induced freezing at 
-3°C. Considering the mechanical behavior of these different frozen lyophilisates, it was 
obvious that not only improved fracture properties of the lyophilisates can have an enhancing 
effect on the fine particle output. In addition, a special structure, such as the fine directional 
lamellar pore structure resulting from freezing in liquid nitrogen, could positively affect the 
ED and FPF. This special structure disaggregated quickly and completely into particles having 
good aerodynamic properties without the need of superfine breakup. The resulting fine 
particles had a geometric size of about 110 µm but an aerodynamic size in the respirable size 
range because of a low density and high porosity.  
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In conclusion, the novel formulation for inhalation based on dispersion of lyophilisates 
enabled an improvement of the FPF by different strategies. This included the utilization of 
excipients showing good disintegration properties as well as the variation of the lyophilization 
process. The freezing method, in particular, resulted in a variation of the lyophilisate structure 
and thereby affected its aerosolization properties. 
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Chapter 6 
Effect of Variation of the Lyophilisate Morphology 
on the Fine Particle Fraction 
Abstract 
New inhaler devices as well as innovative dry powder formulations are important areas of 
research in advanced pulmonary drug delivery. A novel dry powder inhalation system based 
on dispersion of lyophilisates is an interesting technology which was proposed recently. 
Produced via freeze-drying, the system offers the possibility to adapt the inhaled powder 
quality by varying the characteristics of the coherent bulk from which the aerosol is produced. 
Lyophilisates of several model compounds including phenylalanine, valine, lactose, trehalose, 
and cromolyn sodium were investigated. Variations of the solid matrix structure of the 
lyophilisate were achieved by changing the freezing procedure as part of the lyophilization 
process and by addition of tertiary butyl alcohol as co-solvent. The applied freezing methods 
enabled to generate different pore structures of the lyophilisates, which again allowed 
variation of the mechanical properties of the lyophilisates. Only strong changes in the solid 
matrix characteristics, such as a lamellar-oriented morphology or a loss of the ordered 
structure by consolidation compared to the conventional spherulitic morphology, caused 
significant changes in the aerosolization performance. Samples comprising a fine lamellar 
pore morphology (by freezing in liquid nitrogen) were beneficial with respect to emitted dose 
(ED) and predominantly also with respect to fine particle fraction. The ED of liquid nitrogen 
frozen valine cakes, for example, increased to 85% and the FPF doubled. Lactose, trehalose, 
and phenylalanine cakes rendered also an increased ED to 78%, 56%, and 72%, respectively. 
This special structure disaggregated quickly and completely into large, highly porous particles 
with good aerodynamic properties, despite of an elastic behavior of the lyophilisate. The 
addition of tertiary butyl alcohol in the range of 5% to 20% as a co-solvent led to large 
needle-shaped ice crystals resulting in an elastic, lamellar structure and in most cases also 
increased ED of larger particles. Cromolyn sodium samples prepared from 5% to 20% TBA 
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solutions exhibited an increased ED of approx. 70% compared to 48% for the water based 
lyophilisate. Overall, this study also revealed a great influence of the material property, when 
comparing the different compounds tested, on the lyophilisate characteristics and the 
aerosolization performance.  
1 INTRODUCTION 
For the successful development of dry powder inhalation products (DPIs), the focus has to be 
on both the inhaler device and on the powder formulation [1, 2]. With regard to novel, 
improved powder formulations, a variety of new particle engineering methods emerged such 
as direct controlled crystallization, spray drying and spray freeze-drying, particle formation 
from liquid dispersed systems as well as supercritical fluid technologies [1]. For DPIs, the 
disadvantage of inspiratory flow-dependent de-agglomeration of the powder [3] of the mainly 
breath-activated passive devices was compensated by the introduction of active inhaler 
devices. These devices use, for example, compressed air (Nektar Pulmonary Inhaler [4] or 
Aspirair [5]), a pressurized gas (Pressurized Aerosol Dry-Powder Device [6]), or a high 
frequency piezoelectric vibrator (MicroDose DPI [7]) for powder deagglomeration and 
aerosolization. The combination of an active device with appropriate formulation technologies 
offers a promising approach to minimize patient to patient variation and improve efficacy 
across the full range of patient groups [5]. Yamashita et al. [8] introduced a new active system 
for disintegration of a freeze-dried product into inhalable particles by impacting air at the time 
of inhalation. The formulation is thereby stored as a coherent bulk, avoiding formulation 
problems like poor flowability and redispersibility of powders. Freeze-drying as a 
manufacturing process entails on the one hand accurate dose metering, high preparation yield, 
and suitability for thermolabile (bio)pharmaceuticals but on the other hand it is energy 
intensive and time consuming [9]. Additionally, it could possess the disadvantage of batch 
nonuniformity according to the stochastic nature of ice crystallization [10]. Freezing fixes the 
ice crystal structure and determines cake appearance by the retention of the solid matrix. 
Therefore, freezing is a very critical step in the freeze-drying process [11]. During the 
disintegration process, the lyophilisate structure is completely destroyed and fragments of the 
former pore walls form agglomerative particles with a new morphology (Chapter 3). If 
changes in the matrix morphology affect the aerosolization process, this characteristic could 
potentially be used for an intentional variation and possibly for an optimization of the fine 
particle output. The impact of several freezing process variations on the matrix morphology is 
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already described in the literature and in Chapter 5. The most prevalent freezing method used 
in the pharmaceutical industry is shelf-ramped freezing [12]. It shows a low ice nucleation 
temperature and fast ice crystal growth resulting in a high number of small spherulitic ice 
crystals. Equilibration of the vials at a lowered shelf temperature or two-step freezing with a 
“supercooling” holding is a modification of the shelf-ramped freezing process to obtain a 
more homogeneous temperature distribution across the total fill volume and thus freezing [11, 
13]. Annealing is a secondary holding step after an initial freezing at a temperature above the 
final freezing temperature and is generally performed to allow for complete crystallization of 
crystalline components [13]. The annealing step enables also a rearrangement and further ice 
crystal growth [14]. For freezing on a precooled shelf, higher nucleation temperatures as well 
as slower freezing rates from vial bottom to top compared to shelf-ramped freezing are 
observed and result in a large heterogeneity between vials [10]. The temperature gradient 
inside the sample leads to smaller pores at the bottom and larger pores near the top [15]. 
Immersion of vials in liquid nitrogen is a very fast cooling method where freezing occurs by 
directional solidification, resulting in small lamellar-oriented pores [16]. Vacuum-induced 
freezing allows controlled ice nucleation at a defined temperature. The ice nucleation starts at 
the top surface, followed by a top-down freezing resulting in vertical ice crystals [11]. Besides 
different freezing processes, the presence of high melting point solvents such as tertiary butyl 
alcohol (TBA) results in solvent crystallization between the ice matrix altering the crystal 
habit of the formed ice [17]. Depending on the TBA concentration, the freezing of the co-
solvent system results in crystals of different size and shape [18]. The aim of this study was to 
evaluate the impact of different lyophilisate morphologies on their aerosolization performance 
and applicability for dry powder inhalation. Therefore, six different freezing methods as part 
of the lyophilization process were applied using solutions of several model substances (valine, 
phenylalanine, lactose, trehalose and cromolyn sodium). The morphology and the mechanical 
properties of the lyophilisates were analyzed. The aerosolization performance was assessed by 
the use of high speed camera recordings, emitted dose (ED), and fine particle fraction (FPF) 
analysis as well as investigation of particle morphology. In a second approach, several 
TBA/water co-solvent systems were evaluated according to their ability to change lyophilisate 
properties and aerosolization performance. In order to possibly explain material related 
differences in lyophilisate characteristics and aerosolization performance of different 
substances, mechanical properties of the pulverized freeze-dried substances were additionally 
evaluated by compaction analysis. 
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2 MATERIALS AND METHODS 
2.1 MATERIALS 
Substances used in this study were L-valine (Val), lactose-monohydrate (Lac), cromolyn 
sodium (CS) (all Fagron GmbH&Co. KG, Barsbüttel, Germany), L-phenylalanine (Phe) 
(Merck KGaA, Darmstadt, Germany) and trehalose (Tre) (Hayashibara Co Ltd, Okayama, 
Japan). Solutions were prepared with highly purified water (Purelab Plus, Elga LabWater, 
Celle, Germany).  
2.2 FORMULATION PREPARATION (AQUEOUS SOLUTIONS) 
1 ml aqueous solutions of 12 mg/ml of valine, lactose, trehalose and cromolyn sodium or 
8 mg/ml of phenylalanine was filled into 2R glass vials (Fiolax® clear, Schott AG, Müllheim, 
Germany) and vials were equipped with rubber stoppers (1079-PH 701/40/ow/wine-red, West 
Pharmaceutical Services, Eschweiler, Germany). Freeze-drying was carried out in a 
laboratory scale freeze-drier (Lyostar II, FTS Systems, Stone Ridge, NY, USA). The samples 
were frozen at -1°C/min to -45°C for 1 h. Primary drying was performed at a shelf 
temperature of -15°C (shelfs were ramped at +0.2°C/min) and a pressure of 100 mtorr for 
30 h. For secondary drying the shelf temperature was increased to +30°C at a ramp rate of 
+0.1°C/min for 10 h. Five additional freezing methods were tested and compared to the 
standard procedure: 
- Shelf-ramped freezing including two holding steps: The samples were frozen at 
-1°C/min to -45°C including 30 min holding steps at 5°C and -5°C. 
- Annealing at -10°C for 10 h: The samples were frozen at -1°C/min to -45°C with a 
hold at -45°C for 1 h, followed by a shelf temperature increase to -10°C at +1°C/min 
and annealing for 10 h at -10°C before the samples were frozen again at -1°C/min to 
-45°C with another hold at -45°C for 1 h. 
- Precooled shelf at -70°C: The samples were placed on a precooled shelf at -70°C for 
1.5 h.  
- Freezing in liquid nitrogen: Samples were immersed in liquid nitrogen for 1 min and 
were subsequently placed on a precooled shelf at -45°C. 
- Vacuum-induced freezing at -3°C: The samples were equilibrated on the shelfs at -3°C 
for 1 h. According to [11] the chamber was evacuated as fast as possible to 600 mtorr 
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to induce freezing. Subsequently, the shelf temperature was decreased to -45°C for 1 h 
at -3.5°C/min. 
2.3 FORMULATION PREPARATION (TBA/WATER CO-SOLVENT SYSTEMS) 
Four different TBA/water co-solvent systems were produced by mixing TBA (Sigma-Aldrich 
Chemie GmbH, Steinheim, Germany) with highly purified water at 5%, 10%, 20% or 
70% w/w TBA. Formulations were prepared by solving cromolyn sodium or valine at 
12 mg/ml or 8 mg/ml trehalose in the different co-solvent systems. In each case 1 ml of the 
formulation was filled into 2R glass vials, equipped with rubber stoppers and freeze-dried 
using shelf-ramped freezing including two holding steps as described above.  
2.4 X-RAY DIFFRACTOMETRY (XRD) 
The lyophilisates were investigated with a Seifert X-ray diffractometer XRD 3000 TT 
(Seifert, Ahrensburg, Germany) equipped with a copper anode (40 kV, 30 mA, wavelength 
154.17 pm). The samples were measured from 5 – 40° 2-Ө at a step rate of 0.05° 2-Ө with 2 s 
measuring time per step. 
2.5 MECHANICAL TESTING OF LYOPHILISATES 
The mechanical properties of the lyophilisates were investigated using a Texture Analyzer 
(TA.XT.plus, Stable micro Systems, Godalming, United Kingdom) equipped with a 5 kg load 
cell and a cylindrical stainless steel probe with a diameter of 5 mm at a test speed of 1 mm/s 
and a maximal immersion into the lyophilisate of 5 mm. 
2.6 DEVICE 
The lyophilized formulations were dispersed into aerosols using a custom-designed inhaler 
(Chapter 2). Briefly, it consists of two capillaries with a diameter of 0.75 mm pierced through 
the stopper of the vial housing the lyophilisate. One capillary is the air inlet, the other 
capillary the air outlet, which is connected to the mouthpiece. Compressed air is stored in a 
20 ml pressure reservoir at a pressure of 3 bar. Pressing a lever releases the compressed air 
through the inlet capillary, thereby starting dispersion of the powder. 
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2.7 FINE PARTICLE FRACTION (FPF) ANALYSIS 
The FPF was measured using a short stack version of the Andersen cascade impactor (ACI) 
(8-Stage Non-Viable Sampler Series 20-800, Thermo Andersen, Smyrna, GA, USA) at a flow 
rate of 39 l/min (corresponds to a pressure drop of 4 kPa with the HandiHaler®). Baffle plates 
were coated with a solution of 83% glycerin (AppliChem GmbH, Darmstadt, Germany), 14% 
ethanol (central supply LMU, Munich, Germany) and 3% Brij 35 (Serva Electrophoresis 
GmbH, Heidelberg, Germany). Filters used were type A/E glass fiber filters 76 mm (Pall 
Corporation, Ann Arbor, MI, USA). By removing stages 2 to 7, the whole FPF (particle 
fraction <4.94 µm) is collected on the filter directly below stage 1 and can easily be quantified 
by weighing the filter before and after powder deposition. The emitted dose (ED) was 
measured by weighing the vial before and after aerosolization and calculated as the 
percentage of the metered dose (MD). The FPF was calculated as the percentage of the ED 
and of the MD. The measurements were performed in triplicate. 
2.8 MICROSCOPY 
The morphology of the lyophilisates was analyzed by digital light microscopy (VHX-500F, 
Keyence Corporation, Osaka, Japan) equipped with a VH-Z20R objective with variable 
lighting.  
The particle morphology of the dispersed fine particles was analyzed with a Jeol Scanning 
Electron Microscope (JSM-6500F, Jeol, Ebersberg, Germany) at 5 kV. Sample preparation 
was performed using a second short stack version of the ACI where stages 3 to 7 have been 
removed. Conductive self-adhesive tape (Ø 12 mm Leit-Tabs, Plano GmbH, Wetzlar, 
Germany) was placed on the coated baffle plate after stage 2. The particles collected on the 
tape therefore have an aerodynamic cut off diameter between 4-4.94 µm at a flow rate of 
39 l/min (Chapter 3). The samples were sputtered with carbon under vacuum. 
2.9 HIGH SPEED CAMERA RECORDING 
The aerosolization behavior of the lyophilisates in the vial was recorded using a Fastcam 1024 
PCI (Photron, San Diego, CA, USA) with a sample rate of 1000 fps. 
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2.10 MECHANICAL PROPERTY TESTING OF FREEZE-DRIED SUBSTANCES VIA 
COMPACTION 
5 ml of higher concentrated aqueous solutions of valine (50 mg/ml), phenylalanine 
(20 mg/ml), lactose (100 mg/ml), trehalose (100 mg/ml), and cromolyn sodium (100 mg/ml) 
were filled into 10R glass vials (Fiolax® clear, Schott AG, Müllheim, Germany) equipped 
with rubber stoppers (1319 PH 4023/50, gray, 20 mm, West Pharmaceutical Services, 
Eschweiler, Germany) and freeze-dried. The samples were frozen at -1°C/min to -45°C for 
2.5 h. Primary drying was performed at a shelf temperature of -18°C (shelfs were ramped at 
+0.1°C/min) and a pressure of 100 mtorr for 50 h. For secondary drying the shelf temperature 
was increased to +30°C at a ramp rate of +0.1°C/min for 10 h. 
The mechanical properties of the freeze-dried solid substances were analyzed with a 
compaction simulator (Flexitab®, Röltgen GmbH & Co. KG, Solingen, Germany) at a 
compression pressure of approx. 18 kN. The lyophilisates were scraped out of the vials and 
150-300 mg powder was filled into a 10 mm cylindrical biplane die while the lower indenter 
was positioned at -8.5 mm. To facilitate compaction of freeze-dried lactose and trehalose, the 
die was lubricated with oleic acid. During compression, compact heights and compression 
loads were measured. These recorded data of the compaction process and the measured true 
density (see below) were used to generate an “in die” Heckel plot for which the relative 
porosity (Drel) was plotted against the applied pressure (P). The Heckel parameters were 
determined by regression analysis of the terminal linear part of the compression phase of the 
Heckel plot. The slope of the linear regression is the Heckel constant (k) and A the intercept 
according to: 
ln �
1
1 − 𝐷𝑟𝑟𝑟
� = 𝑘 ∗ 𝑃 + 𝐴 
The mean yield pressure is inversely proportional to the slope and renders the material’s 
resistance to deformation. The elastic recovery is calculated as the compact height during 
decompression related to the minimum compact height in percent. Relaxation is the increase 
of compact height in percent after the maximum pressure was reached. Six compaction 
analyses were performed for each substance. 
The true density of the powder was assumed to be equal to the density after compaction at 
approx. 50 kN, calculation using the dimensions at maximum pressure and the weight of the 
compact. Measurements were performed in triplicate. 
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3 RESULTS 
3.1 VARIATION OF THE FREEZING PROCESS 
The freezing step is a key element in lyophilization [19] because the cake structure is 
controlled by the retention of the solid matrix structure formed by freezing [11]. A variation of 
the freezing process and thereby a variation of the ice crystal shape and dimensions 
determines size and morphology of the resulting pores. In this study different freezing 
methods were applied to solutions of the amino acids phenylalanine and valine, the sugars 
lactose and trehalose, as well as the model drug cromolyn sodium to evaluate influences of 
the freezing process on characteristics and ultimately the aerosolization behavior of these 
lyophilisates. Besides the conventional shelf-ramped freezing at -1°C/min, the following five 
additional freezing methods were selected: The addition of two holding steps at 5°C and -5°C 
(to ensure a better equilibration of the solution temperature), the addition of an annealing step 
at -10°C for 10 h, freezing on a precooled shelf at -70°C, freezing by immersion into liquid 
nitrogen, and vacuum-induced freezing at -3°C. An overview of the results is provided in 
Table 1. 
At first, the physical state of the lyophilisates was characterized by XRD. Independent of the 
freezing process, the amino acid lyophilisates showed the crystalline peak pattern of valine 
and phenylalanine monohydrate, respectively. Valine demonstrated the characteristic main 
peaks at 7.45°, 14.75°, 22.2°, and 29.7° 2θ. The characteristic peaks of phenylalanine-
monohydrate were located at 6.55, 14.85, 21.5, and 26.35° 2-θ. Freeze-dried lactose, 
trehalose, and cromolyn sodium were in all cases present in the amorphous state. 
3.1.1 Microscopic appearance 
For the normal shelf-ramped freezing at -1°C/min, microscopy revealed a sponge-like matrix 
with spherulitic pores at the top of the cake and the pore size between 70 and 170 µm 
depending on the substance. Valine and cromolyn sodium exhibited the smallest and 
phenylalanine the biggest pore diameters. The valine lyophilisate demonstrated a whitish 
crystalline skin on the top where crystals were partly arranged in rosettes. In comparison to 
the top, pores at the bottom of the cake were smaller with pore diameters of 30 to 40 µm 
except for the phenylalanine lyophilisate, which demonstrated both small pores and areas with 
pores of approximately 90 µm. Freezing with annealing caused a complete loss of the ordered 
spherulitic pore structure for lactose (Figure 1a) and trehalose lyophilisates with a translucent  
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Table 1: Tabular overview of the freezing process variation results 
 -1°C/min -1°C/min 
with hold 
annealing precooled 
shelf 
liquid 
nitrogen 
vacuum 
induced 
Valine 
Physical state crystalline crystalline crystalline crystalline crystalline crystalline 
Lyophilisate 
morphology 
spherulitic spherulitic - spherulitic lamellar spherulitic 
Pore size 
[µm] 
top: 65 
bottom: 40 
- - top: 70 
bottom: 55 
-  
bottom: 60 
Particle 
morphology 
porous 
agglomerates 
- porous 
agglomerates 
- porous 
agglomerates 
- 
Particle size 61 µm - 42 µm - 80 µm - 
Mechanical 
testing 
plateau at 
0.004 N 
plateau at 
0.003 N 
- plateau at 
0.003 N 
slope of 
0.001 N/mm 
plateau at 
0.006 N 
Disintegration 
characteristics 
fast and 
complete 
fast and 
complete 
- fast and 
complete 
fast and 
complete 
fast and 
complete 
ED 73% 77% 50% 71% 85% 67% 
FPF (ED) 8% 9% 9% 9% 19% 10% 
FPF (MD) 6% 7% 5% 6% 16% 7% 
Lactose 
Physical state amorphous amorphous amorphous amorphous amorphous amorphous 
Lyophilisate 
morphology 
spherulitic spherulitic consolidated spherulitic lamellar spherulitic 
Pore size 
[µm] 
top: 80 
bottom: 40 
- top: 100 top: 104 
bottom: 35 
- - 
Particle 
morphology 
porous 
agglomerates 
- Different 
shaped 
fragments 
- porous 
agglomerates 
- 
Particle size 35 µm - 8 µm - 82 µm - 
Mechanical 
testing 
peak of max. 
0.089 N 
peak of max. 
0.088 N 
plateau at 
0.006 N 
peak of max. 
0.105 N 
slope of 
0.035 N/mm 
plateau at 
0.025 N 
Disintegration 
characteristics 
separation 
into subunits 
and scaling 
off1 
separation 
into subunits 
and scaling 
off1 
fast and 
complete 
(finished 
after 100 ms) 
separation 
into subunits 
and scaling 
off 
fast and 
complete 
fast and 
complete 
ED 46% 46% 18% 40% 78% 46% 
FPF (ED) 32% 34% 14% 31% 34% 26% 
FPF (MD) 15% 16% 2% 12% 27% 12% 
Trehalose 
Physical state amorphous amorphous amorphous amorphous amorphous amorphous 
Lyophilisate 
morphology 
spherulitic spherulitic consolidated spherulitic lamellar spherulitic 
Pore size 
[µm] 
top: 110 
bottom: 30 
- top: 140 top: 90 
bottom: 25 
- - 
Particle 
morphology 
- - - - - - 
Particle size - - - - - - 
Mechanical 
testing 
peak of max. 
0.113 N 
peak of max. 
0.088 N 
plateau at 
0.006 N 
peak of max. 
0.118 N 
slope of 
0.041 N/mm 
plateau at 
0.025 N 
Disintegration 
characteristics 
separation 
into subunits 
and scaling 
off1 
separation 
into subunits 
and scaling 
off1 
fast and 
complete 
(finished 
after 100 ms) 
separation 
into subunits 
and scaling 
off 
fast and 
complete 
fast and 
complete 
ED 41% 44% 13% 26% 56% 44% 
FPF (ED) 38% 33% 19% 44% 41% 34% 
FPF (MD) 16% 14% 2% 10% 23% 15% 
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 -1°C/min -1°C/min 
with hold 
annealing precooled 
shelf 
liquid 
nitrogen 
vacuum 
induced 
Phenylalanine 
Physical state crystalline crystalline crystalline crystalline crystalline crystalline 
Lyophilisate 
morphology 
spherulitic spherulitic spherulitic spherulitic lamellar spherulitic 
Pore size 
[µm] 
top: 170 
bottom: 30-
40 / 90 
- top: 170 
bottom: 110 
top: 130 
bottom: 35 
- top: 4 
bottom: 100 
Particle 
morphology 
porous 
agglomerates 
- porous 
agglomerates 
porous 
agglomerates 
porous 
agglomerates 
porous 
agglomerates 
Particle size 70 µm - 74 µm 68 µm 109 µm 91 µm 
Mechanical 
testing 
plateau at 
0.067 N 
plateau at 
0.060 N 
plateau at 
0.079 N 
plateau at 
0.062 N 
slope of 
0.005 N/mm 
peak of max. 
0.108 N 
Disintegration 
characteristics 
separation 
into subunits 
and scaling 
off1 
separation 
into subunits 
and scaling 
off1 
separation 
into subunits 
and scaling 
off1 
separation 
into subunits 
and scaling 
off 
fast and 
complete 
separation 
into subunits 
and scaling 
off1 
ED 49% 43% 38% 63% 72% 68% 
FPF (ED) 57% 59% 61% 45% 42% 55% 
FPF (MD) 27% 25% 23% 29% 30% 36% 
Cromolyn sodium 
Physical state amorphous amorphous amorphous amorphous amorphous amorphous 
Lyophilisate 
morphology 
spherulitic spherulitic spherulitic lamellar 
(bottom to 
top) 
lamellar 
(outside to 
middle) 
spherulitic 
Pore size 
[µm] 
top: 80 
bottom: 30 
- top: 50 
bottom: 30 
top:  lamellar 
bottom: 14 
- top: 15 
bottom: 90 
Particle 
morphology 
porous 
agglomerates 
- porous 
agglomerates 
porous 
agglomerates 
porous 
agglomerates 
porous 
agglomerates 
Particle size 44 µm - 40 µm 75 µm 123 µm 58 µm 
Mechanical 
testing 
plateau at 
0.135 N 
plateau at 
0.153 N 
plateau at 
0.121 N 
slope of 
0.062 N and 
0.017 N 
slope of 
0.070 N 
peak of max. 
0.124 N 
Disintegration 
characteristics 
separation 
into subunits 
and scaling 
off1 
separation 
into subunits 
and scaling 
off1 
separation 
into subunits 
and scaling 
off1 
fast and 
complete 
fast and 
complete 
separation 
into subunits 
and scaling 
off1 
ED 67% 48% 37% 64% 68% 50% 
FPF (ED) 28% 44% 45% 38% 18% 42% 
FPF (MD) 19% 21% 16% 24% 12% 21% 
1incomplete disintegration 
skin on top of the cake. The structure of the valine lyophilisates could not be evaluated due to 
destruction during the ventilation process in the freeze-drier. For phenylalanine lyophilisates, 
the annealing process had no effect on the morphology except that the upper surface skin 
appeared thicker. Cromolyn sodium lyophilisates revealed a more homogenous pore size 
distribution after the annealing step (Figure 1b), with a mean pore diameter of 30 µm. After 
freezing on a -70°C precooled shelf most lyophilisates showed small spherulitic pores of 25-
35 µm at the bottom and bigger pores of 73-100 µm near the top of the cake. The top layer of 
valine lyophilisates was again composed of crystal rosettes, whereas phenylalanine 
lyophilisates showed needle shaped furrows and the sugars lactose and trehalose showed  
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Figure 1: Microscopic appearance of lyophilisates: bottom of 12 mg/ml lactose frozen with 
annealing (a), bottom of 12 mg/ml cromolyn sodium frozen with annealing (b), cross section 
of 12 mg/ml cromolyn sodium frozen on a precooled shelf (c), cross section of 8 mg/ml 
phenylalanine frozen in liquid nitrogen (d), cromolyn sodium 12 mg/ml frozen vacuum 
induced (e) and lactose 12 mg/ml frozen vacuum induced (f).  
rectangular pores on top of the cake. A cross sectional cut of cromolyn sodium lyophilisates 
demonstrated lamellar pores in the direction from bottom to top (Figure 1c) and also the upper 
surface showed a lamellar pore morphology, whereas the bottom of the cakes exhibited very 
small pores of around 14 µm. For all samples freezing by immersion into liquid nitrogen 
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resulted in a fine lamellar morphology in the direction from outside to inside. The cross 
sectional cut (exemplarily shown for phenylalanine in Figure 1d) showed directed narrow 
pores reaching from the walls of the vials towards the middle and finally upwards. Besides 
fine disruptions in lactose and trehalose lyophilisates, liquid nitrogen frozen cromolyn sodium 
cakes exhibited distinctive cracks directing from outside to the middle. Vacuum-induced 
freezing at -3°C resulted in a dense upper layer with small pores for cromolyn sodium 
(15 µm), phenylalanine (4 µm), and valine lyophilisates (not distinguishable). Lactose and 
trehalose lyophilisates demonstrated upward pointing villi on top of the cake and irregularly 
shaped oblong pores at the bottom. The inner pore structure of all lyophilisates is composed 
of spherulitic pores.  
3.1.2 Mechanical characterization of the lyophilisates by indentation 
In order to characterize the mechanical properties of the lyophilisates, texture analyzer 
measurements were performed. The cylindrical probe acts on the lyophilisate by proceeding at 
a constant speed. The resulting force needed for the immersion into the cake and therefore the 
force necessary for its breakage is recorded. For the normal shelf-ramped freezing process 
(Figure 2a), steady fracture of the lyophilisate at a constant force resulting in a plateau was 
found for valine, phenylalanine, and cromolyn sodium lyophilisates at 0.004 N, 0.067 N, and 
0.135 N, respectively. For lactose and trehalose cakes, the immersion-force-curve rose until 
1.7 mm immersion to 0.09 N and 0.11 N, followed by a decreasing force for the next 1 mm of 
immersion, thus demonstrating nonuniform fracture properties. Shelf-ramped freezing with 
two holding steps did not change the mechanical properties of all lyophilisates compared to 
the common shelf-ramped process apart from slightly different force values (Figure 2b). The 
annealing step (Figure 2c) caused a dramatic decrease of the force necessary to fracture 
lactose and trehalose cakes and a modification to steady fracture at 0.006 N. Valine 
lyophilisates were not measurable because of the destruction of the cake mentioned above. 
The mechanical properties of phenylalanine and cromolyn sodium lyophilisates were not 
substantially changed compared to the conventional shelf-ramped freezing. Precooled shelf 
freezing (Figure 2d) resulted in a variation of the mechanical properties only for cromolyn 
sodium lyophilisates. Instead of a plateau the force required for immersion into the 
lyophilisate showed a continuous incline, indicating an elastic behavior where mainly 
compression takes place. Similarly, all liquid nitrogen frozen lyophilisates (Figure 2e) 
demonstrated an immersion-force-curve with an almost constant increase as a result of an 
elastic structure.  Thereby, the slope of the curve differed for different freeze-dried substances  
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a b 
c  d
e  f 
a a  
Figure 2: Mechanical testing of lyophilisates prepared with different freezing methods: shelf-
ramped freezing (a), shelf-ramped freezing including two holding steps (b), shelf-ramped 
freezing including an annealing step (c), freezing on a precooled shelf (d), freezing in liquid 
nitrogen (e) and vacuum induced freezing (f). 
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as follows: 12 mg/ml valine lyophilisates 0.001 N/mm, 8 mg/ml phenylalanine lyophilisates 
0.005 N/mm, 12 mg/ml lactose lyophilisates 0.035 N/mm, 12 mg/ml trehalose lyophilisates 
0.041 N/mm, and 12 mg/ml cromolyn sodium lyophilisates 0.070 N/mm. After immersion of 
the probe an elastic relaxation of the compressed cakes occurred, which confirmed the elastic 
behavior. Vacuum-induced freezing showed again steady fracture at a constant force at 
0.025 N, 0.025 N, and 0.006 N for lactose, trehalose and valine lyophilisates, respectively. For 
phenylalanine and cromolyn sodium lyophilisates, the required force for fracture increased at 
the beginning to 0.108 N and 0.124 N, followed by a decreasing force, demonstrating a harder 
top layer of the lyophilisate. 
3.1.3 Aerosolization characteristics 
The aerosolization of the lyophilisates into inhalable particles was achieved by a custom 
designed inhaler which uses compressed air for dispersion (see Chapter 2 for details). To 
analyze the impact of the freezing process on the aerosolization properties several 
characterization methods were applied. For visualization of the disintegration behavior of the 
lyophilisate in the vial, high speed camera recordings were performed. Figure 3 exemplarily 
shows the impact of the freezing process on the disintegration behavior of 12 mg/ml lactose 
lyophilisates. The cakes prepared by conventional shelf-ramped freezing were separated by 
the impacting and swirling air jet into two to three subunits, followed by a scaling off of fine 
particles (Figure 3a). This was the case for all lyophilisates prepared by conventional shelf-
ramped freezing except for valine cakes, which showed fast and complete disintegration. 
After disintegration, particles swirled in the vial until their escape through the outlet capillary. 
At the end, a larger lyophilisate piece was not disintegrated completely and remained in the 
vial, except for valine cakes. The disintegration process for lyophilisates frozen via shelf-
ramping including holding steps were comparable to the normal shelf ramped freezing for all 
substances (Figure 3b). Annealing revealed a disintegration behavior similar to normal 
freezing for phenylalanine and cromolyn sodium. Lactose and trehalose experienced a very 
fast and complete disintegration whereby almost all particles had left the vial already after 
100 ms (Figure 3c). Valine lyophilisates were not taken into account due to the fact that the 
cake was already fragmented after the ventilation process in the freeze-drier. Precooled shelf 
freezing caused a fast and complete disintegration for cromolyn sodium lyophilisates. For all 
other substances the disintegration behavior was similar to the normal shelf-ramped freezing 
but with an always complete disintegration (Figure 3d). For all substances freezing in liquid 
nitrogen delivered cakes which showed very fast and complete disintegration into fibrous and 
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voluminous particles (Figure 3e). These particles partly collected in the top region of the vial 
before reentering the swirling air stream and finally escaping through the outlet capillary. 
Vacuum-induced freezing resulted in a fast and complete disintegration for valine, lactose, 
and trehalose lyophilisates (Figure 3f). A disintegration behavior similar to the conventional 
freezing process was demonstrated for phenylalanine and cromolyn sodium lyophilisates, 
whereby the cromolyn sodium lyophilisate disintegrated into more voluminous particles 
compared to cakes which had been conventionally frozen. 
a 
 
b 
 
c 
 
d 
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Figure 3: High speed camera recordings of lactose lyophilisates prepared with shelf-ramped 
freezing (a), shelf-ramped freezing including two holding steps (b), shelf-ramped freezing 
including an annealing step (c), freezing on a precooled shelf (d), freezing in liquid nitrogen 
(e) and vacuum induced freezing (f). 
3.1.4 Aerosolization performance 
Short stack ACI measurements were performed to evaluate the differently frozen lyophilisates 
with respect to ED and FPF. Figure 4 shows the ED-FPF-plots of the five substances prepared 
with different freezing processes. The ED is thereby plotted against the FPF related to ED 
(right y-axis). From the contour lines and the left y-axis, it is also possible to determine the 
FPF related to MD from the same plot. For valine, lactose, and trehalose lyophilisates 
freezing with holding steps, precooled shelf freezing, and vacuum-induced freezing had no 
significant influence on ED and FPF when compared to the conventional shelf-ramped 
freezing. The annealing step caused a reduction of the ED from 73% to 50% for valine 
lyophilisates and a decreased ED and FPF for lactose and trehalose cakes, resulting in a 
reduction of the FPF related to MD from about 15% to only 2%. Freezing in liquid nitrogen 
resulted in an increased ED for valine, lactose, and trehalose lyophilisates to 85%, 78%, and 
56%, respectively. Additionally, the valine cakes exhibited a twofold elevation of the FPF 
related to ED. With respect to FPF related to ED, the various phenylalanine and cromolyn 
sodium  lyophilisates  showed  a  different  outcome  than  valine,  lactose,  and  trehalose  
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c  d
e  a
a     
Figure 4: ED versus its related FPF as well as the FPF related to MD of 12 mg/ml valine (a), 
12 mg/ml lactose (b), 12 mg/ml trehalose (c), 8 mg/ml phenylalanine (d) and 12 mg/ml 
cromolyn sodium lyophilisates (e) prepared with different freezing procedures. 
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lyophilisates. Phenylalanine lyophilisates showed a significant increase in the ED for the 
liquid nitrogen frozen lyophilisates from 49% to 72% but a decrease in FPF related to ED 
from 57% to 42%. Compared to the conventional shelf-ramped freezing method all other 
freezing processes had no significant influence on the ED. However, freezing with an 
annealing step rendered a change towards a smaller ED (38%). The cromolyn sodium 
lyophilisate frozen via shelf-ramping revealed a relatively high ED of 67% which could not 
be increased by changing the freezing process. Nevertheless, freezing in liquid nitrogen and 
precooled shelf freezing resulted in about the same ED but showed a reduction in FPF related 
to ED from 28% to 18% for liquid nitrogen freezing, whereas precooled shelf freezing 
exhibited a higher FPF related to ED of 38%. The cakes prepared with an annealing step 
demonstrated again a significant decrease in the ED to 37% but an increased FPF related to 
ED of 45%. 
3.1.5 Particle characteristics 
In order to analyze and compare the geometric particle sizes as well as the structural 
properties of the aerosolized particles they were investigated with SEM. For comparison of 
particles with identical aerodynamic size, the specimens were collected on the baffle plate 
after stage 2 of the ACI, which has an aerodynamic cut off diameter of 4 to 4.94 µm at a flow 
rate of 39 l/min. At the border of the impacted particle spots it was possible to observe 
particles which were clearly separated from each other. These isolated particles were used for 
comparison of geometric particle sizes and morphological properties. The particles were 
composed of agglomerates of smaller fragments. Particles generated from valine, lactose, and 
trehalose lyophilisates showed altered particle morphologies for those samples that 
demonstrated a different ED in comparison to shelf-ramped freezing. Exemplarily for lactose 
samples, Figure 5 shows an increasing geometric particle size with increasing ED in the 
following order: lyophilisates frozen with annealing (8 µm), frozen via shelf-ramping 
(35 µm), and frozen in liquid nitrogen (82 µm). Of particular note is thereby an increasing 
porosity combined with decreasing wall thickness of the fragments. The annealing step caused 
a wall thickness of approximately 1 µm, whereas freezing at -1°C/min resulted in 
approximately 0.6 µm and was again reduced to approx. 0.4 µm for freezing in liquid 
nitrogen. Variations in the particle morphologies were less pronounced for phenylalanine and 
cromolyn sodium lyophilisates. For phenylalanine lyophilisates, freezing in liquid nitrogen 
caused particle agglomerates of bigger geometric size and of higher porosity with more 
filigree structures, whereas the annealing step had no influence on the particle morphology. 
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For cromolyn sodium samples, precooled shelf freezing resulted in bigger geometric particle 
sizes compared to normal shelf-ramped freezing but similar structural properties, whereas 
freezing in liquid nitrogen led to even bigger particle sizes with a more porous particle 
morphology. 
a 
 
b 
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d 
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f 
 
Figure 5: SEM structure of particles with an aerodynamic cut off diameter between 4 and 
4.94 µm. Aerosolized 12 mg/ml lactose lyophilisates frozen with annealing (a/b), via shelf-
ramping (c/d) or in liquid nitrogen (e/f). 
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3.2 CHANGING THE ICE CRYSTAL HABITUS USING TBA AS CO-SOLVENT 
The great majority of lyophilized products are freeze-dried from aqueous solutions. The 
presence of an organic co-solvent has been shown to affect the freezing characteristics of the 
solution and to subsequently influence the drying rate and physical appearance of the freeze-
dried product [20]. For the purpose of freeze-drying, the most favored co-solvent is TBA 
because it possesses miscibility with water, a high vapor pressure, freezes completely in most 
commercial freeze-dryers, can increase sublimation rates, and has low toxicity [17]. The size 
and shape of the ice crystals has been found to vary dependent on the concentration of the co-
solvent [18]. In order to alter the lyophilisate morphology and evaluate the effect on 
characteristics and aerosolization behavior, 12 mg/ml solutions of cromolyn sodium and 
valine as well as 8 mg/ml solutions of trehalose with 5%, 10%, 20%, and 70% (w/w) TBA as 
co-solvent were prepared and freeze-dried. None of the substances was soluble in the 70% 
TBA/water co-solvent system, only cromolyn sodium formed a milky crystal suspension after 
ultrasonic treatment and was freeze-dried.  
The morphology of the freeze-dried products was microscopically examined and is 
exemplarily presented for cromolyn sodium samples in Figure 6. In contrast to the aqueous 
lyophilisate with its spherulitic pore morphology (Figure 6a), the sample with 5% TBA 
showed large dendritic pore structures (Figure 6b). Samples with 10% and 20% TBA revealed 
long needle-shaped pores arranged in parallel, as can be seen from Figure 6c/d. A totally 
different appearance was found for the freeze-dried 70% TBA cromolyn sodium crystal 
suspension (Figure 6e/f). The top of the cake showed a coralline morphology composed of 
small spherulitic pores of approximately 25 µm in diameter which homogeneously distributed 
over the whole cake. 
The mechanical properties of the lyophilisates obtained from TBA mixtures were 
characterized using the force necessary for a probe to penetrate into the cake. As already 
reported above, the aqueous cromolyn sodium, valine, and trehalose lyophilisates 
demonstrated steady fracture at a constant force resulting in a plateau at 0.153 N, 0.003 N, 
and 0.013 N, respectively. Samples obtained from 5%, 10%, or 20% TBA containing 
solutions, in contrast, showed an immersion-force-curve with a constant gradient, indicating 
an elastic structure as can be seen for cromolyn sodium lyophilisates in Figure 7. The slope of 
the curves increased with increasing TBA content from 0.020 to 0.071 N/mm. The 70% TBA 
sample in turn exhibited again steady fracture at a smaller force of 0.005 N. The 12 mg/ml 
valine and 8 mg/ml trehalose lyophilisates freeze-dried from a TBA/water co-solvent system  
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Figure 6: Microscopic appearance of freeze-dried TBA/water co-solvent systems. 12 mg/ml 
cromolyn sodium lyophilisates freeze-dried from aqueous solution (a), from the co-solvent 
system containing 5% TBA (b), 10% TBA (c), 20% (d) TBA or 70% TBA: top of the cake (e) 
and bottom of the cake (f). 
demonstrated very soft properties which were below the texture analyzer’s detection limit of 
0.001 N. When doubling the solution concentration of valine to 24 mg/ml, the lyophilisates of 
the TBA/water co-solvent systems demonstrated also an immersion-force-curve with a 
constant gradient between 0.005 and 0.008 N/mm. 
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Figure 7: Mechanical testing of the different TBA/water co-solvent systems of 12 mg/ml 
cromolyn sodium lyophilisates 
The effect of the varied lyophilisate morphology on the aerosolization behavior was evaluated 
based on changes in the ED and FPF of these samples. As can be seen from Figure 8a, 
cromolyn sodium samples prepared with 5%, 10%, and 20% TBA resulted in an increase of 
the ED from 48% to approximately 70% but simultaneously in a strong decrease of the FPF 
related to ED from 44% to approximately 15%. The 70% TBA sample, in contrast, showed a 
decreased ED of 28% and a similar FPF related to ED compared to the aqueous sample. 
Overall, the resulting FPF related to MD of only 10% was the same for all cromolyn sodium 
TBA samples. For valine freeze-dried from different TBA/water co-solvent systems, 
Figure 8b demonstrates a slight increase in ED from 76% to nearly 90%, whereas the FPF 
related to ED remains consistent between 8% and 13%. In contrast, trehalose lyophilisates 
from 5%, 10% and 20% TBA/water systems on the one hand showed a decreased ED from 
49% to 37%, 32%, and 15%, respectively. On the other hand the FPF related to ED increased 
from 25% to around 36% (Figure 8c). 
Aerosolized particles with an aerodynamic cut off diameter between 4 and 4.94 µm were 
investigated with SEM to analyze and compare the geometric particle size and structural 
properties. Cromolyn sodium lyophilisates from the 20% TBA/water co-solvent system 
(Figure 9c) demonstrated a bigger geometric particle size of approximately 100 µm compared 
to the aqueous lyophilisates (52 µm) (Figure 9a). The morphology changed from a smooth 
platelet like structure (Figure 9b) to a wrinkled structure (Figure 9d). For valine lyophilisates 
the particle size of the 20% TBA sample compared to the aqueous sample remained about the 
same of around 94 µm while the particle morphology changed from a very filigree structure  
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Figure 8: ED versus its related FPF as well as the FPF related to MD of 12 mg/ml cromolyn 
sodium lyophilisates (a), 12 mg/ml valine lyophilisates (b) and 8 mg/ml trehalose (c) 
lyophilisates freeze-dried from different TBA/water co-solvent systems. 
into a more leafy structure. The particle morphology of trehalose samples could not be 
evaluated since the particles smoothened and coalesced upon contact with environmental 
humidity. 
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Figure 9: SEM structure of particles with an aerodynamic cut off diameter between 4 and 
4.94 µm. Aerosolized 12 mg/ml cromolyn sodium lyophilisates frozen from an aqueous 
solution (a/b) and from a 20% TBA/water co-solvent system (c/d). 
3.3 ANALYSIS OF THE MATERIAL PROPERTIES BY COMPRESSION STUDIES 
Compaction of substances with an instrumented press gives the opportunity to analyze 
material properties like the degree of elastic recovery and relaxation of the compact. This 
should allow to draw conclusions whether a substance behaves more elastic, plastic, or brittle. 
All substances used in this study were conventionally freeze-dried at higher solution 
concentrations (lactose, trehalose, and cromolyn sodium at 100 mg/ml; valine at 50 mg/ml, 
and phenylalanine at 20 mg/ml due to their limited solubility in water) for analysis by 
instrumented compaction. From the recorded data, the porosity-pressure function according to 
Heckel [21] was calculated for both the compression and decompression phases (Figure 10). 
The obtained Heckel and compression parameters are outlined in Table 2. For all parameters, 
valine showed markedly different values in comparison to all other substances. The Heckel 
plot of valine powder rendered the smallest slope of 4.7*10-3 and the largest intercept of 1.75. 
The valine compact experienced the smallest relaxation of 0.16% during compression and the  
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Figure 10: Heckel plot of freeze-dried lactose, trehalose, cromolyn sodium, phenylalanine and 
valine powder (one analysis curve shown exemplarily for each substance). 
highest elastic recovery of 8% after load removal. Lactose, trehalose, and cromolyn sodium 
demonstrated rather similar values with respect to the compaction behavior. The compacts 
showed a relaxation between 0.52% and 0.56% and the Heckel plots revealed high slopes of 
around 9*10-3 and small intercepts of around 0.7. The Heckel parameters obtained for 
phenylalanine arranged between the ones from valine and the other three substances with a 
slop of 6.5*10-3 and an intercept of 0.87. The phenylalanine compact, in contrast, experienced 
the highest relaxation of 0.69%. 
Table 2: Characteristic Heckel and compression parameters obtained by compression 
analysis of valine, phenylalanine, trehalose, cromolyn sodium and lactose (± S.D. n=6). 
 val phe tre cs lac 
heckel-slope 
*10-3 
4.7 ± 1.2 6.5 ± 0.5 8.5 ± 0.1 8.9 ± 1.1 8.9 ± 0.4 
heckel-intercept 1.75 ± 0.05 0.87 ± 0.04 0.72 ± 0.05 0.71 ± 0.08 0.73 ± 0.01 
residual 4.80*10-6 2.33*10-6 2.67*10-6 3.33*10-6 1.67*10-6 
max. pressure 
[MPa] 
231 ± 3 227 ± 2 230 ± 2 229 ± 3 227 ± 2 
elastic recovery 
[%] 
8.4 ± 1.7 2.7 ± 1.0 1.9 ± 0.1 4.3 ± 0.6 1.6 ± 0.1 
relaxation 
[%] 
0.16 ± 0.03 0.69 ± 0.04 0.56 ± 0.05 0.54 ± 0.08 0.52 ± 0.3 
yield pressure 
[MPa] 
224 ± 53 154 ± 11 118 ± 2 114 ± 15 112 ± 5 
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4 DISCUSSION 
4.1 VARIATION OF THE FREEZING PROCESS 
The size and shape of ice crystals formed during freezing essentially determines the 
morphology of the resulting pores and thereby controls the solid matrix structure [22]. The 
effect of ice formation is thereby strongly dependent on the degree of supercooling and the 
freezing rate [23]. A high degree of supercooling creates a homogeneous, sponge-like 
structure whereas the cake texture changes to an oriented lamellar structure for samples with a 
low degree of supercooling [15]. A lamellar structure was found in this study for all samples 
frozen in liquid nitrogen and also for cromolyn sodium lyophilisates frozen on a precooled 
shelf. Large thermal gradients promote directional solidification, resulting in a directional 
lamellar morphology with connected pores [12] because secondary nucleation will only 
comprise those areas of the liquid volume with sufficient supercooling [10]. Freezing on the 
-70°C precooled shelf caused a large thermal gradient across the fill height, which was 
particularly pronounced for the cromolyn sodium solution. The freezing of this solution 
occurred with a very low supercooling of 1°C whereas, for example, the precooled frozen 
valine solution exhibited a supercooling of approximately 6°C, showing the normal sponge-
like matrix structure after drying. This agrees with the finding that if supercooling exceeds 
5°C, the solution in general freezes by global supercooling, resulting in a dispersed spherulitic 
morphology [15]. However, vacuum-induced freezing led to a normal sponge-like matrix for 
all substances despite the controlled nucleation at -3°C and therefore little supercooling. 
Liquid nitrogen freezing causes extreme temperature gradients along the vial bottom and 
sides, resulting in directional solidification from those surfaces inward as already reported 
[10, 24]. By studying a model food system, Quast and Karel [25] detected that samples frozen 
in liquid nitrogen cracked intensively during drying, which was also noticed for some 
lyophilisates evaluated in the current study. Among those, cromolyn sodium lyophilisates 
exhibited particularly distinctive cracks. These cracks enhance the water vapor flow during 
drying [25] but also allow to start the disintegration process in the vial with a cake that is 
almost separated into several subunits. For all substances the lamellar cake morphology 
caused an elastic structure, which is indicated by the constant gradient of the immersion-
force-curve lacking a horizontal plateau. Instead of fracture mainly compression of the sample 
takes place, which was also confirmed by the observed elastic relaxation of the compressed 
cake after the immersion of the texture analyzer probe. Nevertheless, considering the 
aerosolization process, an elastic structure as a result of lamellar morphology did not hinder a 
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good disintegration. All samples with a lamellar morphology showed a fast and complete 
disintegration in the high speed camera recordings. This special matrix structure fragments 
into aerosol particles without the need for brittleness. In high speed camera recordings, the 
disintegrated particles appeared more voluminous than particles generated by disintegration of 
a sponge-like cake matrix. SEM confirmed a bigger geometric particle size for the same 
aerodynamic size in the case of particles produced from cakes with lamellar morphology. This 
is possible if the particles exhibit a decreased density, which was demonstrated by the more 
filigree and more porous appearance of these particles in SEM. All freeze-dried substances 
featuring a lamellar matrix showed an increased ED or at least a similar value (in the case of 
an already high ED of samples frozen via shelf-ramping). The increased output from the vial 
can be explained by the enlarged particle size because large particles offer greater contact 
surface to the discharging air flow and show reduced adhesion to surfaces. They demonstrate 
in general increased emission (Chapter 2). For a successful delivery of large particles to the 
lung, these particles need to possess a low density in order to meet the required aerodynamic 
size of less than 5 µm. The group of Edwards and Langer [26, 27] already successfully 
demonstrated the enhanced aerosolization efficiency of large porous particles for inhalation.  
Annealing on the one hand is a process to facilitate crystallization of a bulking agent and on 
the other hand allows the unfrozen water to diffuse through the frozen matrix. This leads to 
ice crystal growth due to a ripening effect which may also create channels as a result of ice 
crystal interconnections [22]. After freezing and complete solidification, the frozen 
formulation is treated at a higher temperature between the glass transition temperature of the 
maximally freeze concentrated solution (Tg’) and the ice melting point for a certain period of 
time before refreezing below Tg’ [22]. All samples demonstrated similar XRD patterns 
compared to the conventionally frozen references. Therefore, no further crystallization or 
recrystallization occurred. The annealing temperature at -10°C is clearly above the Tg’ of 
lactose and trehalose (-28°C and -29°C) [28]. This caused a local collapse phenomenon with 
consolidation of fine amorphous structures, which is similarly reported by Searles et al. [29] 
and by Webb et al. [16] for sucrose and hydroxyethyl starch formulations. This can be 
explained by the fact that the initial morphology has an extremely high surface-to-volume 
ratio, and super-Tg’ annealing allows the system to relax to a morphology with a lower 
interfacial area [29]. The consolidation of the fine structures caused a complete loss of the 
ordered spherulitic morphology, resulting in a disordered network comprising large void 
volume. Solely the translucent skin on top of the cake still showed the spherulitic 
morphology. This loss of the ordered structure was mirrored in the changed outcome of the 
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mechanical testing. Compared to conventionally frozen samples, the annealed lyophilisates 
demonstrated steady fracture at a substantially smaller force because an ordered spherulitic 
structure increases resistance against the pressure of the probe, a principle which is for 
example utilized in lightweight construction [30]. The aerosolization behavior in the vial 
visualized by the high speed camera recordings showed also distinctive changes. These are 
possibly a consequence of the consolidation which results in thicker wall and network 
structures forming less porous particles. Visualizing these particles with SEM, a wall 
thickness of approximately 1 µm compared to 0.6 µm for the conventionally frozen lactose 
sample was observed. It was also noticeable that the particles did not demonstrate the same 
agglomerative highly porous structure as all other lactose samples and therefore exhibited a 
significantly smaller geometric size of 8 µm (Figure 5). As a consequence of these 
characteristics, the ED as well as the FPF decreased. A similar effect was also observed for 
the annealed valine sample despite its crystalline nature. Although the evaluation of the 
lyophilisate structure was not possible, the matrix must be very soft in order to fracture during 
the ventilation process in the freeze-dryer. The aerosolized particles generated from cakes 
which were prepared with an annealing step exhibited a smaller geometric size of 41 µm 
compared to approximately 90 µm of the conventionally frozen lyophilisate, which can be an 
explanation for the reduced ED. Annealing of phenylalanine and cromolyn sodium samples, 
in contrast, showed no significant effects. Microscopy revealed no changes in the lyophilisate 
morphology except of a change to more homogeneous pore size distribution. Mechanical 
testing revealed similar results as for the conventional shelf-ramped freezing. Particle 
morphology and size was neither influenced by the annealing step. This resulted altogether in 
comparable aerosolization behavior and only small variations in ED or FPF.  
Further freezing methods resulting in spherulitic pore morphology are conventional shelf-
ramped freezing, shelf-ramped freezing with holding steps, mostly precooled shelf freezing, 
and vacuum-induced freezing. These solutions froze by global supercooling. Hereby the entire 
liquid volume achieves a similar level of supercooling, and the secondary nucleation zone 
comprises the entire liquid volume [10]. As aforementioned, vacuum-induced freezing 
demonstrated freezing by global supercooling despite of the controlled nucleation at -3°C. 
When nucleation was induced by reduced pressure, the solution in the vial changed suddenly 
from a clear liquid into an opaque/translucent slush, which is indicative of global 
supercooling [12]. The mechanical testing of lyophilisates with a spherulitic matrix mostly 
showed steady fracture at a constant force, which is characteristic of a brittle structure. Only 
small variations were observed such as an increased force needed for fracturing the dense 
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upper layer of phenylalanine and cromolyn sodium samples from vacuum-induced freezing. A 
slightly reduced brittleness of lactose and trehalose samples frozen via shelf-ramping was 
indicated by the observed peak, instead of a horizontal plateau, in the immersion-force-curve. 
For disintegration of a spherulitic matrix, the cake is typically first separated into smaller 
subunits by the impacting air, followed by scaling off of fine particles. Some samples showed 
again small variations. Valine frozen via shelf-ramping, for example, disintegrated fast and 
completely as a result of its very soft structure. Lactose, trehalose, and valine prepared with 
vacuum-induced freezing showed also a fast and complete disintegration process and 
demonstrated a soft matrix structure as well. SEM of the aerosolized particles always showed 
agglomerates composed of smaller fragments, giving the particle a highly porous structure. 
The exact appearance varied among the different substances from more smooth and platelet 
like structures to wrinkled or filigree structures. The fragments of phenylalanine, for example, 
showed always the distinctive netting structure of phenylalanine-monohydrate crystals which 
develop when phenylalanine is freeze-dried (Chapter 3, Chapter 5). For lactose, trehalose and 
valine samples, ACI measurements demonstrated about the same FPF and ED values for all 
lyophilisates with a spherulitic matrix, whereas a changed matrix morphology exhibited a 
significantly different aerosolization performance. Phenylalanine and cromolyn sodium 
lyophilisates did not demonstrate such clear differences for the aerosolization performance of 
various matrix structures. Lyophilisates with a spherulitic matrix showed about the same ED 
and FPF as lyophilisates with a lamellar morphology. 
4.2 CHANGING THE ICE CRYSTAL HABITUS USING TBA AS CO-SOLVENT 
As mentioned before and reported by Kasraian and DeLuca [18], TBA alters the ice crystal 
habitus dependent on the amount of co-solvent added. A concentration of at least 3% TBA 
changes the ice structure to large dendritic ice crystals. The addition of 10% TBA results in 
even finer needle-shaped ice crystals whereas at the eutectic at 20% TBA, the frozen solution 
is composed of small eutectic crystals. The 70% TBA solution corresponds to the melting of 
pure TBA-hydrate and results in the formation of very large hydrate crystals [18]. The 
lyophilisate morphologies of the TBA/water co-solvent systems in the concentration of 5% 
and 10% were in accordance with the appearance reported by Kasraian and DeLuca [18], 
showing large-needle shaped pore structures. Liu et al. [11] reported also the formation of 
needle-like ice crystals for a formulation containing 5% TBA. The 20% TBA system, in 
contrast, did not demonstrate the mentioned small eutectic crystals but also needle-shaped 
structures for all lyophilisates. This can be a consequence of solutes influencing crystal 
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formation. Similarly, the 70% TBA/cromolyn sodium system did not show large pore 
formation due to very large TBA-hydrate crystals but a network of small spherulitic pores. 
Possibly the suspended cromolyn sodium crystals prevented the formation of large TBA-
hydrate crystals. The samples with 5%, 10%, and 20% TBA demonstrated large needle-
shaped aligned pores after freeze-drying. The mechanical testing revealed an elastic structure 
which was comparable to the liquid nitrogen frozen samples mentioned above. The spherulitic 
matrix of the 70% TBA/cromolyn sodium sample, in contrast, exhibited steady fracture at a 
constant force comparable to other samples with a sponge-like matrix described above. The 
aerosolization performance demonstrated a decrease in the ED for the 70% TBA sample 
compared to the aqueous sample for cromolyn sodium despite of the similar spherulitic 
matrix. The lamellar samples with 5%, 10%, and 20% TBA showed an increased ED 
compared to the spherulitic aqueous sample for cromolyn sodium and valine lyophilisates. An 
increase in the ED for samples with a lamellar morphology compared to those with a 
spherulitic matrix structure was also described above for various frozen lyophilisates of 
different substances. Trehalose samples, in contrast, demonstrated a decreased ED despite 
similar cake morphology. The samples showed a very soft cake structure, incomplete 
disintegration is therefore unlikely to occur. Visual inspection of the vial after disintegration 
revealed complete cake disintegration but a large particle fraction was collected at the top of 
the vial. Either the expelling air stream was not able to adequately catch the particles and 
export them out of the vial or most of the particles had a geometric size which was too large 
to escape through the outlet capillary (0.75 mm in diameter). Morphological aspects of the 
particles formed could not be evaluated due to destruction upon contact with environmental 
humidity. Most lyophilisates freeze-dried from a TBA/water co-solvent system demonstrated 
a softer structure in the texture analysis compared to the lyophilisates freeze-dried from 
aqueous solutions and the cake decomposed easily when extracted from the protective vial. In 
the literature, lyophilisates produced from TBA/water co-solvent systems were already 
described as readily breaking apart [31]. Possibly residual solvent levels of TBA act as a 
plasticizer and cause the softening of the lyophilisate structure. Wittaya-Areekul et al. [31] 
demonstrated increased residual TBA levels for higher initial TBA concentrations. The soft 
structure of the 70% TBA cromolyn sodium sample could therefore be a result of high 
residual TBA levels. Wittaya-Areekul and Nail [32] showed in another study that residual 
TBA levels were smaller for the crystallizing excipient glycine in contrast to higher levels for 
the amorphous excipient sucrose. Flink and Karel [33] postulated that residual solvents are 
entrapped within microregions of the freeze-dried solids of carbohydrates rather than being 
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adsorbed to the surface and thus are hard to remove. However, crystalline valine and 
amorphous trehalose exhibited both a softening of the structure for the TBA/water co-solvent 
systems. Possibly, the special lyophilisate structure contributed also to the mechanical 
properties of the cake. Considering intravial homogeneity, Liu et al. [11] obtained the best 
results by implementing two-step freezing or by adding TBA to a concentrated formulation 
with high fill depth. In this study, the TBA samples and the aqueous reference were frozen via 
a two-step freezing, including two holding steps at 5°C and -5°C. The very small standard 
deviations (Figure 8) indicate a good vial to vial homogeneity within the batch. 
4.3 ANALYSIS OF THE MATERIAL PROPERTIES BY COMPRESSION STUDIES 
In order to possibly explain material-dependent differences in lyophilisate characteristics and 
aerosolization performance, the material properties of the different substances were analyzed 
under compression. Under an applied load, materials can undergo brittle fracture or elastic or 
plastic deformation. Compaction profiles were recorded and several parameters like elastic 
recovery, relaxation, Heckel-slope, yield pressure, and Heckel-intercept were calculated to 
evaluate differences in plastic deformation or brittle fracture of the substances used. In order 
to compare compacted samples of different height, the tablet porosity was plotted against the 
pressure to obtain a Heckel plot. The Heckel-intercept is a measure for the degree of 
densification by fragmentation and particle reorganization until plastic deformation begins. 
Lactose, trehalose, and cromolyn sodium showed a similarly small value for the intercept of 
about 0.7 compared to the significantly higher values for phenylalanine and valine. Therefore, 
plastic deformation starts earlier for lactose, trehalose, and cromolyn sodium. Another 
indicator for plastic deformation is a high slope of the linear regression of the Heckel plot or a 
small yield pressure, which is inversely related to the slope and the minimum pressure 
required to cause deformation of the material [34]. Additionally, plastic deformation causes a 
high stress relaxation of the compact because of plastic flow [35]. Lactose, trehalose, and 
cromolyn sodium showed similarly high values for the Heckel-slope of around 0.009 and for 
the relaxation of around 0.5%, demonstrating good plastic deformation. The Heckel plot of 
valine, in contrast, showed the largest intercept of 1.75 and a small slope of 0.0047, indicating 
a high degree of fragmentation during compaction [36]. This was additionally confirmed by a 
small relaxation of 0.16%, which points to a brittle material with a low degree of plastic flow. 
Less consolidation of the powder during compaction results in more elastic recovery [34], 
which is the case for valine demonstrating the highest elastic recovery of 8.4%. This 
exceptionally high elastic recovery could also be a result of entrapped air, which is 
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compressed during compaction and will expand again after load removal [37]. The freeze-
dried valine powder had a very low bulk density despite precompaction and therefore 
included large void volume, which potentially could not escape during the compaction 
process. A high degree of elastic deformation during compaction and entrapped air results in 
weaker tablet strength, leading to higher capping tendencies of the compacts [37]. For valine 
compacts a strong capping was noticed. Phenylalanine compacts showed on the one hand the 
highest relaxation of 0.69%, which points to plastic deformation. On the other hand, 
phenylalanine demonstrated a Heckel-slope of 0.0065 which was significantly smaller than 
the slope of lactose, trehalose, and cromolyn sodium and significantly larger than the slope of 
valine. The elastic recovery of 2.7% is considered small in comparison to all other substances, 
which indicates plastic deformation. In summary, phenylalanine demonstrated a more plastic 
deformation than brittle fracture.  
By comparison of the material properties from compaction studies with the mechanical 
properties of the lyophilisates, the brittle behavior of valine is consistent with the very good 
fracture properties of the lyophilisate from texture analysis. This is indicated by the horizontal 
plateau over the complete way of immersion at small force values (Figure 2a). Phenylalanine 
lyophilisates demonstrated good fracture properties as well because of a relatively leveled 
plateau of the immersion-force-curve over a long way of immersion but at higher force 
values. Trehalose and lactose, in contrast, demonstrated plastic deformation during 
compaction and nonuniform fracture properties at texture analysis because of a force peak 
during immersion instead of a horizontal plateau. Cromolyn sodium, in turn, showed also 
good plastic deformation during compaction but a plateau in texture analysis. However, the 
plateau was first reached after 1.25 mm of immersion and extended only over an immersion 
of 1.5 mm. This demonstrates poorer fracture properties compared to valine or phenylalanine. 
In conclusion, the mechanical properties of the freeze-dried substances estimated by 
compaction roughly agree with the mechanical properties of the lyophilisates measured by 
texture analysis. For the characterization of lyophilisate properties texture analysis is therefore 
considered as a useful and easy to perform analysis. Both methods, however, were not able to 
explain commonalities and differences of the aerosolization performance of different 
substances. The sugars and valine demonstrated a similar correlation between the freezing 
process and the aerosolization performance but markedly different material properties. The 
sugars and cromolyn sodium, in contrast, exhibited similar material properties but different 
effects of varied freezing procedures on the aerosolization performance. This demonstrates 
that parameters affecting the aerosolization performance are way too complex for prediction. 
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The aerosolization performance and its possible variation need therefore to be assessed for 
every new substance. 
5 SUMMARY AND CONCLUSION 
This study evaluates several methods for altering the lyophilisate morphology to influence the 
aerosolization performance of the freeze-dried product. Variations of the solid matrix structure 
of a lyophilisate were achieved by changing the freezing process resulting in a different shape 
and size of ice crystals. Furthermore, the addition of TBA as co-solvent changed the ice 
crystal habitus and therefore also the matrix morphology. Significant changes in the 
aerosolization performance were mostly caused only by a strong variation of the solid matrix 
structure for example by a lamellar-oriented morphology or a loss of the ordered structure by 
consolidation. This shows in turn, that small changes in lyophilisate morphology which arise 
as vial to vial inhomogeneities and batch to batch variations according to stochastic ice 
nucleation [10] or differences in drying kinetics due to radiation phenomena, shelf fluid 
temperature gradients and vapor fluid dynamics in the freeze-drying chamber [38] will not 
dramatically impact the aerosolization outcome.  
In conclusion samples with a lamellar morphology showed good results for the ED and 
dependent on the freeze-dried substance also for the FPF. Analyzed mechanical properties of 
the substances could not explain differences in FPF despite similar cake morphology. A 
lamellar matrix structure was achievable by freezing in liquid nitrogen or for a single case in 
this study by freezing on a precooled shelf. In literature directional solidification was also 
realized by immersion of the vial into dry ice/isopropanol [39] or dry ice/ethanol [14] and for 
samples containing Pseudomonas syringae as nucleating agent [10]. Although all quench 
freezing methods of immersing vials into an extremely cold liquid demonstrate a lamellar 
morphology which showed good aerosolization results, they are not applicable in large scale-
manufacturing [40]. Similarly the addition of P. syringae as ice nucleating agent is also not of 
practical use for FDA-regulated and approved pharmaceuticals products [15]. A TBA/water 
co-solvent system in a TBA range of 5% to 20% demonstrated large needle-shaped ice 
crystals resulting in kind of a lamellar morphology with the characteristic elastic structure and 
mostly high ED. For pharmaceutical product manufacturing, the use of such an organic co-
solvent must be properly estimated taking the following issues into account: proper safe 
handling of the flammable solvent, determination and control of residual solvent levels, 
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qualification of an appropriate GMP purity and the toxicity of the remaining solvent [17]. The 
residual solvent in the final product for TBA is influenced by the initial TBA concentration, 
the freezing rate, and the physical state of the solutes [31]. The fact, that the marketed 
pharmaceutical product Caverject® uses an organic co-solvent system for freeze-drying (20% 
v/v TBA/water system) [17] shows that safety, toxicity and regulatory issues are manageable. 
An important aspect of this study is also the great influence of the material property. The 
diverse substances formed different solid matrix structures varying in pore shape and size 
distribution, wall appearance as well as in the mechanical behavior for the same freezing 
process. The variation of the freezing process again had a variable effect on the lyophilisate 
morphology and mechanical property depending on the selected substance. Altogether this 
can result in a different aerosolization behavior demonstrating a different fine particle output. 
Detected variations were thereby independent of morphological aspects like a crystalline or 
amorphous nature. Similar substances like the two amorphous sugars lactose and trehalose 
showed for all freezing variations the same behavior. The crystalline amino acid valine 
revealed similar results. The crystalline amino acid phenylalanine and the amorphous 
cromolyn sodium in contrast demonstrated different outcomes for the same variations in the 
freezing process compared to lactose, trehalose and valine. Mechanical properties of the 
freeze-dried substance analyzed by compression revealed a decrease of brittle fracture and an 
increase of plastic deformation for the substances in the following order: valine, 
phenylalanine, lactose/trehalose/cromolyn sodium. The different mechanical behavior of 
valine compared to the sugars but a similar aerosolization performance of the various frozen 
samples as well as the similar mechanical behavior of the sugars and cromolyn sodium but a 
different outcome for the aerosolization performance demonstrate, that the evaluation of these 
characteristics are not enough to explain substance related variation. Therefore not only the 
formation of a different crystal structure with different properties or distinct mechanical 
properties are responsible for a variation in lyophilisate characteristics but also other material 
properties of the freeze-dried substance.  
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Chapter 7 
Storage Stability of Lyophilized Formulations for 
Dry Powder Inhalation 
Abstract 
Stability is an essential requirement for a drug product. The novel dry powder inhalation 
system comprises a freeze-dried formulation which is disintegrated into inhalable particles at 
the time of inhalation. In this case, the physic-chemical stability of the lyophilisate has to be 
in the focus and the stable disintegration and lung delivery of these products after storage 
need to be verified and was the subject of this study. Sealed lyophilisates of three different 
model substances (phenylalanine, lactose, and cromolyn sodium) were stored for a three 
month period at 25°C/60% RH and 40°C/75% RH, respectively and changes in lyophilisate 
characteristics as well as aerosolization performance were evaluated. A slight moisture 
absorption up to a maximum of 3% due to residual moisture in the stopper could be observed 
for all substances. This resulted in a softening of the lactose lyophilisate structure. 
Aerosolization performance for all samples, however, was not affected. A marginal but not 
relevant increase of the fine particle fraction or the emitted dose after three months storage 
was observed. In a second part of the study, the effect of higher moisture adsorption during 
unintended open storage at higher humidity was tested. For this purpose, lyophilisates were 
stored at 30% RH and 50% RH at RT for three days without stoppers. Despite substantial 
moisture uptake of the amorphous products, which was reflected in a reduction of the force 
necessary to break the cake structures of most samples, hardly any effect on the aerosolization 
performance was detectable. 
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1 INTRODUCTION 
Dry powder formulations for pulmonary drug delivery, in general, comprise the active 
pharmaceutical ingredient in a size between 1 and 5 µm. These small drug particles have poor 
flow properties and are difficult to disperse due to their highly cohesive nature. To improve 
flow, reduce aggregation and aid in dispersion, the micronized drug particles are typically 
blended with larger carrier particles or are loosely agglomerated [1]. During inhalation, the 
drug particles need to disperse for penetration into the lung. The adhesive (drug-carrier 
interaction) and cohesive (drug-drug interaction) forces should therefore be adjusted to a level 
which not only provides a stable formulation but also allows for easy separation during 
inhalation [2]. It is important to note that the dispersibility of a powder formulation is affected 
by storage relative humidity (RH) whereby, in general, storage at high RH adversely affects 
dispersibility [3]. The mechanisms behind this effect are increased capillary forces, solid 
bridging [4] and increased interactions of nearby particles, which are caused by higher polar 
surface energy due to adsorbed moisture [3]. Since deposition characteristics of dry powder 
formulations are sensitive to moisture, the demonstration of stability in long-term storage is 
required [5]. The International Conference on Harmonization provides guidelines for stability 
testing of new drug substances or drug products which recommend the following storage 
conditions: a long-term storage (minimum 12 months) should be performed at either 
25°C/60% RH or 30°C/65% RH and complemented with an accelerated study (minimum 
6 months) under more extreme conditions of 40°C/75% RH [6]. The novel dry powder 
inhalation system is based on dispersion of lyophilisates. In this system the formulation is 
stored as a coherent bulk and disintegrated into fine particles at the time of inhalation. 
Problems like poor flowability and re-dispersibility are thereby avoided. Freeze-drying is 
widely used to improve long-term storage stability of labile drugs, especially 
biopharmaceuticals [7]. Nevertheless, instabilities during storage can occur which in parts are 
a consequence of moisture uptake. In amorphous products water can act as a plasticizer, 
which reduces the glass transition temperature and could induce recrystallization [8]. These 
changes can affect the mechanical properties of the lyophilisates. To be inhalable, the stable 
disintegration and lung delivery of the lyophilized products need to be verified. The aim of 
this study hence was to evaluate phenylalanine, lactose, and cromolyn sodium lyophilisates 
for inhalation with regard to storage stability of the aerosolization performance, in particular, 
over three month at 25°C/60% RH and 40°C/75% RH. In a second part of the study, a 
moisture stress test comprising an un-stoppered storage at 30% RH and 50% RH of several 
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freeze-dried substances for three days was performed to simulate an unintentional open 
storage at high humidity or an alternative moisture-permeable container. Before and after 
storage, lyophilisates were characterized with respect to morphological state by x-ray powder 
diffraction, moisture content, mechanical behavior of the cake up on penetration of a probe, as 
well as aerosolization performance. 
2 MATERIALS AND METHODS 
2.1 MATERIALS 
Aqueous solutions were prepared of L-phenylalanine (Phe) (Merck KGaA, Darmstadt, 
Germany), lactose-monohydrate (Lac) (Fagron GmbH&Co. KG, Barsbüttel, Germany), 
cromolyn sodium (CS) (Fagron GmbH&Co. KG, Barsbüttel, Germany), L-isoleucine (Ile) 
(Fluka Chemie GmbH, Buchs, Switzerland), L-valine (Val) (Fagron GmbH&Co KG, 
Barsbüttel, Germany), D-mannitol (Man) (Riedel-de Haën, Seelze, Germany), trehalose (Tre) 
(Hayashibara Co Ltd, Okayama, Japan) lysozyme (Lys) from chicken egg white (Serva 
Electrophoresis GmbH, Heidelberg, Germany). Dye for quantification was rhodamine B 
(Sigma-Aldrich, Chemie GmbH, Steinheim, Germany). 
2.2 FORMULATION PREPARATION 
For the three-month stability 0.5 ml aqueous solutions of lactose or cromolyn sodium at 
12 mg/ml or phenylalanine at 8 mg/ml were filled into 2R glass vials (Fiolax® clear, Schott 
AG, Müllheim, Germany) and vials were equipped with rubber stoppers (1079-PH 
701/40/ow/wine-red, West Pharmaceutical Services, Eschweiler, Germany). Stoppers used 
were dried before lyophilization at 105°C for 4 h. Freeze-drying was carried out in a 
laboratory scale freeze-drier (Lyostar II, FTS Systems, Stone Ridge, NY, USA). The samples 
were frozen at -1°C/min to -45°C for 1 h. Primary drying was performed at a shelf 
temperature of -15°C (shelfs were ramped at +0.2°C/min) and a pressure of 100 mtorr for 
20 h. For secondary drying the shelf temperature was increased to +30°C at a ramp rate of 
+0.1°C/min for 6 h. All samples were crimped with aluminium caps. 
For the stress test 0.5 ml aqueous solutions of 12 mg/ml excipient (isoleucine, valine, lactose 
or trehalose) or model drug (cromolyn sodium or lysozyme) were filled into 2R glass vials 
and vials were equipped with rubber stoppers (C1503, Stelmi, Villepinte, France). Freeze-
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drying was carried out in the laboratory scale freeze-drier. The samples were frozen at 
-1°C/min to -45°C for 1 h. Primary drying was performed at a shelf temperature of -20°C 
(shelfs were ramped at +0.2°C/min) and a pressure of 34 mtorr for 20 h. For secondary drying 
the shelf temperature was increased to +30°C at a ramp rate of +0.5°C/min for 10 h at a 
decreased pressure of 8 mtorr. 
2.3 STORAGE 
For three-month stability testing the sealed lyophilized samples were stored at 25°C and 60% 
relative humidity (RH) or at 40°C and 75% RH. The desired humidity was achieved by 
storage in a humidor containing saturated ammonium nitrate (VWR International, Leuven, 
Belgium) solution for 60% RH or a saturated sodium chloride (Merck KGaA, Darmstadt, 
Germany) solution for 75% RH in each case monitored by a hygrometer.  
For the stress test, un-stoppered lyophilisates were stored at 30% RH or 50% RH at room 
temperature (RT) for 3 days. The desired humidity was achieved by storage in a humidor 
containing a saturated calcium chloride (Merck KGaA, Darmstadt, Germany) solution for 
30% RH or a saturated calcium nitrate (central supply LMU, Munich, Germany) solution for 
52% RH in each case monitored by a hygrometer. Regarding the saturated solution for control 
of RH see [9] for more details. 
2.4 MOISTURE CONTENT ANALYSIS 
The moisture content of lyophilisates was determined by Karl-Fischer titration (Metrohm 756 
KF Coulometer, Herisau, Switzerland) using Hydranal Coulomat AG (Riedel-deHaën, Seelze, 
Germany) as titration reagent. The lyophilisates were dissolved in 1.0 ml of anhydrous 
methanol (Hydranal-Methanol dry, Riedel-deHaën, Seelze, Germany), additionally dried with 
molecular sieve 3A (VWR International GmbH, Darmstadt, Germany). The dissolution took 
place right in the production vials after injection of methanol through the stopper of the vial 
using a 1 ml-Hamilton syringe. As blanks, empty freeze-dried vials were treated the same 
way. The injection volume was 500 µl each. The measurements were performed in triplicate. 
2.5 MOISTURE SORPTION ANALYSIS 
The moisture sorption behavior of the freeze dried samples was measured using an IGASorp 
moisture sorption analyser (Hiden Isochema, Warrington, United Kingdom). Isothermes were 
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recorded at 25°C with RH from 5% up to 90% in steps of 10%. The samples were previously 
dried for at least 2 h in a dry nitrogen flow at 250 ml/min. During measurement the humidity-
controlled flow had a rate of 200 ml/min. The sample mass was about 6 to 8 mg.  
2.6 MECHANICAL TESTING 
The mechanical properties of the lyophilisates were investigated using a Texture Analyzer 
(TA.XT.plus, Stable micro Systems, Godalming, United Kingdom) equipped with a 5 kg load 
cell and a cylindrical stainless steel probe with a diameter of 5 mm at a test speed of 1 mm/s 
and a maximal immersion into the lyophilisate of 2 mm. The resulting immersion-force curve 
approached steady fracture at a constant force reflected in a horizontal plateau. For 
comparison of the formulations before and after storage, the data points of the plateau were 
averaged and the obtained value represents the force necessary to fracture the lyophilisate.  
2.7 X-RAY DIFFRACTOMETRY (XRD) 
The lyophilisates were investigated with a Seifert X-ray diffractometer XRD 3000 TT 
(Seifert, Ahrensburg, Germany) equipped with a copper anode (40 kV, 30 mA, wavelength 
154.17 pm). The samples were measured from 5 – 40° 2-Ө at a step rate of 0.05° 2-Ө with 2 s 
measuring time per step. 
2.8 FINE PARTICLE FRACTION (FPF) ANALYSIS 
For aerosolization of the lyophilisates, a custom-designed test system (Chapet 2) was used. 
The FPF was measured using a short stack version of the Andersen Cascade Impactor (8-
Stage Non-Viable Sampler Series 20-800, Thermo Andersen, Smyrna, GA, USA) at a flow 
rate of 39 l/min (corresponds to a pressure drop of 4 kPa with the HandiHaler®). Baffle plates 
were coated with a solution of 83% glycerin (AppliChem GmbH, Darmstadt, Germany), 14% 
ethanol (central supply LMU, Munich, Germany) and 3% Brij 35 (Serva Electrophoresis 
GmbH, Heidelberg, Germany). Filters used were type A/E glass fiber filters 76 mm (Pall 
Corporation, Ann Arbor, MI, USA). By removing stages 2 to 7, the whole FPF (particle 
fraction <4.94 µm) is collected on the filter directly below stage 1.  
For three-month stability testing the FPF was quantified by weighing the filter before and 
after powder deposition and was either calculated as the percentage of the metered dose (MD) 
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or the emitted dose (ED). ED was measured by weighing the vial before and after 
aerosolization and calculated as the percentage of MD. 
For stress test FPF was determined by washing the filter with water and rhodamine B 
quantification at 554 nm in an Agilent 8453 UV-Vis spectrophotometer (Agilent 
Technologies, Santa Clara, CA, USA). Therefore the filter solution was ultra-centrifuged 
(OptimaTM TLX Ultracentrifuge, Beckman Coulter, Brea, CA, USA) at 186000 g for 45 min 
before UV-Vis spectroscopic analysis. FPF was again calculated as either the percentage of 
MD or ED. ED was measured by washing the vial with water and quantification by UV-Vis 
spectroscopy; it was calculated as the percentage of MD. 
3 RESULTS AND DISCUSSION 
3.1 THREE-MONTH STABILITY AT 25°C/60% RH AND 40°C/75% RH 
To assess storage stability of freeze-dried formulations for inhalation, lyophilisates were 
stored in the sealed vials at 25°C/60% RH and at 40°C/75% RH for three months. 
Immediately after freeze-drying as well as after one and three months of storage, the 
formulations were characterized. Since the physicochemical stability of a freeze-dried product 
is often sensitive to the level of moisture, residual moisture needs to be reduced during the 
secondary drying process and subsequently controlled during storage [10]. Immediately after 
freeze-drying, all lyophilisates exhibited residual moisture of less than 1%, which is 
considered optimal for storage [7]. A critical aspect for the storage of freeze-dried 
formulations is the slightly rising moisture content caused by residual moisture in the stopper 
[10] and permeation of water through the stopper [11]. Non-dried stoppers can be considered 
as a water reserve, dried stoppers play the role of a buffer limiting the rate of water transfer to 
the product [11]. Stoppers used in this study were therefore dried at 105°C for 4 h prior to 
freeze-drying. Nevertheless, the moisture content of the lyophilisates increased during storage 
for all formulations up to 3%, as can be seen from Figure 1. A higher storage temperature 
caused a faster increase in moisture. This can be explained by the fact that water transfer out 
of the stopper to the lyophilisate is more pronounced at elevated temperature [12]. Pikal and 
Shah [10] demonstrated that the product moisture content increases over time until an 
equilibrium value is reached, which is characteristic for the product, amount of product, and 
stopper treatment method. The time period to reach this equilibrium is thus only dependent on  
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Figure 1: The moisture content of lyophilisates immediately after freeze-drying compared to 
samples after 1 and 3 month of storage at 25°C/60%RH and 40°C/75% RH. 
temperature, whereas the equilibrium water content is temperature independent. Whether the 
equilibrium moisture content was already reached for the tested formulations within three 
months of storage at 40°C cannot be stated. 
Since water has a plasticizing effect on amorphous materials [13], the increased moisture 
content of the freeze-dried product could affect its mechanical characteristics. Mechanical 
testing of the different formulations before and after storage revealed no significant changes 
for cromolyn sodium and phenylalanine lyophilisates. The immersion-force-curves of lactose 
lyophilisates, in contrast, demonstrated a shift to smaller forces after storage, as can be seen 
from Figure 2. Immediately after freeze-drying, the plateau force necessary to fracture the  
 
Figure 2: Immersion-force-curves for lactose lyophilisates immediately after freeze-drying 
and after storage. 
CS 20 Phe 8 Lac 12
0
1
2
3
 
 
 
m
oi
stu
re
 co
nt
en
t [
%
]
 t0
 1m 25°C/60% RH
 1m 40°C/75% RH
 3m 25°C/60% RH
 3m 40°C/75% RH
0.0 0.5 1.0 1.5 2.0
0.00
0.05
0.10
 
 
fo
rc
e [
N]
immersion [mm]
 t0
 1m 25°C/60% rH
 1m 40°C/75% rH
 3m 25°C/60% rH
 3m 40°C/75% rH
Chapter 7 
154 
lyophilisate amounted to 0.057 N. During storage, this force leveled at about 0.03 N for 
sample exhibiting a residual moisture content of 1.5% and did not drop further for samples 
with higher moisture levels up to 3%. 
X-ray powder diffractometry (XRD) is perhaps the gold standard to characterize the physical 
state of freeze-dried solids. For freeze-dried formulations containing amorphous or partially 
crystalline modifications which are thermodynamically unstable, the possibility of 
recrystallization during storage needs to be considered [14]. For phenylalanine XRD 
demonstrated small crystalline reflections at 6.5, 14.85, 21.55 and 33.1° 2-θ, which are 
characteristic for phenylalanine-monohydrate [15]. Peak intensity and location did not change 
during storage. The residual water content immediately after freeze-drying and later during 
storage is remarkably low. Theoretically, the water content of pure phenylalanine-
monohydrate is 9.8%. Therefore, phenylalanine must have been present in a partially 
crystalline state, including a large amorphous fraction. Lactose and cromolyn sodium, in 
contrast, showed a completely amorphous nature, which did not change during storage. 
As mentioned before, the disintegration and deposition performance of traditional dry powder 
formulations are especially sensitive towards moisture exposure during storage. In order to 
identify potential effects of storage on the dispersibility and deposition of lyophilisates for 
inhalation, ED and FPF of the different samples was measured immediately after freeze-
drying and compared to values after one and three months of storage (Figure 3). No 
significant decrease in aerosolization performance could be detected for all three 
formulations. On the contrary, a slightly increased FPF was determined for phenylalanine and 
lactose lyophilisates stored three months and a slightly increased ED was detectable for 
cromolyn sodium lyophilisates stored three months at 40°C. On the one hand, the higher FPF 
of lactose lyophilisates could be a result of a softer cake structure. If less force is needed for 
the fracturing of the cake, potentially the disintegration into inhalable particles becomes 
easier. On the other hand, the mechanical behavior remained stable for lyophilisates 
containing 1.5% moisture or more. This specific moisture content was already reached after 
one month of storage at 40°C/75% RH and those samples did not show significant changes in 
FPF. Furthermore, phenylalanine and cromolyn sodium revealed slightly increased FPF or ED 
for samples stored three months, but otherwise did not demonstrate any changes in the 
mechanical behavior or in the physical state. The slightly higher values after three months of 
storage are considered as not relevant in the context of the small number of samples and the 
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normal variations in the analytics. On this basis, the tested lyophilisates for inhalation were 
considered stable during three months of storage at 25°C/60% RH and 40°C/75% RH. 
a b 
c  
c  
Figure 3: ED versus its related FPF as well as the FPF related to MD of the different 
lyophilisates before and after storage: phenylalanine (a), lactose (b) and cromolyn sodium 
(c). 
3.2 STRESS TEST: OPEN STORAGE AT RT/30% RH AND RT/50% RH 
In order to simulate potential higher moisture sorption due to an unintended open storage at 
high humidity or an alternative moisture-permeable container and to evaluate potential effects 
on the aerosolization performance, lyophilisates of various substances were equilibrated un-
stoppered at 30% RH and 50% RH for three days. Substances included in this study were 
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amino acids (isoleucine and valine), sugars (lactose and trehalose), as well as the model API 
cromolyn sodium and the model protein lysozyme, each at 12 mg/ml. The lyophilisates of the 
two sugars did not survive the moisture stress at 50% RH but collapsed completely rendering 
aerosolization impossible.  
XRD revealed a completely amorphous state for freeze-dried lactose, trehalose, cromolyn 
sodium, and lysozyme before and after moisture stress. Except for lactose and trehalose, 
which collapsed at 50% RH, the moisture stress did not cause crystallization. The amino acids 
demonstrated the characteristic peak pattern of crystalline isoleucine and valine, respectively. 
It has been demonstrated previously that most amino acids crystallize during freeze-drying 
and are therefore suitable as bulking agents [16]. For freeze-drying of protein formulations, it 
is known that proteins and sugars, in general, do not crystallize during freezing, but are 
transformed into an amorphous solid at the glass transition temperature of the maximally 
freeze concentrated solution (Tg’) [14, 17].  
Figure 4 shows the moisture content of the unstressed and stressed samples. The moisture 
content of the crystalline amino acids did not change after equilibration at 30% or 50% RH. 
The amorphous lyophilisates, in contrast, absorbed a substantial amount of water vapor. For 
cromolyn sodium, in particular, the moisture content increased to about 10 and 16 wt. % at 
30% and 50% RH, respectively. Crystalline materials typically adsorb vapors only in small 
quantities at their surfaces or take up larger stoichiometric quantities to form solvates. 
Amorphous  materials,  in  contrast,  absorb  water  vapor  in  relatively  large  amounts [18].  
 
Figure 4: The moisture content of different lyophilisates stressed at 30% RH and 50% RH in 
open vials. 
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Consequently, the moisture sorption isotherm analysis of isoleucine demonstrated significant 
vapor sorption only at more than 80% RH, with a maximum adsorption at 90% RH of less 
than 1% (Figure 5). Lactose and trehalose, in contrast, showed maximum vapor absorption of 
approximately 14 wt. % at 55% RH and collapsed at greater RH. The collapse occurs due to a 
decreased glass transition temperature (Tg) and increased molecular mobility of the 
amorphous solid [19]. In the case of lactose, a decrease in moisture content to about 3% 
followed. The loss of the sorbed moisture is due to the transformation of the amorphous 
lactose to the crystalline state [8]. A mixture of α-lactose monohydrate (theoretical water 
content of 5%) and anhydrous lactose must have been formed as reported previously by 
Elamin et al. [8]. Subsequent to the maximum vapor sorption, crystallization occurred also for 
trehalose forming the dihydrate. This is indicated by the plateau at a water content of 10% 
[20]. Lysozyme in contrast demonstrated steady moisture sorption up to 26 wt. % without 
collapse or recrystallization. For cromolyn sodium lyophilisates, Figure 5 demonstrates a 
maximum vapor absorption of 52 wt. %. The drug is known to be very hygroscopic. Even in 
its crystalline form, it possesses the unique ability to absorb up to nine molecules of water per 
molecule of cromolyn sodium into the crystal lattice without collapse [21]. An adsorption up 
to 24 wt. % water of cromolyn sodium crystals was shown [21]. Such a high water uptake is 
especially critical when considering powders for pulmonary administration. It is reported that 
the hygroscopic particle growth can have a negative impact on the respirable dose [22]. 
 
Figure 5: Moisture sorption isotherm at 25°C for lyophilized isoleucine, lactose, trehalose 
cromolyn sodium and lysozyme. 
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Small amounts of absorbed water can plasticize amorphous solids, hence exposure to 
humidity is considered to be an important factor influencing the solid-state properties of 
amorphous systems [18]. The mechanical properties of the different samples were 
investigated using the texture analyzer. Figure 6 compares the force necessary to fracture the 
lyophilisate of the unstressed and moisture stressed samples. As expected, the mechanical 
behavior of the crystalline lyophilisates of isoleucine and valine did not change after moisture 
exposure. An interesting aspect is the similar mechanical behavior of the unstressed and 
moisture stressed lysozyme lyophilisates, in spite of substantial moisture absorption. Lactose 
and trehalose, in contrast, showed a significant decrease in the force necessary to fracture the 
lyophilisate for a moisture content of 6%. This decrease is comparable to the force reduction 
for stored lactose lyophilisates containing at least 1.5% water detected earlier and confirms a 
maximal softening level that is independent of further moisture absorption. Cromolyn sodium, 
demonstrating the strongest moisture absorption, showed an immersion-force-curve shift to 
significantly smaller values only for samples stressed at 50% RH, which corresponds to a 
moisture content of 16.6%. Thus, the cromolyn sodium lyophilisates which were stored for 
three months and contained a maximum of 3.2% water showed no significant change in their 
mechanical behavior. This demonstrates that the plasticizing effect of water for amorphous 
products does not necessarily result in a softer mechanical property. Additionally, the degree 
of reduction of the force necessary to fracture the lyophilisate varies between different 
substances, requiring a different amount of absorbed water for the same effect. The sugars, for  
 
Figure 6: Plateau force values of the immersion-force curves of various lyophilisates 
immediately after freeze-drying and after moisture stress at 30% and 50% RH in open vials. 
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example, showed a reduction to about half the force for 1.5% moisture content, whereas 
cromolyn sodium demonstrated a similar decrease at a moisture content of 16.6%. 
In order to explore potential disintegration and lung delivery problems of moisture stressed 
lyophilisates, ACI measurements were performed. As can be seen from Figure 7, no 
significant changes in the ED and FPF of various moisture stressed samples compared to the 
unstressed ones were detectable. The only exception was cromolyn sodium, which 
demonstrated the strongest moisture absorption. A marginal but not relevant decrease in the 
FPF related to ED was noticeable, whereas the output from the vial remained the same. 
Possible explanations for this potential trend include a poorer comminution into fine particles 
or, more likely, inferior flight qualities of the fractioned particles due to moisture sorption, 
which results in heavier particles with increased aerodynamic size. The density of cromolyn 
sodium crystals, for example, varies with increasing humidity as a consequence of the relative 
rates of moisture uptake and expansion of the lattice. A reduced density is reported to occur 
between 0 and 10% RH, whereas the density rises rapidly between 60 and 90% RH [21]. 
Keller et al. [22], for example, reported an increase in mass median aerodynamic diameter for 
cromolyn sodium DPI from 3.9 to 5.8  µm when aerosolized in a climate box at 95% RH. 
Overall, however, the stable aerosolization performance of lactose and trehalose lyophilisates 
revealed no influence of structure softening due to moisture absorption. Thus, the absence of 
significant changes in ED and FPF for the moisture stressed samples indicates a rather good 
stability for the formulations even if exposed to higher humidity for short time. 
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Figure 7: The ED versus its related FPF as well as the FPF related to MD of the different 
lyophilisates before and after moisture stress: isoleucine (a), valine (b), lactose (c), trehalose 
(d), cromolyn sodium (e) and lysozyme (f). 
4 SUMMARY AND CONCLUSION 
Freeze-dried formulations for inhalation were evaluated according to their storage stability. 
Potential disintegration and lung delivery problems were of special interest. Therefore, three 
different formulations were studied in a three-month stability study at 25°C/60% RH and 
40°C/75% RH. A slight moisture absorption of less than 3% in maximum resulted in a 
softening of the lyophilisate structure only for lactose, which nevertheless did not hinder 
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aerosolization performance. The tested lyophilisates for inhalation did not show a decrease in 
FPF or ED during three months of storage at 25°C/60% RH and 40°C/75% RH. In order to 
simulate potential higher moisture sorption during short term open storage, various 
lyophilized substances were evaluated after un-stoppered equilibration at 30% and 50% RH. 
In contrast to the crystalline lyophilisates, the amorphous samples exhibited substantial 
moisture uptake up to 16.6% for the hygroscopic drug cromolyn sodium at 50% RH. Due to 
the plasticizing effect of water, the mechanical strength of the tested lyophilisates decreased to 
a softer structure for lactose, trehalose and, at higher moisture content, also for cromolyn 
sodium lyophilisates. Nevertheless, the aerosolization performance remained stable except for 
the two collapsed sugar lyophilisates. Therefore, it is concluded that freeze-dried formulations 
for inhalation which are dispersed into aerosols at the time of inhalation show good storage 
stability. 
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Chapter 8 
Summary of the Thesis 
Pulmonary drug delivery has developed to an appealing option for the treatment of several 
lung diseases, which entail, for example, the delivery of high lung doses or the formulation of 
biopharmaceuticals. New inhaler inventions and formulation strategies for dry powder 
inhalation emerged. Among them was an interesting concept proposed by Yamashita et al. 
(US Patent 7735485, 2010) to prepare the formulation by freeze-drying and disintegrate the 
lyophilisate into inhalable particles by an air impact at the time of inhalation. The evaluation 
and possible further development of this new concept was the subject of this thesis. The main 
focus was thereby on the improvement of the formulation towards the delivery of high lung 
doses. 
At first, an output test system with reproducible and optimized performance was developed 
and characterized. The influence of several variable parameters of the test system on the fine 
particle output was investigated with a screening design of experiments in order to fix the 
system to a standard parameter setting with the best possible performance. Additionally, the 
influence of vial and stopper geometry as well as a mouthpiece with sheath air was 
investigated. For all following experiments, the test system was used in a default setup 
consisting of a compressed air volume of 20 ml with a pressure of 3 bar, a diameter of the air 
inlet and air outlet capillary of 0.75 mm, the basic mouthpiece, and 2R vials equipped with 
lyophilization stoppers. The characterization of the test system by simulation of the air flow 
demonstrated great pressure drops across the narrow inlet and outlet capillaries and high air 
flow velocities of about 90 m/s at impaction on the lyophilisate. Nevertheless, high speed 
camera recordings revealed that the cake was not compressed by the incoming air jet but was 
lifted up and broken apart into fragments, which swirled around the endings of the capillaries. 
The particle aerosol finally left the mouthpiece at a velocity of approx. 3 m/s, which is 
comparable to pressurized metered dose inhalers. With regard to the size distribution of 
emitted particles, the test system demonstrated an enhanced particle emission in particular for 
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larger particles (around 100 µm) due to larger target surfaces offered to the discharging air 
flow and less wall adhesion. Very fine particles (around 3 µm) also showed an increased 
emission as a result of superior flight properties.  
In order to understand the aerosolization behavior of the lyophilisates by impacting air, 
various placebo formulations (isoleucine, phenylalanine, valine, lactose, trehalose, and 
mannitol) at a solution concentration of 4 mg/ml were investigated according to lyophilisate 
characteristics and particle size distributions. The porous lyophilisates disintegrated into 
particles of large geometric size up to above 100 µm. The particles consisted of agglomerates 
of smaller fragments, resulting in a highly porous structure with a low particle density. Due to 
these characteristics, a substantial fraction (20-50%) of these particles had an aerodynamic 
size between 1 and 5 µm (fine particle fraction, FPF), and can thus be deposited in the smaller 
airways of the lung. The amino acid lyophilisates of phenylalanine and valine performed best 
among the tested samples, which must be caused by material properties other than the 
physical state of being crystalline or amorphous. Small standard deviations between 1 and 4% 
of triplicate measurements by cascade impaction demonstrated reproducible lyophilisate 
aerosolization and fine particle output of the test system and robustness against freeze-drying 
batch heterogeneity. 
To test the suitability of this technology for the delivery of high powder doses, the first 
approach was to investigate ways and limitations for an elevation of the metered dose (MD). 
Valine and cromolyn sodium lyophilisates at increasing solution concentration and fill volume 
were examined. An increase in dose could only be achieved by increasing the solution 
concentration at a low fill volume because of a distinct reduction in the FPF at increased fill 
volume. Due to an increased hardness with higher solution concentration, the elevation of MD 
was however limited. The decrease in FPF at higher fill volume was caused by an impaired 
disintegration of the lyophilisate. For soft, instantaneous disintegrating cakes (e.g., valine), 
this was primarily caused by reduced milling efficiency. For harder lyophilisates (e.g., 
cromolyn sodium), the hindered disintegration was attributed to incomplete fragmentation of 
the harder cakes into particles due to a lack of space to perform rotational movements. An 
increased pressure for dispersion of 4 bar resulted in an increased emitted dose (ED) only for 
the highest fill volume of 2 ml and was not able to further enhance the fine particle dose 
(FPD) of cromolyn sodium. In 2R vials at default setting, a maximum FPD of 1.2 mg was 
achieved for valine and of 2.6 mg for cromolyn sodium lyophilisates. By the employment of 
bigger 6R vials, the now available space for rotational movements improved cromolyn 
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sodium cake disintegration of larger fill volume (2 ml). In combination with an adapted 
amount of compressed air to the doubled vial volume (30 ml at 4 bar), which enhanced the 
ED, the FPD could be further elevated to 3.7 mg.  
In a second approach, the possibility to improve the FPF of lysozyme, a substance which 
showed poor aerosolization properties, was evaluated. The crystalline amino acids 
phenylalanine and valine, which performed best as single excipient formulations, were added 
in varying concentration (14-40%) to the high molecular weight model drug lysozyme. The 
dose independent increase of the FPF from 5% to 17% with phenylalanine and to 14% with 
valine was possibly a result of enhanced fracture properties of the lyophilisates. Another 
contributing factor is the reduced particle agglomeration and cohesion due to a rougher 
surface, which was caused by embedded amino acid crystals in the amorphous lysozyme 
matrix. 
In a third approach for a possible improvement of the FPF, the impact of different cake 
morphologies on lyophilisate characteristics and their aerosolization performance were 
investigated. Variations of the solid matrix structure were achieved by changing the freezing 
process and by addition of tertiary butyl alcohol (TBA) as co-solvent. The applied freezing 
methods (shelf-ramped freezing, shelf-ramped freezing including two holding steps, shelf-
ramped freezing with annealing, freezing on precooled shelf, freezing in liquid nitrogen, and 
vacuum-induced freezing) partly resulted in different pore structures of the lyophilisates, 
which again caused a variation of the mechanical properties. Significant changes in the 
aerosolization performance only became apparent for strong variations of the solid matrix 
structure. A lamellar-oriented morphology resulted in an increase in ED, whereas a loss of the 
ordered structure by consolidation caused a decreased ED and FPF compared to the 
conventional spherulitic morphology. This robust outcome demonstrated that the 
aerosolization performance is less sensitive to minor changes in the lyophilisate morphology, 
which can occur due to freeze-drying batch heterogeneity. Samples featuring a fine directional 
lamellar pore morphology, achieved by freezing in liquid nitrogen, could positively affect the 
ED and mostly also the FPF. Despite the demonstration of elastic lyophilisate properties, this 
special structure disaggregated quickly and completely into large but highly porous particles 
with good aerodynamic properties. The addition of TBA in the range of 5% to 20% as co-
solvent rendered needle-shaped ice crystals, resulting in a lamellar-like morphology with the 
characteristic elastic structure and mostly also high ED of larger particles. The investigation 
of various freeze-dried substances (phenylalanine, valine, lactose, trehalose, cromolyn 
Chapter 8 
166 
sodium, and lysozyme + phenylalanine/valine) prepared with different freezing procedures 
emphasized the great influence of the material property on lyophilisate characteristics and the 
aerosolization performance. Mechanical material properties measured by compaction analysis 
were not able to fully explain commonalities and differences of the aerosolization 
performance of different substances. This demonstrated that properties affecting the 
aerosolization of lyophilisates are very complex and make it difficult to draw general 
conclusions or predict performance. 
Finally, storage stability for three months at 25°C/60% RH and 40°C/75% RH was 
investigated for selected formulations (8 mg/ml phenylalanine, 12 mg/ml lactose, 20 mg/ml 
cromolyn sodium, and 12 mg/ml lysozyme + 4 mg/ml phenylalanine). Despite a slight 
increase in the moisture content which resulted in a softening of lactose lyophilisates, all 
formulations demonstrated unchanged aerosolization performance. In order to simulate 
potential higher moisture sorption due to an unintended open storage at high humidity or an 
alternative moisture-permeable container, an un-stoppered storage at 30% and 50% RH for 
three days was performed as stress test for several model substances (isoleucine, valine, 
lactose, trehalose, cromolyn sodium, and lysozyme). In contrast to the amino acid 
lyophilisates, which demonstrated crystallinity, the amorphous samples exhibited substantial 
moisture uptake of up to 16.6% for the hygroscopic drug cromolyn sodium at 50% RH. 
Except of the lyophilized sugars lactose and trehalose, which collapsed at 50% RH, storage at 
30% and 50% RH showed hardly any effect on the aerosolization performance of all. It can 
therefore be concluded that the lyophilisates show good storage stability with regard to their 
aerosolization performance. 
In conclusion, the disintegration of lyophilisates by an air impact represents a promising new 
concept for dry powder pulmonary delivery. It combines a formulation process which is 
friendly for thermolabile drugs like biopharmaceuticals with the idea of creating fine particles 
at the time of inhalation which avoids formulation problems of most respiratory powders like 
poor flowability and redispersibility. Depending on the lyophilized substance, it demonstrated 
rather large FPF compared to dry powder inhalation products on the market and it can keep up 
with products of higher metered dose regarding the FPD. The aerosolization performance was 
shown to be less sensitive to minor changes in the lyophilisate morphology, which refers to 
robustness against freeze-drying batch heterogeneities like variation within and between 
batches. Nevertheless, it is important to note that the aerosolization performance is strongly 
affected by material properties. 
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LIST OF ABBREVIATIONS 
A Heckel-intercept 
ACI Andersen cascade impactor 
API active pharmaceutical ingredient 
CF cystic fibrosis 
COPD chronic obstructive pulmonary disease 
CS cromolyn sodium 
dA aerodynamic diameter 
DD delivered dose 
DoE design of experiment 
DPI dry powder inhaler 
Drel relative porosity 
DSC differential scanning calorimetry 
DSPC distearoylphosphatidylcholine 
dV volume-equivalent diameter 
ED emitted dose 
EMA european medicines agency 
FPD fine particle dose 
FPF fine particle fraction 
ICD inlet capillary diameter 
ICP inlet capillary position 
Ile L-isoleucine 
k Heckel constant/Heckel-slope 
Lac lactose-monohydrate 
LD laser diffraction 
Lys lysozyme 
Man D-mannitol 
MD metered dose 
MLI multistage liquid impinger 
MMAD mass median aerodynamic diameter 
MRSA methicillin-resistant Staphylococcus aureus 
OCD outlet capillary diameter 
List of Abbreviations 
168 
OCP outlet capillary position 
P pressure 
P0 baffle plate after stage 0 of ACI 
P1 baffle plate after stage 1 of ACI 
Phe L-phenylalanine 
PLGA poly(lactide-co-glycolide) 
pMDI pressurized metered dose inhaler 
PSD particle size distribution 
RH relative humidity 
SEM scanning electron microscopy 
SIP suction induction port 
TBA tertiary butyl alcohol 
Tg' glass transition temperature of the max. freeze concentrated solution 
Tg glass transition temperature 
TOF time of flight 
Tre trehalose 
Val L-valine 
Vol volume 
XRD x-ray diffractometry 
ρ density 
χ shape factor 
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